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Confucius said: In a group of three people, there is always something I can learn from. Choose to 
follow the strengths of others, use the shortcomings to reflect upon ourselves. 
 
Konfuzius sprach: Wenn ich mit drei Menschen zusammen wandere, kann immer einer von 
ihnen mein Lehrer sein: Denn was ich Gutes an ihm erkenne, waehle ich fuer mich aus, und 
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1.1 Transition Metal-Catalyzed Direct C–H Functionalizations 
In the past decade, transition metal-catalyzed direct C−H functionalizations
1
 emerged as a new 
stage for innovations owing to their widespread applications to the rapid assembly of diversified 





and natural product synthesis.
4
 The direct catalytic method bypasses the need of preactivated 
reaction partners and has advantages over classical cross-coupling reactions based on 
organometallics arylating reagents and therefore leads to more environmentally friendly and 
atom-economical
1p–r
 processes (Scheme 1). 
 
Scheme 1 Traditional cross-coupling (a) vs. direct C–H arylation (b). 








                                                             
1 For recent reviews on C–H bond functionalizations, see (a) S. De Sarkar, W. Liu, S. I. Kozhushkov, L. 
Ackermann, Adv. Synth. Catal. 2014, 356, 1461–1479; (b) K. Gao, N. Yoshikai, Acc. Chem. Res. 2014, 47, 
1208−1219; (c) X.-F. Wu, H. Neumann, M. Beller, Chem. Rev. 2013, 113, 1−35; (d) B. Li, P. H. Dixneuf, Chem. 
Soc. Rev., 2013, 42, 5744–5767; (e) T. A. Ramirez, B. G. Zhao, Y. Shi, Chem.Soc. Rev. 2012, 41, 931–942; (f) 
Z.-Z. Shi, C. Zhang, C.-H. Tang, N. Jiao, Chem. Soc. Rev. 2012, 41, 3381–3430; (g) D. A. Colby, A. S. Tsai, R. 
G. Bergman, J. A. Ellman, Acc. Chem. Res. 2012, 45, 814–825; (h) J. L. Bras, J. Muzart, Chem. Rev. 2011, 111, 
1170–1214; (i) L. Ackermann, Chem. Commun. 2010,46, 4866-4877; (j) T.W. Lyons, M. S. Sanford, Chem. Rev. 
2010, 110, 1147–1169; (k) A. A. Kulkarni, O. Daugulis, Synthesis 2009, 4087–4109; (l) R. Giri, B.-F. Shi, K. M. 
Engle, N. Maugel, J.-Q. Yu, Chem. Soc. Rev. 2009, 38, 3242–3272; (m) X. Chen, K. M. Engle, D.-H. Wang, 
J.-Q. Yu. Angew. Chem. Int. Ed. 2009, 48, 5094–5115; (n) L. Ackermann, R. Vicente, A. Kapdi, Angew. Chem. 
Int. Ed. 2009, 48, 9792–9826. For the principles of atom- and step-economy, see: (o) B. M. Trost, Acc. Chem. 
Res. 2002, 35, 695–705. (p) B. M. Trost, Science 1991, 254, 1471–1477; (q) P. A. Wender, V. A. Verma, T. J. 
Paxton, T, H. Pillow, Acc. Chem. Res. 2008, 41, 40–49. 
2 Y. Segawa, T. Maekawa, K. Itami, Angew. Chem. Int. Ed. 2014, 53, 2–18. 
3 And following the recent reviews on C–H functionalizations in medicinal chemistry, see (a). P. M. Wright, I. B. 
Seiple, A. G. Myers, Angew. Chem. Int. Ed. 2014, 53, 8840–8869; (b) J. Yamaguchi, A. D. Yamaguchi, K. Itami, 
Angew. Chem. Int. Ed. 2012, 51, 8960–9009; (c) J. Magano, J. R. Dunetz, Chem. Rev. 2011, 111, 2177–2250.  
4 For recent reviews on C–H bond functionalizations in the synthesis of natural products, see: (a) D. Wang, S. Gao, 
Org. Chem. Front. 2014, 1, 556–566; (b) Y.-K. Chen, S. W. Youn, Chem. Eur. J. 2012, 18, 9452–9474; (c) W. 






 direct site-, chemo- and enantioselective C–H activations have been 
explored. Based on this research, detailed mechanistic studies were also carried out. Traditionally, 
four different modes of action were primarily considered, that is (i) oxidative addition with 
electron-rich late transition metals, (ii) σ-bond metathesis with early transition metals, (iii) 
electrophilic activation with electron deficientlate transition metals, and (iv) 1,2-addition of early 
to middle transition metals with imido, alkylidene, and oxo complexes (Scheme 2). These results 







Scheme 2 Different Mechanisms for C–H Bond Metalation. 
 
However, more recent computational mechanistic studies carried out by Ess and Periana
6
 showed 
that quantitative dissection of directional charge-transfer stabilization (orbital occupied to 
unoccupied stabilization) between the metal-ligand complex and the C(sp
3
)–H bond energies that 
revealed a continuum of electrophilic, ambiphilic, and nucleophilic interactions. Detailed 
experimental analysis provided strong evidence for novel C–H metalation mechanisms relying on 
the assistance of a bifunctional ligand bearing an additional Lewis-basic heteroatom, such as 
                                                             
5 (a) L. Ackermann, Chem. Rev. 2011, 111, 1315–1345; (b) D. Balcells, E. Clot, O. Eisenstein, Chem. Rev. 2010, 
110, 749–823. 




(heteroatom-substituted) secondary phosphine oxides
7
 or most prominently carboxylates (Scheme 
2).5a 
As early as 1972, Shaw
8
 and coworkers found that the additive NaOAc accelerated 
cyclometalation reactions with iridium, platinum, or palladium complexes. A representative 
example was the cyclometalation of N,N-dimethylaminomethyl ferrocene (5) with Na2[PdCl4] in 
the presence of stoichiometric amounts of this base. Control experiments showed that the NaOAc 
was essential for the transformation. Subsequently, Davies
9
 and coworkers carried out similar 
cyclometalation reactions of N,N-dimethylbenzylamines with [Cp*IrCl2]2 at ambient temperature. 
Detailed mechanistic studies through computational studies provided evidence for 
acetate-promoted process. 
 
Scheme 3 NaOAc Assisted Cyclopalladation of Amine 5. 
 
Based on these previous studies, Fagnou
10
 reported palladium-catalyzed direct arylations of 
perfluorobenzenes in the presence of potassium carbonate. However, electron-deficient arenes 
were favored in this reaction indicating a pathway different from the electrophilic aromatic 
substitution. Furthermore, computational studies showed that the reaction proceeds via a concerted 
arene metalation and that the C–H bond cleaving process depends directly on the acidity of the C–
H bond being cleaved. They proposed the transformation via a 6-membered transition state 
(Scheme 4). Fagnou used the term concerted metalation deprotonation (CMD),
11
 which also 
emphasized the dual role of the metal and the (intramolecular) base. Subsequently, Ess and 
coworkers carried out a transition state energy decomposition study of C–H activation of benzene 
and methane by [Ir(acac’)2(X)] (X = OAc and OH).
12
 Hydroxide can only act as an intramolecular 
base with a 4-membered transition state (Scheme 4), but acetate can through a 4-membered or 
                                                             
7 (a) L. Ackermann, Isr. J. Chem. 2010, 50, 652–663; (b) L. Ackermann, Synlett 2007, 507–526; (c) L. 
Ackermann, Synthesis 2006, 1557–1571; (d) N. V. Dubrovina, A. Börner, Angew. Chem. Int. Ed. 2004, 43, 5883–
5886. 
8 (a) J. C. Gaunt, B. L. Shaw, J. Organomet. Chem. 1975, 102, 511–516; (b) J. M. Duff, B. E. Mann, B. L. Shaw, 
B. Turtle, J. Chem. Soc. Dalton Trans. 1974, 139–145; (c) J. M. Duff, B. L. Shaw, J. Chem. Soc., Dalton Trans. 
1972, 2219–2225. 
9 D. L. Davies, O. Al-Duaij, J. Fawcett, M. Giardiello, S. T. Hilton, D. R. Russell, Dalton. Trans. 2003, 4132–
4138. 
10 M. Lafrance, C. N. Rowley, T. K. Woo, K. Fagnou, J. Am. Chem. Soc. 2006, 128, 8754–8756. 
11 D. Lapointe, K. Fagnou, Chem. Lett. 2010, 39, 1118–1126. 




6-membered transition state, whereas the later is favored due to its lower energy state. The term 
internal electrophilic substitution (IES) was suggested for the C–H metalation of benzene with an 
Ir–OH bond. However, Davies
13
 suggested that this did not show the importance of the 
heteroatom lone pair in the activation of the C–H bond, and this concerted dual activation made 
these processes different from a conventional electrophilic process and their selectivity different to 
conventional electrophilic aromatic substitution. Hence, to differentiate these intramolecular 





Scheme 4 Different types of transition states. 
1.2 Ruthenium-Catalyzed Direct C–H Functionalizations 
In recent years, transition metal-catalyzed C–H bond functionalizations as an efficient tool to 
construct C–C and C–X (X = halide, N, O, S) bonds with great progress have been achieved. 
However, these transition metal catalysts were typically based on platinum, rhodium, iridium and 
palladium. Inexpensive ruthenium complexes (prices of platinum, rhodium, iridium, palladium, 
and ruthenium = $1238, $1180, $570, $787 and $ 56 US per troy ounce, respectively) have not 
been explored widely for this C–H bond transformation. Notably, pioneering studies
15
 highlighted 
the potential of efficient ruthenium-catalyzed C–H bond activation with the development of 
effective catalysts for site-selective addition reactions of C–H bonds onto C–C multiple bonds. 
Encouraged by these previous studies, Ackermann’s group focused attention on the application of 
ruthenium complexes for chelation-assisted C–H bond functionalizations. A variety of cocatalytic 
additives
16
 such as NHCs, phosphines and SPOs were tested in the ruthenium-catalyzed arylation 
reaction with triazole substrates 7.
17
 Finally, they found hindered carboxylates emerged to be the 
                                                             
13 Y. Boutadla, D. L. Davies, S. A. Macgregor, A. I. Poblador-Bahamonde, Dalton Trans. 2009, 5820–5831. 
14 Y. Boutadla, D. L. Davies, S. A. Macgregor, A. I. Poblador-Bahamonde, Dalton Trans. 2009, 5887–5893. 
15 (a) S. Murai, F. Kakiuchi, S. Sekine, Y. Tanaka, A. Kamatani, M. Sonoda, N. Chatani, Nature 1993, 366, 529–
531; (b) L. N. Lewis, J. F. Smith, J. Am. Chem. Soc. 1986, 108, 2728–2735. 
16 (a) L. Ackermann, M. Mulzer, Org. Lett. 2008, 10, 5043–5045; (b) L. Ackermann, R. Born, R. Vicente, 
ChemSusChem, 2009, 546–549. 




most effective catalyst and exerted an optimal rate acceleration in direct C–H bond arylations, 
whereas carbonate-assisted formation of cyclometalated ruthenium(III)–NHC complexes as not of 
any relevance (Scheme 5).
18
 It is noteworthy that the carboxylate-assisted ruthenium(II) catalytic 
system can be broadly applied in direct arylations with various organic electrophiles, including 
aryl halides, pseudohalides and phenols. The mechanism was studied in great detail as well. 
 
additive --- HIPrCl PPh3 Ad2PO(H) (PhO)2PO(H) NaOAc AdCO2H tBuCO2H MesCO2H 
Yield (%) 0 9 20 85 50 79 85 66 93 
Scheme 5 Efficacy of different additives in ruthenium(II)-catalyzed arylations. 
1.2.1 Carboxylate-Assisted Ruthenium-Catalyzed Oxidative Alkyne Annulation 
Based on the previous studies on ruthenium-catalyzed direct arylations, Ackermann’s group tested 
carboxylates as cocatalytic additives for ruthenium(II)-catalyzed oxidative C−H bond 
functionalizations,
19






Considering the importance of step-economical syntheses of bioactive heterocycles, we 
particularly became attracted by oxidative annulations through C−H/Het−H bond cleavages. As a 
proof of concept, our group set out to devise ruthenium-catalyzed oxidative annulations of alkynes 
through C−H and N−H bond cleavages for the synthesis of potential bioactive isoquinolones 
(Scheme 6).
22
 Notably, optimization studies revealed less expensive [RuCl2(p-cymene)]2 to be 
                                                             
18 (a) L. Ackermann, N. Hofmann, R. Vicente, Org. Lett. 2011, 13, 1875–1877; (b) L. Ackermann, R. Vicente, H. 
K. Potukuchi, V. Pirovano, Org. Lett. 2010, 12, 5032–5035.  
19 Selected reviews: (a) L. Ackermann, Org. Process Res. Dev. 2015, 18, 260–269; (b) L. Ackermann, Acc. Chem. 
Res. 2014, 47, 281–295; (c) P. B. Arockiam, C. Bruneau, P. H. Dixneuf, Chem. Rev. 2012, 112, 5879–5918. 
20 (a) G, Song, F. Wang, X. Li, Chem. Soc. Rev. 2012, 41, 3651–3678; (b) T. Satoh, M. Miura, Chem. Eur. J. 2010, 
16, 11212–11222. 
21 (a). C. Zhu, R. Wang, J. R. Falck. Chem. Asian J. 2012, 7, 1502–1514; (b) K. M. Engle, T. Mei, M. Wasa, J.-Q. 
Yu, Acc. Chem. Res. 2012, 45, 788–802. 




optimal among a variety of ruthenium complexes, while Cu(OAc)2·H2O was found to be the 
terminal oxidant of choice. The annulation reaction occurred efficiently in polar protic solvent 
tAmOH, whereas the corresponding hydroarylation product was also formed in apolar solvents. 
The optimized ruthenium(II) catalyst proved to be tolerant of valuable electrophilic functional 
groups, and was found to be applicable to benzamides 10 with different substituents on nitrogen. 
Furthermore, the ruthenium(II) catalyst also enabled the C–H/N–H functionalizations with 
alkenyl-substituted amides
23
 10, giving the desired isoquinolone in good yield and with high 
selectivity. Importantly, the annulation process proceeded with excellent regioselectivity when 
using unsymmetrical aryl/alkyl or alkenyl/alkyl alkynes 11.  
 
Scheme 6 Ruthenium (II)-catalyzed alkyne annulations with amides 10. 
  
Detailed mechanistic studies revealed that the ruthenium-catalyzed oxidative annulation 
proceeded through an initial intermolecular carboruthenation via initial rate-limiting 
acetate-assisted C–H bond ruthenation, followed by a migratory insertion of alkyne 11, and 
subsequent intramolecular C–N bond formation by reductive elimination (Scheme 7). 
 
 
Scheme 7 Proposed mechanism of carboxylate-assisted oxidative annulation reactions. 
                                                             




Subsequently, Ackermann’s and Wang’s group developed two protocols for the synthesis of 
isoquinolones by ruthenium-catalyzed redox-neutral annulations of alkynes with N-methoxy- and 
N-hydroxybenzamides 18, respectively (Scheme 8).
24
 These reactions were performed under mild 
reaction conditions with a wide range of substrates. Importantly, this redox-neutral strategy 
bypassed the need of wasteful metal oxidant and led to a more economic synthesis. Additionally, 
the extraordinary robustness and chemoselectivity of the ruthenium(II) carboxylate catalyst 
allowed for the direct use of free hydroxamic acids in annulations of alkynes. 
 
Scheme 8 Ruthenium-catalyzed alkyne annulations by C–H/N–O bond cleavages. 
 
Indoles are ubiquitous structural motifs in biologically active compounds and natural products. 
Therefore, their modular syntheses continued to be of strongly interest. In this context, 
Ackermann’s group
25
 developed a new approach to ruthenium-catalyzed oxidative annulations 
employing simple aniline derivatives 20 (Scheme 9). Notable features of the new protocol include 
the unprecedented use of cationic ruthenium(II) complexes for oxidative annulations of alkynes 
along with a removable directing group, and an excellent chemoselectivity that enabled C–H bond 
transformations in water as a green reaction medium. 
 
 
Scheme 9 Pyrimidine-directed ruthenium-catalyzed alkyne annulations. 
 
Shortly after, the same group reported on the ruthenium-catalyzed oxidative annulation of alkynes 
with ambient air as the ideal sacrificial oxidant.
26
 The aerobic annulation reactions were 
accomplished with co-catalytic amounts of Cu(OAc)2·H2O employing differently substituted 
2-arylindoles 22. Moreover, the remarkably broad scope of the ruthenium catalyst was exploited 
                                                             
24 (a) L. Ackermann, S. Fenner, Org. Lett. 2011, 13, 6548–6551; (b) B. Li, H. Feng, S. Xu, B. Wang, Chem. Eur. J. 
2011, 17, 12573–12577; (c) F. Yang, L. Ackermann, J. Org. Chem. 2014, 79, 12070–12082. 
25 L. Ackermann, A. V. Lygin, Org. Lett. 2012, 14, 764–767. 




for oxidative annulations with 2-arylpyrroles to deliver pyrrolo[2,1-a]isoquinolines 24, structural 
analogues of bioactive marine alkaloids (Scheme 10). Compared to previously reported 
rhodium-catalyzed transformations,
27
 the highly selective conversion of n-alkyl-substituted 
alkynes is a beneficial feature which can be achieved in ruthenium-catalyzed annulation processes. 
Experimental mechanistic studies provided strong evidence for a concerted deprotonative 
metalation through acetate assistance. Additionally, Chandrasekhar’s group
28
subsequently 
developed an alternative reaction procedure wherein the metal catalyst can be recycled
29
 for 
preparing various benzimidazoisoquinolines. Interestingly, all reactions when carried out in PEG 
400 as a solvent medium delivered the desired products in similar yields even at ambient 
temperature. Moreover, employment of PEG 400
29
 resulted in the enhanced cyclability of the 
catalyst, thus providing its successful use for a few times with minimal loss of activity (Table 1). 
 
Scheme 10 Ruthenium-catalyzed alkyne annulations with indoles, pyrroles and pyrazoles. 
 
In 2012, Ackermann’s and Jeganmohan’s groups independently developed an atom- and step 
economical method for the synthesis of isocoumarins 26 through oxidative annulations of alkynes 
with carboxylic acids 25 using an inexpensive ruthenium catalyst (Scheme 11).
30
 A wide range of 
substrates with differently substituted functional groups such as halogen, ester and hydroxyl group 
were well tolerated and afforded the corresponding products in high yields and excellent 
regioselectivity. Unsymmetrical alkynes 11 reacted with benzoic acid regioselectively as well to 
afford the decorated isocoumarins in good yield. This catalytic reaction was also compatible with 
heteroaromatic and alkenyl acids as substrates. 
                                                             
27 K. Morimoto, K. Hirano, T. Satoh, M. Miura, Org. Lett. 2010, 12, 2068–2071. 
28 N. Kavitha, G. Sukumar, V. P. Kumar, P. S. Mainkar, S. Chandrasekhar, Tetrahedron Lett. 2013, 54, 4198–
4201. 
29 L. Ackermann, R. Vicente, Org. Lett. 2009, 11, 4922–4925. 
30 (a) S. Warratz, C. Kornhaaß, A. Cajaraville, B. Niepötter, D. Stalke, L. Ackermann, Angew. Chem. Int. Ed. 2015, 
DOI: 10.1002/anie.201500600; (b) R. K. Chinnagolla, M. Jeganmohan, Chem. Commun. 2012, 48, 2030–2032; 





Scheme 11 Ruthenium-catalyzed oxidative alkyne annulations with substituted benzoic acids 25. 
 











 achieved annulations of 
enamides in the presence of a ruthenium(II) catalyst (Scheme 12). These protocols could be 
applied to the annulations of a variety of different substrates 27 bearing electron-deficient groups. 
Moreover, dialkylsubstituted substrates and unsymmetrical alkynes 11 were also converted 
smoothly in this catalytic system and delivered the desired products 28 in high yields. 
 
Scheme 12 Ruthenium-catalyzed oxidative alkyne annulations with enamides 27. 
 
The hydroxyl group was firstly employed as weakly-chelation directing group by Miura in 1997.
36
 
In the following decades, significant advances in direct C–H bond functionalizations were 
represented by the development of palladium, rhodium and iridium catalysts that proved 
applicable to hydroxyl group as a versatile Lewis basic directing group.
37
 Based on these reports, 
Ackermann’s group developed ruthenium-catalyzed alkyne annulations with naphthols 29
38
 and 
benzylic alcohols 31 (Scheme 13).
39
 These transformations could be extended to compounds 
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33 L. Wang, L. Ackermann, Org. Lett. 2013, 15, 176–179. 
34 B. Li, N. Wang, Y. Liang, S. Xu, B. Wang, Org. Lett. 2013, 15, 136–139. 
35 K. Murugan, S. Liu, Tetrahedron Lett. 2013, 54, 2608–2611. 
36 T. Satoh, Y. Kawamura, M. Miura, M. Nomura, Angew Chem Int. Ed. Engl. 1997, 36, 1740–1742. 
37 (a) E. M.Simmons, J. F. Hartwig, Nature 2012, 483, 70–73; (b) Y. Lu, D. Leow, X. Wang, K. M. Engle, J.-Q. 
Yu, Chem. Sci. 2011, 2, 967–971; (c) B. Xiao, T.-J. Gong, Z.-J. Liu, J.-H. Liu, D.-F. Luo, J. Xu, L. Liu, J. Am. 
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Coles, M. B. Hursthouse, M. E. Limmert, Angew. Chem. Int. Ed. 2003, 42, 112–114; (h) Y. Kawamura, T. Satoh, 
M. Miura, M. Nomura, Chem. Lett. 1999, 961–962; (i) T. Satoh, Y. Kawamura, M. Miura, M. Nomura, Angew. 
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38 V. S. Thirunavukkarasu, M. Donati, L. Ackermann, Org. Lett. 2012, 14, 3416–3419. 




containing a variety of different functional groups including both electron-donating and 
electron-withdrawing ones. Remarkably, the resulting annulated pyrans 32 possess fluorescence 
properties which can potentially be used in material science. Mechanistic studies provided 
evidence for a carboxylate-assisted C–H bond ruthenation. 
 
Scheme 13 Ruthenium(II)-catalyzed alkyne annulations with naphthols 29 and benzylic alcohols 31. 
 
In 2012, Lam’s group
40
 reported on the synthesis of spiroindenes by enolate-directed 
ruthenium-catalyzed oxidative annulation of alkynes with 2-aryl-1,3-dicarbonyl 33 compounds. 




)–H bonds, thus 
resulting in products containing all-carbon quaternary centers 34. A wide range of spiroindenes 
were obtained with high levels of regioselectivity under this catalytic condition. Thereafter, when 
using 3-aryl-4-hydroxyquinolin-2-ones 33 as substrates for the ruthenium-catalyzed oxidative 
annulation reactions, the benzopyran derivatives 35 were obtained as the main products in high 
isolated yields (Scheme 14), whereas only minor amounts of the spiroindenes 34 were formed. On 
the other hand, employing a palladium catalyst, the spiroindene compounds 34 can be obtained 
predominantly in high yields with high regioselectivity.  
Scheme 14 Ruthenium-catalyzed alkyne annulations with 2-aryl-1,3-dicarbonyl compounds 33. 
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Shortly thereafter, inspired by previous works on hydroxyl-directed transition-metal-catalyzed C–
H bond functionalization, Wang
41
 developed a ruthenium-catalyzed vinylative dearomatization 
reaction of 1-aryl-2-naphthols 36 via C–H activation strategy (Scheme 15). At the beginning of 
this study, rhodium and palladium catalyst were also evaluated under the optimized reaction 
conditions, but only resulted in unsatisfactory yields. The effective ruthenium catalyst can enable 
this transformation successfully to deliver the desired spirocyclic products in high yields. 
Importantly, unsymmetrical alkynes were also applicable as the coupling partners and afforded the 
corresponding products 37 with excellent regioselectivity. This transformation provides a facile 
route to access a class of highly functionalized spirocyclic compounds.  
 
 
Scheme 15 Ruthenium(II)-catalyzed alkyne annulations with 1-aryl-2-naphthols 36. 
 
Very recently, Ackermann’s group developed ruthenium(II)-catalyzed oxidative alkyne 
annulations with amidines 38 (Scheme 16a).
42
 This ruthenium catalytic system was also 
applicable to the ketimine substrates 40 (Scheme 16b)
43
 for the preparation of isoquinolines 41 





Scheme 16 Ruthenium-catalyzed alkyne annulations with substituted amidines 38 and ketimines 40. 
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Lately, Jeganmohan and coworkers
44
 successfully developed a highly regioselective cyclization of 
phenones 42 with alkynes which provided an efficient route to the preparation of indenols 43 and 
benzofulvenes 44. Interestingly, the amount of silver salt plays an important role in the reaction. 
When the amount of silver salt exceeded 8 mol % in the presence of 2 mol % of 
[RuCl2(p-cymene)]2, a different type of dehydration product, namely a benzofulvene derivative 44, 
started to appear. Therefore, two different products were obtained by controlling the amount of 
AgSbF6 under otherwise identical reaction conditions (Scheme 17). 
 
Scheme 17 Ruthenium(II)-catalyzed alkyne annulations with phenones 42. 
1.3 Transition-Metal-Catalyzed Direct Alkenylation of Arenes 
Styrene derivatives are useful intermediates in synthetic organic chemistry and represent key 




 and material sciences.
47
 Among 
others, several catalytic methods for the preparation of styrene derivatives have been developed. 
For example, the palladium-catalyzed Mizoroki-Heck reaction is one of the most popular and 
powerful tools for the formation of C–C bonds that offer a straightforward approach for the 
construction of olefinated products (Scheme 18a).
48
 Under these reaction conditions, aryl halides 
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45 (a) P. Nguyen, J. Yang, M. N. Uddin, S. Park, S. Lim, D. Jung, D. R. Williams, W. Oh, J. Nat. Prod. 2013, 76, 
2080−2087; (b) S. W. Chae, A. Han, J. H. Park, J. Y. Rhie, H. Lim, E. Seo, H. J. Lee, J. Nat. Prod. 2013, 76, 
2277−2281; (c) B. H. Park,Y. R. Lee,W. S. Lyoob, Synthesis 2009, 13, 2146–2154; (d) B. S. Siddiqui, H. Aslan, 
S. Begus, S. T. Ali, Nat. Prod. Res. 2007, 21, 736–741; (e) J. Cheel, C.Theoduloz, J. Rodriguez, G. Saud, P. D. 
S. Caligari, G. Schmeda-Hirschmann, J. Agric. Food Chem.2005, 53, 8512–8518. 
46 (a) R. S. P. Singh, D. Michel, U. Das, J. R. Dimmock, J. Alcorn, Bioorg. Med. Chem. Lett. 2014, 24, 5199–
5202; (b) T. Chuprajob, C. Changtam, R. Chokchaisiri, W. Chunglok, N. Sornkaew, A. Suksamrarn, Bioorg. 
Med. Chem. Lett. 2014, 24,2839–2844; (c) N. Sharma, D. Mohanakrishnan, A. Shard, A. Sharma, A. K. Sinha, 
D. Sahal, J. Med. Chem. 2012, 55, 297−311; (d) Q.-Y. Wei, H. Jiang, J.-X. Zhang, C. Zhang, P.-F. Guo, Asian J. 
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47 (a) J. Wencel-Delord, F. Glorius, Nat. Chem. 2013, 5, 369–375; (b) Q. Jiang, Z. Lei, Biotechnol. Bioprocess 
Eng. 2011, 16,1187–1195; (b) M. M. da Silva Paula, C. V. Franco, M. C. Baldin, L. Rodrigues, T. Barichello, G. 
D. Savi, L. F. Bellato, M. A. Fiori, L. da Silva, Mater. Sci. Eng. C, 2009, 29, 647–650; (c) J. C. Garay-Jimenez, 
D. Gergeres, A. Young, D. V. Limand, E. Turos, Nanomed.Nanotechnol. Biol. Med. 2009, 5, 443–451. 
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and pseudohalides can be used as the coupling partners. However, the stoichiometric amounts of 
halide salts as side products generated by this transformation can cause extensive environmental 
pollution. Another method is the transition-metal-catalyzed alkenylation of organometallic 







 However, most of these starting materials were prepared in 
several steps from the corresponding aryl halides. Some side products generated from these 
transformations were also not environmentally friendly. In contrast, the cross-dehydrogenative 
alkenylations developed by Fujiwara and Moritani
52
 between unactivated arenes and olefins by 
twofold C–H bond activation is one of the most ideal strategies to achieve olefination of arenes 
because it bypasses the need of preactived starting materials (Scheme 18c). Therefore, different 
methods for the preparation of styrene derivatives by cross-dehydrogenative olefination reaction 
were reported in the past decades. 
 
Scheme 18 Strategies for the metal-catalyzed preparation of styrenes. 
However, as several C–H bonds of similar reactivity are usually available in a molecule, in the 




Scheme 19 Ruthenium(III)-catalyzed oxidative alkenylations with anisole 45. 
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To overcome this disadvantage, a new method that utilized a directing group preinstalled in the 
substrate has been explored in recent years.
54
 In most cases, directing groups always contain a 
heteroatom which can coordinate to the transition metal catalyst to achieve C–H functionalization 
in good yield and high regioselectivity. In this context, a great number of 
transition-metal-catalyzed alkenylations of arene bearing different directing group have been 
reported in the last decade. 
1.3.1 Ruthenium-Catalyzed Direct Alkenylation of Arenes 
Transition metal-catalyzed alkenylations have been achieved with great progress since 1967, when 
Fujiwara and Moritani reported the first example of the palladium-catalyzed direct oxidative 
coupling reactions.
52a
 However, almost all of these reactions were performed in the presence of 
expensive rhodium and palladium catalysts. In contrast, significantly less expensive ruthenium 
complexes have been only recently exploited as catalysts for oxidative C–H bond alkenylations of 
arenes. 
As early as 1986, Lewis and Smith
15b
 reported that ruthenium complexes containing 
ortho-metalated triphenyl phosphite linkages reacted with ethylene to give ortho alkylation on the 
triphenyl phosphite ligands. The ruthenium complex together with phenoxide catalyzed the 
selective ortho alkylation of phenol. Inspired by this study, in 1993, Murai
15a
 reported 
ruthenium-catalyzed couplings of alkenes with arenes 42 bearing ketone as an ortho-directing 
group (Scheme 20). In this reaction, the low valent ruthenium(0) species is coordinated by the 
aromatic carbonyl group and subsequently activates the neighboring aromatic C–H bond. 
However, the double bond was not preserved in this coupling reaction. Therefore, this reaction is 
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not an alkenylation reaction, but rather a hydroarylation of an alkene 46. 
 
 




 reported on chelation-assisted coupling reactions of arylamides 10 and 





BF4– enabled these alkenylation reactions efficiently to give the 
ortho-alkenylamides 51 in good yields (up to 84%). Interestingly, an excess of the alkene 50 as 
well as of the newly formed alkenylated benzamide 51 served as the hydrogen scavenger which 
enabled this transformation without any external oxidant. 
 
 
Scheme 21 Ruthenium-catalyzed alkenylations of substituted benzamides 10.  
 
Shortly thereafter, a great number of ruthenium-catalyzed alkenylation reactions appeared in the 
literature, and these transformation were rapidly expanded to a variety of directing groups 



















 These transformations 
proceeded smoothly in the presence of cationic ruthenium(II) complexes and copper oxidants to 
give the desired products in good yield with high regio- and site-selectively. Importantly, some of 
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the oxidative C–H bond alkenylations were also viable in an aerobic fashion, using cocatalytic 
amounts of Cu(OAc)2·H2O under an atmosphere of ambient air. It is noteworthy that heterocyclic 






Scheme 22 Recent ruthenium-catalyzed alkenylations of arenes with various directing groups. 
 
It is important to mention that all these transformations relied on copper(II) acetate as the 
reoxidant or oxidant. Thus, in most case, the Cu(OAc)2·H2O proved to be essential for these 
transformations, since it not only acted as the (co)oxidant but also served as the source of acetate 
for the carboxylate-assisted C−H bond activation step. However, the using of stoichiometric or 
cocatalytic amount of metal oxidant in these reactions led to the generation of stoichiometric 
amounts of undesired waste. Based on this context, Wang (Scheme 23a)
61
 and Ackermann 
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 reported ruthenium-catalyzed oxidative alkenylations under notably mild reaction 
conditions of N-methoxy- and N-hydroxybenzamides 18 bearing the C(O)NH(OMe) and 
C(O)NHOH groups, respectively, as oxidizing directing group. Remarkably, cocatalytic amounts 
of carboxylates were found to be indispensable for achieving efficient C−H bond 
functionalizations, with optimal results being accomplished with KO2CMes or NaOAc as the 





Scheme 23 Ruthenium-catalyzed C–H alkenylations by using internal oxidizing directing groups. 
1.3.2 Transition Metal-Catalyzed Direct Alkenylation of Arenes with Removable 
Directing Groups 
In recent years, directing group-assisted transition metal-catalyzed oxidative alkenylations have 
been achieved with great progress, and a large variety of decorated styrenes were prepared from 
this protocol. However, the directing groups are always difficult to be removed or transformed to 
other functional groups under mild conditions. This restriction has greatly limited the structural 
diversity of the products and subsequent application in the synthesis of complex molecules. 
Therefore, the necessity of novel, readily accessible substrates containing easily attachable and 
removable directing groups is obvious (Scheme 24).
54aa
 
                                                             









 succeeded in preparing a series of meta-substituted stilbenes and 2- or 
3-vinylindole derivatives 71 from readily available carboxylic acids and alkenes through precisely 
ordered ortho-olefination/decarboxylation under palladium and rhodium catalysis (Scheme 25). 
For the unsubstituted benzoic acid 25, double olefination took place at the 2- and 6-positions to 
form selective 1,3-dialkenylbenzenes 72 which are important organic intermediates in material 
science (Scheme 25b). 
 
Scheme 25 Palladium- and rhodium-catalyzed oxidative alkenylations of carboxylic acids. 
 
In 2011, Zhang’s group
64
 disclosed an efficient method for the palladium(II)-catalyzed 
alkenylation and arylation of arenes 73 by using 2-pyridyl sulfoxide as the directing group 
(Scheme 26). The directing group can easily be removed or converted to another synthetically 
useful moiety. 
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Scheme 26 Palladium-catalyzed alkenylations of substituted 2-pyridyl sulfoxides 73.  
 
Subsequently, Huang and coworkers
65
 developed the triazene-directed aromatic C–H bond 
activation followed by oxidative coupling to synthesize olefinated arenes 71 (Scheme 27). This 
versatile directing group can participate in various transformations such as facile removal, halogen 
exchange, and direct C–H cross-coupling. 
 




 and subsequently Wang’s
67
 group reported ruthenium(II)-catalyzed oxidative C–
H alkenylations using carbamates as the directing groups. Substrates 77 decorated with different 
functional groups, such as halides, were tolerated very well and afforded the corresponding 
products 78 in good yields with high regio- and stereo-selectivities. Importantly, the carbamate 
directing group was easily removed under basic reaction conditions to deliver the desired phenol 
derivatives 71 (Scheme 28). 
 
Scheme28 Ruthenium-catalyzed C–H alkenylations of aryl carbamates 77. 
 
Besides this, You’s group
68
 found that (2-pyridyl)methylether can serve as an efficient directing 
group for amino acid ligand-accelerated ortho-C–H olefination of aryl (2-pyridyl)methyl ethers 79. 
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A variety of differently substituted substrates 79 could be employed in this transformation, giving 
the ortho-alkenylated products 80 in good to excellent yields with high regioselectivity. Especially, 
non-activated alkenes can also serve as coupling partners. Additionally, the scope of this 
methodology can be expanded to the diolefination of substrate 79. At last, the 2-pyridylmethyl 
group can easily be removed through several different methods giving the ortho-alkenyl phenols 
71 or ortho-alkylphenols (Scheme 29). 
 
Scheme 29 Palladium-catalyzed C–H alkenylations of aryl (2-pyridyl)methyl ethers 79. 
 
The 2-pyridylsulfonyl directing group was found to be efficient for the palladium-catalyzed 
alkenylation of pyrroles and indoles 81, as was reported by Carretero and coworkers (Scheme 
30a).
69a
 Both electron-withdrawing and electron-donating substituents on the aryl ring of the 
indole 81 did not significantly affect the transformation. It is noteworthy that substituted alkenes 
82, such as methylmethacrylate, α-ethylacrolein, and methyl styrene also reacted smoothly under 
this reaction condition. Subsequently, it was found that this directing group was also suitable for 
carbazole substrates 85 when changing the oxidant to N-fluoro-2,4,6-trimethylpyridinium triflate 
([F
+
] in Scheme 30b).
70b
 Importantly, the 2-pyridylsulfonyl group can easily be removed under 
reductive conditions to generate the potential bioactive NH-free pyrrole, indole and carbazole 
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 introduced silanol as an effective directing group for the 
direct olefination of arenes through palladium-catalyzed C–H activation. Substrates 88 decorated 
with both electron-donating and electron-withdrawing groups were successfully transformed 
under this reaction conditions to afford the desired products 89 in high yields. Some important 
functional groups, such as chloride and ester, were well tolerated in this catalytic system. In 
addition, the silanol group can be removed in the presence of TBAF at ambient temperature. 
Importantly, the C–H activation/desilylation transformation of benzyldiisopropylsilanol and 
phenol-derived silanols 88 can be achieved in an one-pot or a semi-one-pot fashion which 
provided a novel and attractive approach for the synthesis of ortho-alkenyl-substituted styrene 
derivatives 71 (Scheme 31). 
 






 reported highly efficient and selective ruthenium-catalyzed 
C2-olefination of indoles 90 by using the N,N-dimethylcarbamoyl as a removable directing group. 
In this olefination reaction, the non-activated styrene derivatives 82 successfully participated as 
well. Other related N-heteroarenes such as pyrroles and carbazoles could also be used and yielded 
the corresponding products in good yields with high site-selectivity. The employment of O2 as the 
terminal oxidant allows performing this reaction in an economical fashion (Scheme 32). 
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)–H bond alkenylation by using the thioether directing group 
has been achieved by Shi’s group.
74
 Interestingly, monoalkenylated products 93 could be 
obtained selectively by using MeOH as the solvent, whereas only dialkenylation can be achieved 
in tBuOH. The directing group can easily be removed at ambient temperature in the presence of 
Raney nickel (Scheme 33). Notably, the double C–H bond functionalization of alkenes could not 
be preserved under these conditions, thus providing o-tolylpropanoates 94, which are also 
important substrates in organic synthesis. 
 
Scheme 33 Controllable (di)alkenylations of benzyl thioether 92 through rhodium-catalyzed C–H activation. 
 
So far, great progress has been achieved in transition metal-catalyzed oxidative alkenylations with 
different removable directing groups. These protocols usually use the σ-chelating directing groups, 
which lead to ortho-selectivity through the formation of conformationally rigid five- to 
seven-membered cyclic intermediates. Despite the broad utility of this approach, proximity-driven 
reactivity prevents the activation of remote C–H bonds. Subsequently, Yu
75a–d
 developed a 
template approach to activate remote meta C–H bonds of several different classes of substrates 
(Scheme 34). The detailed strategy was the installation of a linear “end-on” coordinative nitrile 
group which can be accommodated in a macrocyclic cyclophane-like pre-transitionstate, thus 
overcoming the inherent limitations of traditional directed ortho C–H activation. After the 
removal of the directing group, a series of 7-vinylquinoline derivates 100 and diacids 97, which 
                                                             
74 X. Zhang, Q. Zhu,Y. Zhang, Y. Li, Z.-J. Shi, Chem. Eur. J. 2013, 19, 11898–11903. 
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Scheme 34 Activation of remote meta C–H bonds assisted by an “end-on” template. 
1.4 Transition Metal-Catalyzed C–H Functionalizations Assisted by 
Bidentate Directing Groups 
As discussed above, chelation-assisted transition metal-catalyzed direct C–H functionalizations 
were considered to be an effective protocol for the formation of C–X (X = C, O, S, N, halides) 
bonds though a C–H cleavage. So far, a variety of heteroatom-containing directing groups such as 
pyridine, pyrimidine, oxazoline, amide, ester and ketone, were employed in these transformations. 
In this context, a number of catalytic systems aimed at C(sp
2
)–H bonds functionalizations of 
arenes and heteroarenes have been developed. Additionally, in several cases the benzylic C(sp
3
)–H 
bonds were also viable in these reactions.
76
 However, the number of more challenging 
functionalizations of unactivated C(sp
3
)–H bonds under these catalytic conditions still remains 
greatly limited.  
In 1993, van Koten
77
 and coworkers found that bidentate coordination limits the degree of 
freedom of the ligand around the coordination sphere of the metal thus allowing one to govern the 




)–H bond activation via five- or 
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Scheme 35 Palladium-catalyzed direct C(sp3)–H bonds arylation. 
 
Inspired by this study, in 2005, Daugulis
78
 realized and reported palladium-catalyzed direct 
C(sp
3
)–H bond arylations assisted by 8-aminoquinoline-derived bidentate directing group, which 
surmounts the limitations of monodentates. This new process based on C(sp
3
)–H activation allows 
for the β-arylation of carboxamides 101 (Scheme 35a) and γ-arylation of amine derivatives 104 
(Scheme 35b) to afford the corresponding products 103 and 106, respectively, in good yields. 
























                                                             
78 V. G. Zaitsev, D. Shabashov, O. Daugulis, J. Am. Chem. Soc. 2005, 127, 13154–13155. 
79 (a) S. Zhang, Q. Li, G. He, W. A. Nack, G. Chen, J. Am. Chem. Soc. 2015, 137, 531–539; (b) S. Zhang, G. He, 
W. A. Nack, Y. Zhao, Q. Li, G. Chen, J. Am. Chem. Soc. 2013, 135, 2124−2127; (c) Y. Zhao, G. Chen, Org. Lett. 
2011, 13, 4850–4853. 
80 (a) Y. Zhao, G. He, W. A. Nack, G. Chen, Org. Lett. 2012, 14, 2948−2951; (b) Y. Ano, M. Tobisu, N. Chatani, Org. 
Lett. 2012, 14, 354–357; (c) Y. Ano, M. Tobisu, N. Chatani, J. Am. Chem. Soc. 2011, 133, 12984–12986. 
81 (a) S. Zhang, G. He, Y. Zhao, K. Wright, W. A. Nack, G. Chen, J. Am. Chem. Soc. 2012, 134, 7313–7316; (b) R. 
K. Rit, M. R. Yadav, A. K. Sahoo, Org. Lett. 2012, 14, 3724–3727; (c) L. D. Tran, O. Daugulis, Angew. Chem. 
Int. Ed. 2012, 51, 5188–5191; (d) B. V. S. Reddy, L. R. Reddy, E. J. Corey, Org. Lett. 2006, 8, 3391–3394; (e) F. 
Gou, X. Wang, P. Huo, H. Bi, Z. Guan, Y. Liang, Org. Lett. 2009, 11, 5726–5729. 
82 (a) Y. He, C. Zhang, M. Fan, Z. Wu, D. Ma, Org. Lett. 2015, 17, 496–499; (b) G. He, Y. Zhao, S. Zhang, C. Lu, 
G. Chen. J. Am. Chem. Soc. 2012, 134, 3−6; (c) E. T. Nadres, O. Daugulis, J. Am. Chem.Soc. 2012, 134, 7−10.  
83 H. Kodama, T. Katutira, T. Nishida, T. Hino, K. Tsubata, 2001, Patent WO 2001083421A 








 catalysts were also found to be applicable in this bidentate-assisted catalytic 
system, meanwhile, variety of bidentate directing groups were introduced for this C–H 
functionalization (Scheme 36). 
 
 
Scheme 36 Representative bidentate directing groups developed in recent years. 
 
In 2014, Ackermann and coworkers
89
 found easily accessible 1,2,3-triazoles 107 which are 
available in a modular fashion can also serve as the bidentate directing group for the 
iron-catalyzed arylation reactions. With this catalytic system, benzamides substrates bearing 
differently substituted groups direct transformed efficiently under a considerably mild reaction 
conditions. Importantly, alkenylic substrate was also compatiable and delivering the 
thermodynamically less-stable Z-olefin as the sole product. It is noteworthy that the user-friendly 
iron catalyst was not limited to C(sp
2
)–H arylations of arenes, but also enabled more challenging 
C(sp
3
)–H functionalizations (Scheme 37).  
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Scheme 37 Iron-catalyzed C–H arylations directed by TAM. 
 




)–H alkylations achieved in high yields with 
broad substrate scope, these transformations inolve using of expensive diphosphine ligand, 
stoichiometric amounts of sacrificial oxidants which make this reaction not in a economically 
fashion. What’s more, the using of highly reactive Grignard reagents as the arylating reagent led a 
lower functional group tolerance. Therefore, Ackermann’s group
90
 developed 
ruthenium-catalyzed alkylations with the TAM (triazolyldimethylmethyl) directing groups. The 
ruthenium(II) catalyzed C–H functionalization protocol was applicable to user-friendly aryl 
bromides as the arylating reagents under mild reaction conditions which allowed chemoselective 
C–H arylations of TAM amides bearing variety of functional groups (Scheme 38). 
 
Scheme 38 Ruthenium-catalyzed arylations directed by TAM. 
  
Very recently, Daugulis and coworkers reported on the cobalt(II)-catalyzed alkyne annulations 
assisted by bidentate directing group in the presence of Mn(OAc)2 as the oxidant (Scheme 39).
91
 
Electron-rich or electron-poor, amides 110 were efficiently annulated, and a large variety of 
alkynes could be employed. Additionally, heteroarene-substituted amides 11 were also suitable in 
this cobalt catalyzed system. It is noteworthy that terminal alkynes 11 were reactive and gave the 
product in good yields with excellent chemo- and regioselectivity. 
 
Scheme 39 Cobalt-catalyzed oxidative alkyne annulations of amides 110. 
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Shortly thereafter, the same research group extended the scope of this reaction to alkenylations 
using an analogous method.
92
 These transformations proceeded efficiently at ambient temperature 
with good functional groups tolerance. Importantly, unactivated alkenes such as ethylene and 
cyclopentene were also reactive in this reaction (Scheme 40). 
 
Scheme 40 Cobalt-catalyzed oxidative alkenylations of amides 110. 
1.5 Transition Metal-Catalyzed Benzophosphole Syntheses 
Phosphorus-containing heterocycles represent important structural building blocks in organic 
synthesis, medicinal chemistry, and material science.
93
 They have been found widespread 
applications ranging from ligands in transition metal complexes
94
 to organic semiconductor 
devices in material science.
95
 Particularly, benzophosphole derivatives have been extensively 
studied because of their unique optical and electronic properties. Representative examples of 
useful benzophospholes include n-type molecular material di(benzo[b]phosphole oxide)benzene 
(DBPOB, 113), electron-transporting material (ETM) di(benzo[b]phosphole) sulfide(DBPSB, 
114)
96
 and highly luminescent π-conjugated materials 115.
97
 Therefore, there is a continued 
strong demand for chemo-and site-selective syntheses of this heteroaromatic scaffold. 
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Scheme 41 Selected functional material structures of benzophosphole derivatives. 
 
In 1971, Mislow and coworkers
98
 reported the first route for the synthesis of benzophospholes 
117. However, this multistep method not only involved metalation of a P–X bond with a 
stoichiometric amount of organolithium or organomagnesium species, but also delivered the 









developed several similar protocols for the synthesis of decorated benzophospholes 117 consisting 
of the cyclization of diphenylphosphinoxides 116 or diphenylphosphines 118 with alkynyl groups 
preinstalled in the ortho position (Scheme 42). However, these cyclization reactions were 
performed under strongly basic reaction conditions which reduced the functional group tolerance. 
 
Scheme 42 Preparation of benzophospholes 117 under strong basic conditions. 
 
In order to address these drawbacks, Tanaka’s group
103
 developed a rhodium-catalyzed 
asymmetric synthesis of benzopyrano- or naphthopyrano-fused helical phosphafluorenes via 
double [2+2+2] cycloaddition of dialkynyl phosphorus compounds 119 with phenol- or 
naphthol-linked tetraynes 120 (Scheme 43). These reactions proceeded in CH2Cl2 at ambient 
temperature to give the product in acceptable yield with good enantioselectivities. Importantly, the 
phosphafluorene compounds possess special photophysical properties which can be potentially 
applied to organic semiconducting material. 
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 developed a new protocol for the synthesis of dibenzophosphole 
oxides catalyzed by palladium (Scheme 44). This reaction successfully transformed P–H and C–H 
bond via intramolecular dehydrogenative cyclization under mild reaction conditions, which 
tolerated a wide range of functional groups. Especially, the chloride- and thiophene-substituted 
substrates were also compatible under this catalytic system and afforded the desired products in 
high yields. Additionally, more complicated molecules such as ladder-type dibenzophosphole 
oxides 122 were synthesized using this method. 
 
Scheme 44 Palladium-catalyzed intramolecular dehydrogenative cyclization reactions. 
 
Encouraged by Takai’s study, Nozaki
105
 reported on palladium-catalyzed intramolecular arylation 
reaction of phosphine triflate 123. After the final oxidation with H2O2 at ambient temperature, the 
desired dibenzophosphole products were obtained in high yields (Scheme 45). It is noteworthy 
that the λ
5
-phospha[7]helicenes 117 obtained by this method exhibited unique packing structure.  
Scheme 45 Synthesis of λ5-phospha[7]helicenes 117. 
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However, the instability of the hydrophosphine group in 123 limited the applicability of this 
method towards the synthesis of more complicateds compound. Thus, this method needs 
considerable improvement. In this context, in 2013, Chatani
106
 reported the palladium-catalyzed 
direct synthesis of phosphole derivatives from stable triarylphosphines 125 through cleavage of 
C–H and C–P bonds (Scheme 46). A wide range of substrates bearing ether, amine, ketone, ester, 
nitrile, and fluoride substituents worked very well in this reaction. Particularly, the chlorides and 
bromides were also well tolerated, thus can serve as handles for further structural modification of 
the useful phosphole skeleton 117. 
 
Scheme 46 Palladium-catalyzed direct synthesis of phosphole derivatives from triarylphosphines 125. 
 
.
                                                             





During recent years, remarkable progress was achieved in transition metal-catalyzed C−H bond 
functionalization. Among such methods, oxidative C−H bond functionalizations are particularly 
attractive because they bypass the need for preactivated reaction partners. For example, oxidative 
annulations that involve sequential C−H and Het−H bond cleavages allow for the modular 
assembly of regioselectively decorated heterocycles. These structures are key motifs of natural 
products, functional materials and pharmaceutical drugs.
107
 Whereas other researchers have 
devised relatively expensive palladium or rhodium
54v, 108
 complexes for oxidative alkyne 
annulations, this project focused on the application of significantly less expensive, yet robust 
ruthenium complexes. 
Rhodium-catalyzed oxidative alkyne annulation with pyrazoles has been reported in 2011.
109
 
Undesired heavy metal salt as by-product resulted from stoichimetric amounts of copper(II) salt as 
the sacrificial oxidant, which made this catalytic system to work not in an atom economical 
fashion. Importantly, that attempts to activate heteroaryl C−H bonds by rhodium(III) catalyst only 
resulted in low yields. Therefore, we became interested in ruthenium-catalyzed oxidative alkyne 
annulations with substituted 1H-pyrazoles 126 (Scheme 47). 
 
Scheme 47 Ruthenium-catalyzed oxidative annulations with substituted pyrazoles 126. 
 
As mentioned above, transition metal-catalyzed alkenylations of arenes became an attractive tool 
for the preparation of styrene derivatives. Prompted by the results on rhodium-catalyzed oxidative 
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alkenylations of arenes assisted by sulfonic acid directing group,
110 
we explored the alternative 
ruthenium-catalyzed alkenylations with arylsulfonic acids 128, which also expanded the synthetic 
utility of ruthenium catalytic systems.
111
 These reactions were carried out by using 
Cu(OAc)2·H2O as oxidant in DMA or DMF as a solvent (Scheme 48).  
 
Scheme 48 Ruthenium-catalyzed oxidative alkenylations with substituted 2-arylsulfonic acids 128. 
 
In the transition metal-catalyzed alkenylations, directing groups were usually introduced to 
achieve site-selective C–H functionalization.
54
 However, the commonly applied directing groups 
are usually difficult to remove or modify under mild conditions. Herein, we devised 
ruthenium-catalyzed oxidative alkenylations with 2-aryloxypyridines 130
112a–c
 as a preparative 
approach to the synthetically valuable alkenylated phenols 78
112d,e
 in the third part of this work. 
 
Scheme 49 Ruthenium-catalyzed oxidative alkenylations with substituted 2-aryloxypyridines 130. 
 
The last few decades have witnessed significant progress in the area of transition metal-catalyzed 
C−H bond functionalization. However, most of the catalytic processes employ scarce second-row 
transition metal catalysts. The development of catalysts based on earth-abundant first-row 
transition metals that allow mild C−H functionalization are still in challenge.
1c, 113
 Thus, we 
became attracted by cobalt-catalyzed C–H/N–H functionalization reactions of substituted 
benzamides 110 with activated alkenes 46 (Scheme 50).  
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Scheme 50 Cobalt-catalyzed oxidative functionalizations with benzamides 110. 
 
The preparation of benzophosphole derivatives 117 mainly relied on the cyclization of 
phenylphosphoric compounds with alkynyl groups being preinstalled in the ortho position. 
However, these precursors are usually synthesized through complicated multistep preparations. 
Therefore, the silver-mediated C–H/P–H bonds functionalization reactions of substituted 
phosphine oxides 121 with alkynes 11 could be the most ideal strategy for the convenient 
benzo[b]phosphole oxide synthesis (Scheme 51). 
 
Scheme 51 Silver-mediated alkyne annulation with substituted phosphinates and aryl-substituted SPOs. 
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Result and Discussion 
3 Ruthenium (II)-Catalyzed Alkyne Annulation with 
Aryl-substituted 1H-Pyrazoles by C–H/N–H Functionalizations 
Pyrazole derivatives are an important class of compounds, because of their wide applications in 
organic synthesis, pharmaceutical chemistry and material science. Especially they play an 
important role in organometallic chemistry and in catalysis as they have been employed as 
precursors for N-heterocyclic carbenes.
114
 Several synthetic methodologies for the construction of 
these pyrazole derivatives have been developed in the past decades, particularly, reactions that 
involve the sequential functionalization of C–H and N–H bonds. Unfortunately, as of yet these 
transformations have mostly relied on the use of rhodium complexes. Conversely, significantly 
less expensive ruthenium(II) complexes were only very recently identified as catalysts for 
alkenylations and annulations via oxidative C–H bond functionalizations. 
3.1. Optimization Studies 
Initially, we chose 5-arylpyrazole 126a and diphenylacetylene (11a) as model substrates to 
optimize the reaction conditions (Table 1). The results summarized in entries 1–8 showed that the 
reaction was most efficient with AgSbF6 as an additive, giving the desired product in 78% yield 
(entry 8). The carboxylate additives such as NaOAc, MesCO2K CsOAc were not effective, and 
only gave the product in low yield. We were pleased to find that nearly the same yield can be 
obtained by using 1.0 equivalence of Cu(OAc)·H2O in the presence of air (entry 9). Likewise, the 
desired oxidative annulation was not accomplished with CuBr2 in lieu of Cu(OAc)2·H2O as the 
terminal oxidant, thereby indicating the importance of carboxylate assistance (entry 10). Upon 
further screening of a variety of protic and aprotic solvents, DCE was identified as being the 
optimal reaction medium, whereas tAmOH only afforded the desired product in a moderate yield 
(entries 12
_
17). Control experiments showed that the catalytic reaction was completely inactive in 
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Table 1 Optimization of oxidative annulation with pyrazole 126aa 
 
 
Entry Additive Solvent T (°C) Yield (%) 
1 − DCE 100 13 
2 NaOAc DCE 100 19 
3 CsOAc DCE 100 6 
4 KO2CMes DCE 100 16 
5 KPF6 DCE 100 30 
6 AgSO3CF3 DCE 100 38 
7 AgBF4 DCE 100 46 
8 AgSbF6 DCE 100 78 
9 AgSbF6 DCE 100 77
b
 
10 AgSbF6 DCE 100 0
c
 
11 AgSbF6 DCE 100 0
d
 
12 AgSbF6 NMP 120 0 
13 AgSbF6 t-AmOH 120 41 
14 AgSbF6 o-xylene 120 12 
15 AgSbF6 1,4-dioxane 120 17 
16 AgSbF6 DMF 120 0 
17 AgSbF6 H2O 120 13 
a Reaction conditions: 126a (0.5 mmol), 11a (1.0 mmol), Cu(OAc)2·H2O (1.0 mmol), 
[RuCl2(p-cymene)]2 (5.0 mol %), solvent (2.0 mL), additive (20 mol %); isolated yields. 
b 1.0 equiv 
of oxidant. c CuBr2 as oxidant. 
d No catalyst. 
3.2 Scope of the Ruthenium-Catalyzed Oxidative Alkyne Annulations 
3.2.1 Ruthenium-Catalyzed Annulations with Arylsubstituted Pyrazoles 
With the optimized catalytic system in hand, the reaction scope with respect to arylpyrazole 126 
was investigated by using diphenylactylene (11a) as the standard coupling partner. To our delight, 
the catalyst was widely applicable, and thus, proved to be tolerant of various important functional 
groups (Table 2). Regardless of the electron-rich groups such as metoxy and amino (entries 6 and 
8) or the electron-withdrawing groups, such as nitro-, trifluoro-, chloro- or cyano-substituted 
substrates (entries 1–4), in the para position of the 5-arylpyrazoles 126, all of the annulations gave 
the anticipated results with good to excellent yields. On the other hand, arenes bearing 
electron-withdrawing substituents were found to be significantly more reactive. The oxidative 
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functionalizations of meta-substituted arenes 126i and 126j proceeded with excellent site 
selectivities at the less sterically encumbered C−H bond (entries 9 and 10). However, 
ortho-substituted substrates, such as compound 126k, were not compatible in this reaction (entry 
11). The cationic ruthenium(II) catalyst was not restricted to the use of aryl-substituted pyrazole 
derivatives, but efficiently converted heteroaromatic pyrazole (126l) as well (entry 12). 
Importantly, employment of rather expensive rhodium(III) catalyst in these annulations only 
resulted in unsatisfactory low yields. 
Table 2 Oxidative annulation of diphenylacetylene 11a with pyrazoles 126aa 
 





























































































a Reaction conditions: 126 (0.50 mmol), 11a (1.00 mmol), Cu(OAc)2·H2O (1.00 mmol), 
[RuCl2(p-cymene)]2 (5.0 mol %), DCE (2.0 mL), and AgSbF6 (20 mol %); isolated yields. 
 
3.2.2 Scope of the Annulation with Different Alkynes 
Thereafter, we probed different tolane derivatives 11 in the oxidative annulation reactions. Thus, 
Ruthenium-Catalyzed Oxidative Alkyne Annulations 
38 
 
electron-rich groups such as methoxyl (11c) and electron-deficient ones such as fluoro (11d), 
chloro (11e), and ester (11g), diphenylacetylences reacted with pyrazole 126a smoothly to afford 
the corresponding product 127ac, 127ad, 127ae and 127ag, respectively, in good yields (entries 
2–4, 6). However, methyl- and bromo-decorated tolanes 11b and 11f were less efficiently 
converted and gave only moderate yields (entries 1 and 5). Additionally, the ruthenium catalyst 
was not limited to the use of tolane derivatives but was also found to be applicable to aliphatic 
alkynes, such as oct-4-yne (11h). Treatment of these aliphatic alkynes with differently decorated 
pyrazoles afforded the annulation products in 46–65% yield (entries 7–10). Unsymmetrically 
substituted alkynes 11i–11k displayed good regioselectivities, thereby furnishing the products 
127ai–127ak and 127dj in high isolated yields (entries 11–14). 
 
Table 3 Scope of oxidative annulations of alkynes 11 with pyrazoles 126 
 
 








































































































































































































a Reaction conditions: 126 (0.5 mmol), 11 (1.0 mmol), Cu(OAc)2·H2O (1.0 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), 
DCE (2.0 mL) and AgSbF6 (20 mol %); isolated yields. 
 
3.3 Mechanistic Studies 
3.3.1 Intermolecular Competition Experiments 
Given the remarkable catalytic activity of the ruthenium(II) catalyst, its mode of action was also 
studied in detail. To this end, intermolecular competition experiments between two different 
substituted arylpyrazoles showed that the electron-deficient substrate 126a was more reactive than 
the electron-rich one 126f (Scheme 52a), in contrast to the recently reported rhodium-catalyzed 
annulation process.
109
 Competition experiments between differently decorated alkynes highlighted 
alkyl alkyne 11h to be less reactive than aryl alkyne 11a (Scheme 52b), particularly when the 


















Scheme 52 Intermolecular competition experiments  
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3.3.2. Ruthenium-Catalyzed H/D Exchange Experiments 
For the better understanding of the mechanism, two deuteration experiments conducted with D2O 
as the cosolvent were carried out. The results of H/D scrambling in the annulation product 
[D]n-127aa (Scheme 53a) and pyrazole substrate [D]n-127a (Scheme 53b) indicated that the C–H 






Scheme 53 Oxidative annulations with D2O as the cosolvent. 
3.4 Proposed Catalytic Cycle 
Based on our mechanistic studies, the following catalytic cycle for the ruthenium(II)-catalyzed 
aerobic annulations is proposed (Scheme 54). Initially, the chloride ligands in the complex 




 ones through interaction with AgSbF6 
assisted by of Cu(OAc)2·H2O to generate the cationic ruthenium(II) complex 17. The unique 
activity of 17 allowed it to react with arylpyrazole 126 to form five-membered intermediate 133 
through a reversible metalation process. Thereafter, alkyne coordination and a subsequent 
migratory insertion furnished a seven-membered ruthenacycle 135 through the intermediate 134. 
The formed complex 135 would then undergo reductive elimination to deliver the desired product 
127 and a ruthenium(0) species 16. Finally, the active ruthenium complex can be regenerated via a 
reoxidation process. 
 




Scheme 54 Proposed catalytic cycle. 
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4. Ruthenium(II)-Catalyzed C–H Bond Alkenylation of Arenes 
4.1 Ruthenium(II)-Catalyzed Oxidative C–H Alkenylation with 
Substituted Benzenesulfonic Acids 
Aromatic sulfonic acid derivatives represent an important class of structural constituents in 
biologically active compounds, such as pharmaceuticals and agrochemicals, and also serve as 
building blocks for natural products and pharmaceutical synthesis.
115
 Furthermore, due to the 
hydrophilicity of sulfonic acid and sulfone group, they were widely used in the modification of 
drug basic skeleton. Therefore, the preparation of compound containing benzenesulfonic acid 
moieties is of continued strong interest. Particularly, transition metal-catalyzed direct C–H bond 
transformations are highly attractive because of their ideal step economy.
1r
 Previous reported 
studies on alkenylations with sulfonic acids as directing groups employed rhodium complexes. 
However, the use of less expensive ruthenium catalysts for sulfonic acid group directed C–H bond 
activation has, thus far, proven to be elusive. 
4.1.1 Optimization Studies 
We commenced our studies by exploring the effect of representative co-catalytic additives, 
solvents and ruthenium precursors for the proposed twofold C–H bond functionalizations. The 
alkenylation of substituted benzenesulfonic acid 128a was carried out at 120 °C in the presence of 
Cu(OAc)2·H2O (2.0 equiv) in DMA under N2 and gave the desired product 129ab in 43% yield 
(Table 4, entry 1). A set of representative additives was subsequently probed, and AgSbF6 was 
identified as being optimal (entries 2−8). Among various solvents, the desired C−H bond 
functionalization occurred most efficiently in polar aprotic solvents such as DMF and NMP, 
affording product 129ab in 70% and 85% yield, respectively (entries 9 and 15). Upon employing 
RuCl3, [RuCl2(PPh3)3] and [Ru(O2CMes)2(p-cymene)] as catalysts (entries 17−19) as well as 
without ruthenium complex (entry 16), no product or only trace amounts were obtained. Notably, 
the use of CuBr2 as the oxidant did not deliver the desired product (entry 20), thereby indicating 
carboxylate assistance to be of key relevance. It is noteworthy that the yield decreased when the 
                                                             
115 (a) J. Wrobel, D. Green, J. Jetter, W. Kao, J. Rogers, M. C. Pe′rez, J. Hardenburg, D. C. Deecher, F. J. Lo′pez, 
B. J. Arey and E. S. Shen, Bioorg. Med. Chem., 2002, 10, 639–656; (b) L. Zhuang, J. S. Wai, M. W. Embrey, T. 
E. Fisher, M. S. Egbertson, L. S. Payne, J. P. Guare Jr., J. P. Vacca, D. J. Hazuda, P. J. Felock, A. L. Wolfe, K. 
A. Stillmock, M. V. Witmer, G. Moyer, W. A. Schleif, L. J. Gabryelski, Y. M. Leonard, J. J. Lynch Jr., S. R. 
Michelson, S. D. Young, J. Med. Chem., 2003, 46, 447–453. 
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reaction was performed at lower temperature (entry 21) or under air (entry 22). 
 
Table 4 Optimization of oxidative alkenylation of 128a with sulfonic acid 46ba 
 
Entry Solvent Additive cat.[Ru] Yield (%) 
1 DMA --- [RuCl2(p-cymene)]2 43 
2 DMA MesCOOK [RuCl2(p-cymene)]2 56 
3 DMA KPF6 [RuCl2(p-cymene)]2 60 
4 DMA NaOAc [RuCl2(p-cymene)]2 56 
5 DMA AgSO3CF3 [RuCl2(p-cymene)]2 52 
6 DMA AgPF6 [RuCl2(p-cymene)]2 58 
7 DMA AgBF4 [RuCl2(p-cymene)]2 56 
8 DMA AgSbF6 [RuCl2(p-cymene)]2 91 
9 DMF AgSbF6 [RuCl2(p-cymene)]2 70 
10 DCE AgSbF6 [RuCl2(p-cymene)]2 trace 
11 tAmOH AgSbF6 [RuCl2(p-cymene)]2 trace 
12 1,4-dioxane AgSbF6 [RuCl2(p-cymene)]2 trace 
13 H2O AgSbF6 [RuCl2(p-cymene)]2 trace 
14 PhMe AgSbF6 [RuCl2(p-cymene)]2 trace 
15 NMP AgSbF6 [RuCl2(p-cymene)]2 85 
16 DMA AgSbF6 ---  0
b
 
17 DMA AgSbF6 RuCl3 0 
18 DMA AgSbF6 [Ru(O2CMes)2(p-cymene)] trace 
19 DMA AgSbF6 [RuCl2(PPh3)2] trace 
20 DMA AgSbF6 [RuCl2(p-cymene)]2  0
c
 
21 DMA AgSbF6 [RuCl2(p-cymene)]2 85
d
 
22 DMA AgSbF6 [RuCl2(p-cymene)]2 59
e
 
23 DMA AgSbF6 [RuCl2(p-cymene)]2 48
f
 
a Reaction conditions: 128a (0.50 mmol), 46b (1.50 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), 
additive (20 mol %), Cu(OAc)2·H2O (1.0 mmol), solvent (2.0 mL), 120 °C, 16 h, under N2; isolated 
yield. b Without catalyst. c CuBr2 as oxidant. 
d 100 °C. e Under air. f 2.5 mol % catalyst. 
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4.1.2. Scope and Limitations 
With the optimized conditions in hand, we explored the scope of alkenylations with differently 
substituted benzenesulfonic acids 128 (Table 5). The cationic ruthenium(II) precatalyst proved to 
be broadly applicable, as both electron-deficient (entries 2, 3 and 8) as well as electron-rich 
benzenesulfonic acids (entry 5) were found to be suitable substrates and delivered the 
corresponding alkenylated products 129 in high yields with excellent E-diastereoselectivities. 
Notably, when we employed 2,5-dimethoxybenzenesulfonic acid (128f) as the substrate (entry 6), 
the reaction successfully provided the product 129fb in 72% yield as a mixture of two 
diastereomers (E:Z = 2.3:1). If the substrate altered to p-toluenesulfonic acid (128j), only 
monoalkenylated product 129jb was obtained (entry 10). To examine the regioselectivity, 
meta-substituted substrate 128k was tested, and the sole product 128kb was obtained in high yield 
(entry 11). This indicated the selectivity of this conversion to be strongly influenced by steric 
interactions. 
Table 5 Scope of oxidative alkenylations of substituted benzenesulfonic acids 128a 
 
































































a Reaction conditions: 128 (0.50 mmol), 46b (1.50 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), AgSbF6 (20 mol %), 
Cu(OAc)2·H2O (1.0 mmol), solvent (2.0 mL), 120°C, 16 h, under N2; isolated yield. 
b 128:46b = 2:1. 
 
We then investigated the scope of alkenes 46 that can be used for the ruthenium-catalyzed ortho- 
alkenylation reaction (Table 6). A variety of alkenes appeared to be suitable substrates for this C–
H bond activation. When n-butyl acrylate (46c) (entry 2), benzyl acrylate (46d) (entry 3), methyl 
vinyl ketone (46f) (entry 5), (vinylsulfonyl)benzene (46g) (entry 6), acrylonitrile (46h) (entry 7) 
and diethyl vinylphosphonate (46i) (entry 8) were used in this reaction, and the corresponding 
products were obtained in excellent isolated yields. However, the ethyl methacrylate (46e) (entry 4) 
as well as 2-vinylpyridine (46o) (entry 14) were not compatible in this reaction. To our delight, 
electron-poor styrenes such as 1,2,3,4,5-pentafluoro-6-vinylbenzene (46l) (entry 11), 
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1-fluoro-4-vinylbenzene (46m) (entry 12) or 1-fluoro-2-vinylbenzene (46n) (entry 13) reacted 
with 2,4-dimethylbenzenesulfonic acid (128l) to afford the corresponding olefinated sulfonic acid 
derivatives 129ll–129ln in good to excellent yields. 2-Vinylnaphthalene (46k) was also found to 
be a good olefin substrate under the tested reaction conditions (entry 10), whereas the reactivity of 
styrene (46j) (entry 9) was lower.  
 
Table 6 Scope of oxidative alkenylations with different alkenes 46a 
 





R = Et (129lb) 85 
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R = nBu (129lc) 78 
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a Reaction conditions: 126l (0.50 mmol), 46 (1.50 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), AgSbF6 (20 
mol %), Cu(OAc)2·H2O (1.0 mmol), DMA (2.0 mL), 120 °C, 16 h, under N2; isolated yield. 
b 100 °C, 
DMF. c AgSbF6. (40 mol %) 
 
Notably, 4-methylbenzenesulfonyl chloride (136) and methyl benzenesulfonate (137) also 
performed in this oxidative alkenylations very well and afforded the olefinated sulfonic acids 
129jb and 129ib in good yields (Scheme 55a). In the latter case, the bisalkenylated product 129jb’ 
was obtained as well, albeit in low yield (Scheme 55b). 







Scheme 55 Ruthenium-catalyzed oxidative alkenylations with substrates 136 and 137. 
4.1.3 Mechanistic studies 
4.1.3.1 Intermocular Competition Experiment 
Given the remarkable catalytic activity of the cationic ruthenium(II) complex, we initiated 
mechanistic studies to unravel its mode of action. To this end, we performed intermolecular 
competition experiment between differently substituted arenes 128l and 128h which revealed 
electron-rich aromatic sulfonic acid 128l to be preferentially converted (Scheme 56). 
 
 
Scheme 56 Competition experiment between arene sulfonic acids 128l and 128h. 
4.1.3.2 Ruthenium-Catalyzed H/D Exchange Experiment 
Further experimental support to provide the mechanistic rationale was obtained from oxidative 
alkenylations with D2O as a cosolvent. The results indicated a significant H/D scrambling in the 
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ortho positions of the reisolated substrate [D]n-128j and in the product [D]n-129jb. 
 
 
Scheme 57 Oxidative alkenylations with D2O as the cosolvent. 
4.1.4 Proposed Catalytic Cycle 
Based on these mechanistic experiments and on the results of previously reported studies, we 
proposed a plausible catalytic cycle (Scheme 58). Initially, the [RuCl2(p-cymene)]2 species reacted 
with AgSbF6 and Cu(OAc)2·H2O to form a cationic ruthenium(II) complex 17. After coordination, 
reversible cyclometalation through a base-assisted internal electrophilic substitution (BIES) gave 
five-membered ruthenium intermediate 138. Thereafter, coordination and insertion of the alkene 
46 into the Ru–C bond of the complex 138 provided the seven-membered species 139. Finally, 
acetate-initiated β-hydride elimination and released the desired product 129 and regenerated the 
catalytically active ruthenium(II) complex 17 for the next catalytic cycle. 
 
Scheme 58 Proposed mechanism for the alkenylation reaction. 
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4.2 Ruthenium(II)-Catalyzed C–H Bond Alkenylationof Arene 
Bearing Removable Directing Group 
In recent years, a number of directing groups for the C−H alkenylation reaction catalyzed by 
ruthenium complex have been developed. However, the transformation of these directing groups 
in a number of cases remains a major problem, whereas the methods that exploited removable 
directing groups are scarce. Therefore, we developed ruthenium-catalyzed twofold C−H 
functionalization with arenes and heteroarenes using easily cleavable pyridin-2-yloxy directing 
groups.  
4.2.1 Optimization Studies 
Initially, we selected 2-(o-tolyloxy)pyridine (130a) and ethyl acrylate (46b) as model substrates to 
screen the reaction conditions (Table 7). While carboxylate additives were found to be mandatory 
for ruthenium-catalyzed direct arylations with aryl halides,
116
 they proved to be ineffective for the 
desired oxidative C–H bond alkenylation of 130a (entries 1–3). To our delight, the coupled 
product 131ab was isolated in 83% yield when using AgSbF6 (20 mol %) as an additive in 
tAmOH (entry 5). Importantly, this alkenylation product was also obtained in 73% yield with 
cocatalytic amounts of Cu(OAc)2·H2O under an atmosphere of ambient air as the sacrificial 
oxidant (entry 6). Furthermore, control experiments verified that no desired product was observed 
in the absence of Cu(OAc)2·H2O or the ruthenium catalyst (entries 7 and 8). 
 
Table 7 Optimization of C−H bond alkenylation of substituted pyridine 130aa 
 
Entry Additive Cu(OAc)2.H2O Yield (%) 
1 KO2CMes 2.0 <5 
2 CsOAc 2.0 <5 
3 AgOAc 2.0 <5 
4 KPF6 2.0 25 
5 AgSbF6 2.0 83 
6 AgSbF6 0.3 73 
7 AgSbF6 -- 0 
8 AgSbF6 2.0 0
b
 
a Reaction conditions: 130a (1.0 mmol), 46b (0.5 mmol), Cu(OAc)2·H2O (1.0 mmol), 
[RuCl2(p-cymene)]2 (2.5 mol %), tAmOH (2.0 mL), AgSbF6 (10 mol %); isolated yields. 
b Without [RuCl2(p-cymene)]2. 
                                                             
116 L. Ackermann, E. Diers, A. Manvar, Org. Lett. 2012, 14, 1154–1157. 
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4.2.2 Scope and Limitations of the Ruthenium-Catalyzed Oxidative 
Alkenylations 
With the optimized conditions in hand, we explored the versatility of this monoalkenylation 
reaction (Table 8). Gratifyingly, substrates with both electron-donating (entries 1–5, 12–16) and 
electron-withdrawing substituents (entries 6–11) at the ortho position of the phenyl ring were 
viable and furnished the desired products 131 in high isolated yields, thus indicating the general 
applicability of phenoxylpyridine substrates 130. Notably, halogen substituents at the ortho 
position of the phenyl ring in substrates 130c and 130d were also tolerated under this catalytic 
system (entry 9). This could provide a versatile synthetic handle for further functionalization of 
the products 130db. Furthermore, oxidative alkenylations with α- and β-naphthol derivatives 130h 
and 130i, respectively, delivered the desired alkenylated products with excellent site selectivities 
(entries 17–21). In contrast, 2-(cyclohex-1-en-1-yloxy)pyridine (130j) decomposed under this 
reaction condition, thus led no desired product. Importantly, the catalytic C−H bond 
functionalizations occurred with excellent diastereoselectivities, delivering the E diastereomers as 
the sole products in all cases. 
Table 8 Scope of oxidative alkenylation with arenes (130)a 
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R2 = Et (131cb) 
 
81 
7 46p R2 = tBu (131cp) 87 
8 46d R2 = Bn (131cd) 92 


























































R2 = Et (131gb) 
 
76 
15 46p R2 = tBu (131gp) 75 





R2 = Et (131hb) 76 










































aReaction conditions: 130 (1.0 mmol), 46 (0.5 mmol), Cu(OAc)2·H2O (1.0 mmol), [RuCl2(p-cymene)]2 (2.5 mol 
%), tAmOH (2.0 mL), AgSbF6 (10 mol %); isolated yields. 
 
Moreover, this catalytic system could not only be applied in substrates bearing ortho substituents, 
but also various of phenol derivatives with para substitution provided the mono-alkenylated 
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products 131 in good yields with good chemo- and site- selectivities as well (Table 9). Notably, 
starting materials with both electron-donating and -withdrawing groups, including methoxy (130k) 
(entry 1) and important electrophilic functional groups, such as chloro (130l), ester (130o), ketone 
(130p), or nitro (130q) substituents (entries 3, 7–9), were well tolerated under this catalytic 
conditions. However, cyano group (130r) was not compatible in this reaction, probably as a result 
of the competitive coordination of the cyano group to the metal center, thus inhibiting the C–H 
activation. In addition, this C–H bond alkenylation was also readily feasible in compound 130s 
with substituted pyridine ring (entries 11 and 12). 
Table 9 Scope of oxidative alkenylations with substituted substrates 130a 
 



























































































































R2 = tBu (131sp) 
 
76 
a Reaction conditions: 130 (1.0 mmol), 46 (0.5 mmol), Cu(OAc)2·H2O (1.0 mmol), [RuCl2(p-cymene)]2 (2.5–5 
mol %), tAmOH (2.0 mL), AgSbF6 (10–20 mol %); isolated yields. 
 
Furthermore, it was delighted to observe that heteroarenes proved to be suitable substrates as well, 
delivering the synthetically useful indole 131tb (Scheme 59a) and thiophene 131ub (Scheme 59b). 
However, the benzo[b]thiophene 130v with a pyridin-2-yloxy directing group was less compatible 



















Scheme 59 Scope of oxidative alkenylation with heterocyclic substrates. 
 
The site-selectivity of the oxidative C–H bond functionalization with meta-substituted phenol 
derivatives 130w and 130x was largely controlled by steric interactions, thus delivering the 
alkenylated products 131wb, 131wp and 131xb in good yields (Table 10, entries 1–3). In contrast, 
the substrate 130y reacted with alkenes 46b and 46p affording the alkenylated products 131yb and 
131yp on the more sterically hindered position, most probably as a result of a notable secondary 
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Table 10 Oxidative alkenylations with meta-substituted substratesa 
 

















































 = tBu (131yp) 
 
79 
a Reaction conditions: 130 (1.0 mmol), 46 (0.5 mmol), Cu(OAc)2·H2O (1.0 mmol), [RuCl2(p-cymene)]2 (2.5 
mol %), AgSbF6 (10 mol %), tAmOH (2.0 mL); isolated yields. 
 
Replacement of the oxygen between the pyridine and the aryl rings in substrate 130 with 
methylene (as in benzylpyridine 140) or amino moieties (as in compounds 143 and 144) 
completely inhibited the C–H functionalizations (Scheme 60). The same effect was observed upon 
changing the pyridine directing group with a pyrimidine (substrate 142) or quinoline (compound 
141) ones. Besides, unactivated simple alkenes such as cyclohexene (50b) and styrene (46j) were 
not compatible in this reaction. Acrylonitrile (46h), ethyl (E)-but-2-enoate (46p) and but-3-en-2-ol 
(46q) were also not efficient coupling partners, as they delivered the corresponding products with 
low conversions (Scheme 60). 





Scheme 60 Substrates with limited activity towards the alkenylation process. 
4.2.3 Removal of the directing group 
Furthermore, we were delighted to find that the directing group could easily be removed from 
pyridin-2-yloxycinnamate 131ab employing the previously published protocol,
116 thereby yielding 
the desired free phenol 71a in high yield (Scheme 61). 
 
Scheme 61 Removal of the directing group 
4.2.4 Mechanistic Studies 
4.2.4.1. Intermolecular Competition Experiments 
Given the remarkable catalytic activity of the cationic ruthenium(II) complex, we initiated 
mechanistic studies to elucidate its mode of action. To this end, we performed intermolecular 
competition experiments between electron-rich (130a and 130k) and electron-deficient (130c and 
130n) substrates. The results of this study revealed the electron-rich substrates 130a versus 130c 












Scheme 62 Intermolecular competition experiments 
4.2.4.2 H/D Exchange Experiment 
Mechanistic studies on the oxidative alkenylations in the presence of D2O as a cosolvent showed a 
significant H/D scrambling in the ortho positions of the reisolated substrate [Dn]-130k as well as 
of the product [D]n-131kb, thus indicating the reversible nature of a C–H ruthenation step 
(Scheme 63). 




Scheme 63 Oxidative alkenylation with D2O as the cosolvent. 
 
4.2.5 Proposed Catalytic Cycle 
Based on these studies and literature precedence, we proposed the C–H bond activation to occur 
by a reversible electrophilic-type metalation event (Scheme 64). The catalytic cycle is likely 
initiated by the removal of chloride from [RuCl2(p-cymene)]2, followed by a reversible C–H bond 
insertion directed by the nitrogen atom of the pyridine moiety. The formed six-membered 
cycloruthenated complex 145 subsequently underwent a migratory insertion with the alkene 46 to 
furnish the intermediate 146. Finally, β-hydride elimination yielded the desired product 131, 
whereas reductive elimination and oxidation by Cu(OAc)2·H2O regenerated the catalytically 
active ruthenium(II) complex 17. 
 
Scheme 64 Proposed mechanism for the ruthenium(II)-catalyzed C–H alkenylations. 
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5. Cobalt(II)-Catalyzed Oxidative Annulation through C–H 
Alkenylations: Regio- and Site-Selective Access to 
Isoindolin-1-one 
Over the last decades, a vast majority of complexes of transition metals such as palladium, 
rhodium or ruthenium, have been developed and employed for catalyzed alkenylations, 
annulations, aminations and hydroxylations.
54y, 117
 However, high cost of these catalysts greatly 
limited their application in industry. Thus, the developments of catalysts based on earth-abundant 
first-row transition metals are valuable. 





 reported on cobalt-catalyzed intermolecular hydroarylation of alkynes. 
Pyridine, pyrimidine, ketimine and aldimine were employed as the directing group for these 
reactions at ambient temperature, and gave the styrene derivatives in good yields and high 
stereoselectivities. Ackermann’s group
120
 reported cobalt-catalyzed C–H arylation with organic 
electrophiles. However, employment of Grignard reagents was essential for these transformations 
which caused low functional groups tolerance. Daugulis
91
 reported cobalt-catalyzed alkyne 
annulation using 8-aminoquinoline-derived bidentate directing groups (Scheme 38). These 
reactions were performed under mild reaction conditions without using the Grignard reagent, thus 
enabling a wide range of substrates to be applied. Encouraged by this work, we became attracted 
to develop cobalt-catalyzed oxidative alkenylations with easily accessible 
N-(quinolin-8-yl)benzamides 110. 
5.1 Optimization Studies 
Initially, we examined the reaction conditions previously established by Daugulis for the 
cobalt-catalyzed oxidative alkenylations of 4-methyl-N-(quinolin-8-yl)benzamide (110a) and ethyl 
acrylate (46b). Unfortunately, no desired product was obtained (Table 11, entries 1–3). Further 
attempts showed that not the alkenylated, but the cyclic product isoindolin-1-one 132ab could be 
obtained in 37% yield in the presence of 20 mol% Co(OAc)2 and 2.0 equivalents of base using 
                                                             
117
 V. S. Thirunavukkarasu, S. I. Kozhushkov, L. Ackermann, Chem. Commun. 2014, 50, 29−39, and references 
cited therein. 
118 (a) S. Murahashi, J. Am. Chem. Soc. 1955, 77, 6403−6404; (b) A. C. Cope, R. W. Siekman, J. Am. Chem. Soc. 
1965, 87, 3272−3273. 
119 (a) K. Gao, P.-S. Lee, T. Fujita, N. Yoshikai, J. Am. Chem. Soc. 2010, 132, 12249−12251; (b) P. -S. Lee, T. 
Fujita, N. Yoshikai, J. Am. Chem. Soc. 2011, 133, 17283−17295; (c) Z. Ding, N. Yoshikai, Angew. Chem. Int. 
Ed. 2012, 51, 4698–4701. 
120
 (a) W. Song, L. Ackermann, Angew. Chem. Int. Ed. 2012, 51, 8251−8254; (b) B. Punji, W. Song, G. A. 
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Mn(OAc)2 as the oxidant in PEG 400 as the solvent at 100 °C for 18 h under air (entry 4). To our 
delight, among the tested solvents (entries 5–18) the mixture of PEG 400 and CF3CH2OH (4/1) 
proved to be optimal, affording the product 132ab in 60% yield. The oxidants such as AgOAc, 
AgCOCF3, AgNO3, AgCO3 and AgCO2Ad were not effective for this transformation furnishing 
only moderate yields of isoindolin-1-one132ab (entries 21–24, 26). AgOPiv turned out to be the 
most efficient oxidant and resulted in complete consumption of substrate 110a, yielding 
compound 132ab in 65% yield. Decreasing the temperature to 60 °C led to a lower yield (entry 
31). Interestingly, the absence of any base resulted in a higher yield (entry 33). Furthermore, 
additional experiments verified that the transformation did not proceed without oxidant or catalyst 
(entries 18 and 34). Therefore, the optimized conditions were ultimately identified as 20 mol % 
Co(OAc)2, 2.0 equivalents AgOPiv in a solvent mixture (PEG 400/CF3CH2OH = 4/1) at 100 °C 
under air (entry 34). 
 
Table 11 Optimization of C–H bond alkenylation of amide 110aa 
 
Entry cat.[Co] Solvent Oxidant Yield (%) 
1 [Cp*CoI2]2 CF3CH2OH Mn(OAc)2 <5
b
 
2 Co(acac)2 CF3CH2OH Mn(OAc)2 <5
b
 
3 Co(OAc)2 CF3CH2OH Mn(OAc)2 <5
b
 
4 Co(OAc)2 PEG 400 Mn(OAc)2 37 
5 Co(OAc)2 PEG 400 Mn(OAc)2 <5
b,c
 
6 Co(OAc)2 Toluene Mn(OAc)2 <5
b
 
7 Co(OAc)2 DMF Mn(OAc)2 <5
b
 
8 Co(OAc)2 DMSO Mn(OAc)2 0 
9 Co(OAc)2 1,4-dioxane Mn(OAc)2 0 
10 Co(OAc)2 PhCl Mn(OAc)2 0 
11 Co(OAc)2 PEG1000 Mn(OAc)2 <5
b
 
12 Co(OAc)2 DMPU Mn(OAc)2 <5
b
 
13 Co(OAc)2 DCE Mn(OAc)2 0 
14 Co(OAc)2 PEG 400/H2O (4/1) Mn(OAc)2 0 
15 Co(OAc)2 PEG 400/CF3CH2OH (4/1) Mn(OAc)2 60 
16 Co(OAc)2 glycerol Mn(OAc)2 0 
17 Co(OAc)2 ethylene glycol Mn(OAc)2 <5
b
 
18 --- PEG 400/CF3CH2OH (4/1) Mn(OAc)2 0 
19 Co(OAc)2 PEG 400/CF3CH2OH (4/1) Ag2SO4 39
b
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20 Co(OAc)2 PEG 400/CF3CH2OH (4/1) Ag2O 22 
21 Co(OAc)2 PEG 400/CF3CH2OH (4/1) AgNO3 61 
22 Co(OAc)2 PEG 400/CF3CH2OH (4/1) Ag2CO3 47 
23 Co(OAc)2 PEG 400/CF3CH2OH (4/1) AgOAc 48 
24 Co(OAc)2 PEG 400/CF3CH2OH (4/1) AgCOCF3 51 
25 Co(OAc)2 PEG 400/CF3CH2OH (4/1) AgOPiv 65 
26 Co(OAc)2 PEG400/CF3CH2OH (4/1) AgCO2Ad 59 
27 Co(OAc)2 PEG400/CF3CH2OH (4/1) Cu(OAc)2·H2O 0 
28 Co(OAc)2 PEG 400/CF3CH2OH (4/1) Zn(OAc)2 0 
29 Co(OAc)2 PEG400/CF3CH2OH (4/1) PhI(OAc)2 <5
b
 
30 Co(OAc)2 PEG 400/CF3CH2OH (4/1) AgOPiv <5
b
 
31 Co(OAc)2 PEG 400/CF3CH2OH (4/1) AgOPiv 49
d
 
32 Co(OAc)2 PEG 400/CF3CH2OH (4/1) AgOPiv 12
b
 
33 Co(OAc)2 PEG 400/CF3CH2OH (4/1) AgOPiv 73
e
 




 Reaction conditions: 110a (0.25 mmol), ethyl acrylate 46b (0.50 mmol), Co(OAc)2 (20 mol %), NaOAc (2.0 
equiv), solvent (2.5 mL), 100 °C, 18 h; isolated yields. b GCMS conversion. c Under N2. 
d 60 °C. e Without 
NaOAc. 
 
5.2 Scope and Limitations 
With the optimized reaction conditions in hand, we expanded the scope of the alkenylations (Table 
12). Various alkenes, such as benzyl acrylate (46d) and methyl vinyl ketone (46f), were 
successfully employed under this condition, affording the corresponding product 132bd and 132bf 
in good yields (entries 2 and 4). Despite its high tendency to polymerize, acrylonitrile (46h) was 
also compatible in this reaction, furnishing compounds 132bn and 132nh in 75% and 64% 
isolated yields, respectively (entries 3 and 19). Good to excellent yields were obtained when a 
series of para-substituted N-(quinolin-8-yl)benzamides 110 was used as substrates with 
electron-deficient (entries 13 and 14) or electron-rich substituents (entries 7, 13 and 16). More 
importantly, various functional groups, such as halides (Cl, Br, I) (110d–110f), nitril (110g), nitro 
(110h) or trifluoro (110i) were well tolerated by this catalytic system (entries 8–13). The 
ortho-substituted substrates, such as 110j and 110k, also reacted efficiently, however, giving the 
desired product 132jb and 132kb in moderate yield (entries 14 and 15). Unfortunately, 
heteroarenes 110o and 110p (entries 20 and 21) as well as ferrocene (110q) or acrylamide 
derivative (110r) (entries 22 and 23) were not compatible in this reaction. 
 
 
Table 12 Scope of cobalt-catalyzed annulations with amides (110)a 
































































































































































































































































a Reaction conditions: 110 (0.25 mmol), alkene 46 (0.50 mmol), Co(OAc)2 (20 mol %), solvent (2.5 mL), 100 °C, 
18 h, isolated yields. 
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Thereafter, an investigation of cobalt(II)-catalyzed alkenylations with ethyl acrylate 46b using 
different directing groups was carried out (Scheme 65). Not surprisingly, no reaction occurred 
when the quinolyl substituent in substrate 110 was replaced by methyl as in N-methylbenzamide 
(10a). On the other hand, whereas arenes with bidentate DGs commonly demonstrated high 









 benzamides 147, 149–153 with bidentate 
auxiliaries did not afford the desired products. Reaction of benzamide 148 bearing a TAM 
directing group,
89,90
 which has been demonstrated to be a powerful auxiliary in various ruthenium- 




Scheme 65 Substrates displaying limited activity in the cobalt-catalyzed alkenylations. 
5.3 Mechanistic Studies 
5.3.1 Inter- and Intramolecular Competition Experiments 
Given the high catalytic activity of the optimized cobalt(II) catalyst, we became interested in 
delineating its mode of action. For this purpose, intermolecular competition experiments with 
amides 110c and 110d were performed. The reaction selectively yielded chloro-substituted 
isoindolin-1-one 132cb as the sole product (Scheme 66).  
                                                             
121 R. Giri, N. Maugel, B. M. Foxman, J.-Q. Yu, Organometallics 2008, 27, 1667–1670; (b). M. Shang, H. Wang, 
S. Sun, H. Dai, J.-Q. Yu. J. Am. Chem. Soc.2014, 136, 3354–3357. 
122 N. Hasegawa, V. Charra, S. Inoue, Y. Fukumoto, N. Chatani, J. Am. Chem. Soc.2011, 133, 8070–8073.  
123 F.-J. Chen, S. Zhao, F. Hu, Chen, K. Zhang, Q. Zhang, B.-F. Shi, Chem. Sci. 2013, 4, 4187–4192. 




Scheme 66 Intermolecular competition reaction between different amides. 
 
Additionally, intramolecular competition experiments with meta-fluoro- (110s) (Scheme 67a) and 
meta-methyl-substituted amide (110t) (Scheme 67b) were carried out and gave essentially the 
same result: in both cases sterically less hindered isomers 132sb and 132tb were obtained as the 
major products in 50% and 42% yield, respectively, whereas the yields of compounds 132sb' and 






Scheme 67 Intramolecular competition reactions of amides 110s and 110t.  
5.3.2 Cobalt-Catalyzed Attempted H/D Exchange Experiments 
Mechanistic studies with either deuterated solvent [D]4-MeOH (Scheme 68a) or isotopically 
labeled substrate [D]5-110b (Scheme 68b) showed no H/D scrambling. These observations allow 
one to postulate an irreversible C−H metalation step accomplished by a bidentate- coordinated 
cobalt complex 154. 







Scheme 68 Oxidative alkenylation with cosolvent [D]4-MeOH or with isotopically labeled substrate [D]5-110b. 
5.3.3 Kinetic Isotope Effect Studies 
Furthermore, cobalt-catalyzed C–H alkenylations with isotopically labeled substrate [D4]-110b 
revealed an intermolecular kinetic isotope effect (KIE) of kH/kD ≈ 1.4 (Scheme 69a), and the 
intramolecular KIE determined with substrate [D]1-110b was kH/kD ≈ 1.6 (Scheme 69b). This is in 















Scheme 69 Studies on the kinetic isotope effect. 
5.4 Proposed Catalytic Cycle 
Based on the mechanistic studies discussed above and taking into account previous report,
91
 a 
plausible catalytic cycle was proposed (Scheme 70). Initially, the cobalt species chelated with the 
amide and the quinoline moieties in 110 undergoes ortho-C–H bond activation to give the 
corresponding Co–Ar intermediate 154. Subsequent coordination of the alkene coupling partner 
and 1,2-migratory insertion provided a seven-membered cobalt intermediate 156. The latter 
underwent β-hydride elimination assisted by HOAc to provide the uncyclized alkenylation product 
157. At last, compound 157 entered the intramolecular aza-Michel addition to give the 
isoindolin-1-one 132. 
 
Scheme 70 Proposed catalytic cycle. 
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6 Silver-Mediated Alkyne Annulations by C−H/P−H 
Functionalizations: Step-Economical Access to Benzophos-
pholes 
Phosphorus-containing heterocycles play an integral role in organic synthesis, medicinal 
chemistry and material science.
93 Particularly the phosphorous analogues of indole 
benzophospholes 117, have emerged as an indispensable structural motif for the construction of 
conjugated heteroarenes with potential applications in advanced electronic devices. Therefore, 
their site-selective preparation is of increasing interest. Several methods have been devised for the 
synthesis of benzo[b]phospholes.
99–103
 However, most of these approaches relied on the 
cyclization with pre-functionalized arenes bearing phosphorus- or halide-substituted moieties. In 
recent years, transition metal-catalyzed derivatizations have emerged as a valuable tool for organic 
synthesis. Thereby, various N-heterocyclic compounds were prepared mostly employing 
ruthenium, rhodium, palladium, or nickel catalysts in combination with a stoichiometric oxidant. 
In contrast, the synthesis of phosphorus-containing heterocycles through C−H functionalizations 
continues to be scarce.
104–106 Given our interest in ruthenium-catalyzed C−H bond activation as 
well as in the use of secondary phosphine oxides (SPO) as preligands in metal catalysis,
124
 we 
became attracted by silver-mediated C−H/P−H functionalization of substituted phosphine oxides 
with alkynes for the convenient benzo[b]phosphole oxides synthesis. 
6.1. Optimization Studies 
Our initial efforts focused on the annulation of diphenylacetylene (11a) with ethyl 
phenylphosphinate (121a) (Table 13). The use of catalytic amounts of ruthenium complex along 
with AgOAc as the oxidant in DCE provided the desired product 
1-ethoxy-2,3-diphenylphosphindole 1-oxide (117aa) in unsatisfactory yield (entry 1). Control 
experiments verified that the reaction proceeded even in the absence of a metal catalyst, and the 
product was obtained in 17% yield (entry 2). Among various solvents, DMF and DMSO were 
found to be optimal (entries 3−9). It is notable that a change of the silver salt to Ag2CO3, Ag2O or 
AgOTs led to inferior results (entries 10−12), whereas only traces of the product were obtained 
when using AgO2CCF3 or AgO3SCF3 (entries 13 and 14). Switching the oxidant from silver salts 
                                                             
124 (a) L. Ackermann, S. Barfüsser, C. Kornhaass, A. R. Kapdi, Org. Lett. 2011, 13, 3082–3085; (b) L. Ackermann, 
A. R. Kapdi, S. Fenner, C. Kornhaaß, C. Schulzke, Chem. Eur. J. 2011, 17, 2965–2971; (c) L. Ackermann, R. 
Born, J. H. Spatz, D. Meyer, Angew. Chem. Int. Ed. 2005, 44, 7216–7219; (d) L. Ackermann, Org. Lett. 2005, 7, 
3123–3125; (e) L. Ackermann, R. Born, Angew. Chem. Int. Ed. 2005, 44, 2444–2447; Reviews: (f) L. 
Ackermann, Isr. J. Chem. 2010, 50, 652–663; (g) L. Ackermann, Synthesis 2006, 1557–1571. 
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to Zn(OAc)2 or MnO2 furnished the desired product only in trace quantities as well (entries 15 and 
16). Furthermore, it is noteworthy that the addition of 2.0 equivalents of 2,2,6,6- 
tetramethylpiperidine-1-oxyl (TEMPO) as radical scavenger completely suppressed the reaction 




Table 13 Silver-mediated oxidative cyclization of ethylphenylphosphinate 121a with diphenylacetylene 11aa 
 
Entry cat. Solvent Oxidant T (°C) Yield (%) 
1 [RuCl2(p-cymene)]2 DCE AgOAc 80 21 
2 --- DCE AgOAc 80 17 
3 --- DCE AgOAc 120 46 
4 --- o-xylene AgOAc 120 51 
5 --- tAmOH AgOAc 120 51 
6 --- DMF AgOAc 120 60 
7 --- DMSO AgOAc 120 60 
8 --- NMP AgOAc 120 52 
9 --- DMA AgOAc 120 51 
10 --- DMSO Ag2CO3 120 31 
11 --- DMSO Ag2O 120 25 
12 --- DMSO AgOTs 120 17 
13 --- DMSO AgO3SCF3 120 trace 
14 --- DMSO AgO2CCF3 120 trace 
15 --- DMSO Zn(OAc)2 120 trace 
16 --- DMSO MnO2 120 trace 
17 --- DMSO AgOAc 120 trace
b
 
a Reaction conditions: 121a (0.50 mmol), 11a (1.00 mmol), catalyst (5.0 mol %), oxidant (2.0 
equiv), solvent (2.0 mL), under N2; isolated yield. 
b TEMPO (2.0 equiv). 
6.2 Scope of the Silver-Mediated Alkyne Annulations  
Having identified the optimal reaction conditions (Table 13, Entry 7), we explored the scope of the 
silver-mediated alkyne annulation by varying the substitution pattern of substrate 121 (Table 14). 
A wide range of phosphinates and aryl- or alkyl-substituted SPO bearing groups, such as methyl, 
tert-butyl, cyclohexyl, and ethoxy, were converted efficiently, thus affording the corresponding 
products 117aa–117ea in good yield (entries 1–5). Notably, phosphinate-substituted thiophene 
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121f proved to be a suitable substrate as well (Scheme 71). 
 
















































































Scheme 71 Silver-mediated oxidativeannulation with heterocycle substrate 121f. 
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Thereafter, differently decorated tolane derivatives were tested in the silver-mediated annulation 
process (Table 15). The C–H/P–H bonds functionalizations with tolanes 11 occurred with high 
catalytic efficacy, affording products 117ad, 117ae, 117am, 117ha, 117hc and 117ge in good 
yields (entries 1–7). Symmetrical dialkylalkynes, such as oct-4-yne (11h) reacted with 
diphenylphosphine oxide (121g) to furnish the desired product 117gh in moderate yield (entry 8). 
Unsymmetrically substituted alkynes 11i, 11n, 11o likewise delivered the desired products 117gi, 
117gn and 117go (entries 9−11). Notably, the cyclizations with alkyl-substituted phenylacetylenes 
proceed with excellent regioselectivities, and only the 3-phenylsubstituted regioisomers bearing 
the alkyl substituent neighboring to the phosphorus atom was obtained. Such regioselectivity was 
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a Reaction conditions: 121 (0.50 mmol), 11 (1.00 mmol), AgOAc (2.0 equiv), DMSO (2.0 mL), under N2; isolated 
yield. 
During further studies on the reactivity of various substrates 121, we were surprised to find that 
the promoted annulation by AgOAc with di(o-tolyl)phosphine oxide (121h) afforded the 
phosphindole derivative 117ha as a 1:2 mixture with the unexpected regioisomer 117ha' as a 
major product (Scheme 72). This result can be explained as a consequence of a [1,2] migration of 
the phosphor-containing moiety in the aryl fragment in one of the intermediates. Most probably, 
this unexpected C−P bond cleavage proceeded through a radical mechanism. 
 
Scheme 72 Silver-mediated oxidative annulations with SPO 121h. 
 
6.3 Mechanistic Studies 
6.3.1 Intermolecular Competition Experiments 
Intermolecular competition experiments with an excess of alkynes 11c and 11e indicated 
electron-deficient alkynes to be more reactive (Scheme 73a). Furthermore, intermolecular 
competition experiments between diaryl- and dialkylalkynes 11a and 11h revealed tolane (11a) to 
be preferentially converted (Scheme 73b) 
a) 
 





Scheme 73 Competition experiments between alkynes 121. 
 
An intermolecular competition experiment between tert-butylphenylphosphine oxide (121b) and 
diphenylphosphine oxide (121g) disclosed the reaction to be less dependent on the substitution at 
the phosphorus atom (Scheme 74). 
 
Scheme 74 Competition experiments between phosphine oxides 121b and 121g. 
6.4 Proposed Mechanism 





 we proposed a plausible mechanism for this silver-mediated reaction (Scheme 75). First, 
a phosphoryl radical 158 was generated from di-o-tolylphosphine oxide (121h) through a P–H 
bond cleavage via oxidation with silver acetate, followed by the radical addition to the alkyne 11a 
to afford alkenyl radical species 159. Subsequently, the intramolecular attack of the alkenyl 
radical 159 onto the ortho position of an aryl ring furnished bicyclic radical intermediate 161. 
After oxidation with a second equivalent of AgOAc to remove a hydrogen atom, the 
phosphorus-containing heterocyclic product 117ha was obtained. However, formation of an 
unexpected isomer 117ha' in this reaction (Scheme 72) indicated that this annulation reaction 
could involve an [1,2] migration step as an unanticipated pathway. The detailed process was 
supposed to start with an attack of the alkenyl radical 159 onto the phosphorus-substituted carbon 
atom to form a spiro[3.5]nonatrienyl radical 160 containing a four-membered intermediate. 
Subsequent C−P bond cleavage furnished the phosphoryl radical 162, which attacked the 
neighboring carbon atom of the aryl ring and then underwent oxidation with AgOAc to afford the 
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phosphorus heterocycle 117ha'. 
 
Scheme 75 Proposed mechanism of silver-mediated oxidative annulations. 
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7 Summary and Outlook 
Transition metal-catalyzed direct C–H functionalizations have emerged as an attractive strategy in 
the development of sustainable green chemistry. By using this approach, the C–H transformations, 
such as alkenylation and annulation reactions, can be successfully achieved under mild reaction 
conditions.  
In the first part of this work, we devised ruthenium(II)-catalyzed oxidative alkyne annulations 
with substituted 1H-pyrazoles 126 by C–H/N–H bond functionalizations under air. In this project, 
the desired oxidative annulation was not accomplished with CuBr2 in lieu of Cu(OAc)2·H2O as the 
terminal oxidant, thereby indicating the importance of carboxylate assistance. For the substrate 
scope, we were pleased to find that these reactions are tolerant of different substituent on the aryl 
ring. A wide range of alkynes 11 such as dialkylalkynes and tolanes were also suitable substrates 
under the optimized reaction conditions. Furthermore, oxidative annulations with unsymmetrically 
substituted alkynes occurred with excellent regioselectivities. (Scheme 76). 
 
 
Scheme 76 Ruthenium(II)-catalyzed alkyne annulations with pyrazoles 126 by C–H/N–H functionalization. 
 
A ruthenium(II) catalyst could also be applied to the oxidative alkenylations with benzenesulfonic 
acids 128 via twofold C–H bond cleavages (Scheme 77). Not only differently substituted aromatic 
sulfonic acids, but also benzenesulfonyl chloride (136) and methyl benzenesulfonates 137 can 
efficiently be transformed to afford the corresponding products 129 in high yields. Importantly, 
unactivated styrenes as alkenylating agents were also compatible for this reaction. 




Scheme 77 Ruthenium-catalyzed oxidative alkenylations with substituted sulfonic acid. 
 
In the third project, the ruthenium(II)-catalyzed direct alkenylation of arenes 130 bearing a 
removable directing group was achieved. The established catalytic system proved to be broadly 
applicable and, hence, furnished the desired products 131 in high yields. Especially, heteroarenes 
as substrates such as substituted indole 130t and thiophene 130u were efficiently converted. 
 
 
Scheme 78 Ruthenium(II)-catalyzed oxidative alkenylations of substituted phenyloxylpyridines 130. 
 
Importantly, the directing group could be removed easily yielding the ortho-vinyl phenol 71a 
which is an important intermediate in organic synthesis (Scheme 79). 




Scheme 79 Removal of the directing group. 
In the fourth project, cobalt acetate was found to be an efficient catalyst for the C–H 
functionalization in benzamides 110 by using a bidentate directing group (Scheme 80). This 
earth-abundant first-row transition metal catalyst can enable the transformation smoothly with a 
widely range functional groups tolerance, to furnish the isoindolin-1-ones 132 in high yields. In 
contrast, ruthenium- and rhodium-catalyzed reactions of the substrates 110 with acrylates 46 




Scheme 80 Cobalt-catalyzed oxidative C–H alkenylations with bidentate directing group. 
 
In the fifth project, the silver-mediated alkyne annulation via C–H/P–H bonds was developed. 
This transformation proceeded with excellent chemo- and site-selectivities in the presence of 
silver acetate as the terminal oxidant, thereby furnishing substituted phosphindole 117 with broad 
scope. The radical mechanism of the C–H/C–P functionalization was unraveled though detailed 
mechanistic studies.  
 
Scheme 81 Silver mediated alkyne annulations via C−H/P−H functionalization. 
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In summary, the rapid progress of C–H functionalization chemistry over the last decade has 
provided numerous efficient protocols for forming new chemical bonds. Especially, the 
ruthenium(II)-catalyzed direct C–H alkenylations and annulations have been proven viable with a 
broad substrates scope and excellent chemo-, regio-, and site-selectivity. These 
carboxylate-assisted ruthenium(II)-catalyzed C–H functionalizations were even allowed in an 
aerobic fashion with Cu(OAc)2·H2O under an atmosphere of ambient air. Yet, less expensive 
first-row transition metal complexes such as cobalt salts were also identified as versatile catalysts 
for step-economical chelation-assisted direct C−H alkenylations in user-friendly solvent. Finally, 
we developed silver-mediated alkyne annulations by C–H/P–H functionalizations. 
Although the development of new reactions and catalysts continues to evolve at a rapid pace, 
successful applications of these methods to the synthesis of complex natural products, bioactive 
compounds and functional materials are still rare. Therefore, the development of new transition 
metal-catalyzed direct C–H functionalizations that can be used in the synthesis of complex 





8 Experimental Section 
8.1 General Remarks 
Unless otherwise noted, all reactions were performed under a N2 atmosphere using 
pre-driedglassware and standard Schlenk techniques. 
Solvents 
All solvents for reactions involving moisture-sensitive reagents were dried, distilled and stored 
under inert atmosphere (argon or nitrogen) according to the following standard procedures. 
tert-Amylalcohol (tAmOH) was used as supplied by Merck or stirred over sodium chips for 5 h at 
120 °C and distilled under ambient pressure; water (H2O) was degassed before its use applying 
repeated Freeze-Pump-Thaw degassing procedure; 1,2-dichloroethane (DCE), 
N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile (MeCN) and 
dimethylacetamide (DMA) were dried over CaH2 for 8 h, degassed and distilled under reduced 
pressure; dichloromethane and tetrahydrofuran (THF) were purified using a solvent purification 
system (SPS) from MBRAUN; N-methyl-2-pyrrolidone (NMP) was stirred over CaH2 for 4 h at 
150 °C and subsequently distilled under reduced pressure; ethanol (EtOH) was distilled from 
magnesium ethanolate; toluene (PhMe) was pre-dried over KH followed by distillation from 




The following pressures were measured on the used vacuum pumps and were not corrected: 
membrane pump vacuum (MPV): 0.5 mbar, oil pump vacuum (OPV): 0.1 mbar. 
 
Melting Points (M. p.) 
Melting points were measured using a Stuart® Melting Point Apparatus SMP3 fromBARLOWO- 
RLD SCIENTIFIC. Reported values are uncorrected. 
 
Chromatography 
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F-plates 
(MACHEREY-NAGEL) with 254 nm fluorescent indicator from MERCK. Plates were visualized 
under UV-light or developed by treatment with a KMnO4 solution followed by careful applying a 




chromatography on MERCK silica gel, grade 60 (0.040–0.063 mm and 0.063–0.200 mm). 
 
Gas Chromatography (GC) 
The conversion of the reactions was monitored applying coupled gas chromatography/mass 
spectrometry using G1760C GCD plus with mass detector HP 5971, 5890 Series II with mass 
detector HP 5972 from HEWLETT-PACKARD and 7890A GC-System with mass detector 5975C 
(Triplex-Axis-Detector) from AGILENT TECHNOLOGIES equipped with HP-5MS columns 
(30 m × 0.25 mm × 0.25 m) instruments. 
 
High Performance Liquid Chromatography (HPLC) 
Preparative and analytical separations were performed on an HPLC-System from KNAUER 
(Smartline Pump 100, Dynamic Mixing Chamber, Injection- and Control-Valve, Smartline UV 
Detector 2500). Separation normal phase column (250 × 10 mm) from MACHEREY-NAGEL 
(MN) was used. Organic solvents of HPLC grade were employed. All samples were filtered 
through Polytetrafluoroethylene Filter from ROTH (Ø 25 mm, 0.2 μm) or VWR (Ø 13 mm, 0.2μm) 
prior to separation. 
 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) spectroscopy was performed at 300 400 or 600 MHz (
1
H 
NMR), 75, 100 or 125 MHz (
13
C NMR, APT), 283 MHz (
19
F NMR) and 122 MHz (
31
P NMR) on 
BRUKER AM 250, VARIAN Unity-300 and Inova 500 instruments. Chemical shifts are reported 
as δ-values in ppm relative to the residual proton peak of the deuterated solvent or its carbon atom, 
respectively, or the standard trimethylsilyl (TMS) peak. For characterization of the observed 
resonance multiplicities the following abbreviations were applied: s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet), dd (doublet of doublet), dt (doublet of triplet), or analogue 
representations. The coupling constants J are reported in Hertz (Hz). 
 
Infrared Spectroscopy (IR) 
Infrared spectra were recorded on a BRUKER Alpha-P ATR-spectrometer. Liquid probes have 
been measured as films and solid probes neat. Analysis of the spectral data has been done by using 
the OPUS 3.1 software from BRUKER, respectively OPUS 6. Absorption (ṽ) is given in wave 
numbers (cm
–1








MS (EI) and HR-MS (EI) were measured on a Time-of-Flight mass spectrometer Accu TOF from 
JOEL. ESI-mass spectra were recorded on an Ion-Trap mass spectrometer LCQ from FINNIGAN 
or on a Time-of-Flight mass spectrometer microTOFfrom BRUKER. ESI-HR-MS spectra were 
recorded on a BRUKER APEX IV or a BRUKER DALTONIC {7T, Fourier Transform Ion Cyclo- 
tron Resonance (FTICR)} mass spectrometer. The ratios of mass to charge (m/z) are indicated, 
intensities relative to the base peak (I = 100) are given in parentheses. 
 
Reagents 
Chemicals obtained from commercial sources with purity above 95% were used without further 
purification. Anhydrous arylsulfonic acid (128) was prepared by heating the monohydrate to 
160 °C under vacuum for 1 h. 
8.2 Synthesis of Starting Materials 
The following starting materials were synthesized according to previously described methods: 
Alkynes 11b–11g, 11j–11l,
129
 pyrazoles 126a–126l, 141,
130










110r, 147, 149, 150, 152, 153,





 phenylphosphinates 121a, 121f,
138
 SPOs 121b–121e, 121g–121h.
139
 
The following compound was obtained by the generous courtesy of the person named below: 
Karsten Rauch: [RuCl2(p-cymene)]2. 
                                                             
129 (a) M. J. Mio,L. C. Kopel, J. B. Braun,T. L. Gadzikwa, K. L. Hull, R. G. Brisbois,C. J. Markworth, P. A. 
Grieco, Org. Lett. 2002, 4, 3199–3202; (b) K. Parka, G. Baea, A. Parka, Y. Kima, J. Choec, K. H. Song, S. Lee, 
Tetrahedron Lett. 2011, 52, 576–580. 
130 (a) A. Pleier, H. Glas, M. Grosche, P. Sirsch, W. Thiel, Synthesis 2001, 55–62; (b) S. Al-Mousawi, M. Moustafa, 
M. Abdelkhalik, M. Elnagdi, ARKIVOC, XI, 2009, 1–10; (c) Organikum. Organisch-chemisches 
Grundpraktikum (Hrsg.: R. Becker, P. Metz, E. Fanghänel, D. Pavel, W. Habicher, K. Schwetlick), Wiley-VCH, 
Weinheim, 2004, 22. Auflage, S. 380.  
131 (a) K. Viswanathan, D. J. Hoover, J. Hwang, M. L. Wisniewski, U. S. Ikonne, B. A. Bahr, D. L. Wright, ACS 
Med. Chem. Lett. 2012, 3, 920−924; (b) M. T. Bovino, S. R. Chemler, Angew. Chem. Int. Ed. 2012, 51, 3923–
3927; (c) J. Waser, B. Gaspar, H. Nambu, E. M. Carreira, J. Am. Chem. Soc. 2006, 128, 11693–11712; (d) M. 
Pal, M. Madan, S. Padakanti, V. R. Pattabiraman, S. Kalleda, A. Vanguri, R. Mullangi, N. V. S. R. Mamidi, S. 
R. Casturi, A. Malde, B. Gopalakrishnan, K. R. Yeleswarapu, J. Med. Chem. 2003, 46, 3975–3984. 
132 (a) D. Maiti, S. L. Buchwald, J. Org. Chem. 2010, 75, 1791–1794; (b) J. Niu, P. Guo, J. Kang, Z. Li, J. Xu, S. 
Hu, J. Org. Chem. 2009, 74, 5075–5078.  
133
 S. Gu,C. Chen, W. Chen, J. Org. Chem. 2009, 74, 7203–7206. 
134 J. Chen, Q. Pang, Y. Sun, X. Li, J. Org. Chem. 2011, 76, 3523–3526. 
135 X. Li, Y. Liu, W. Gu, B. Li, F. Chen, B.-F. Shi, Org. Lett. 2014, 16, 3904–3907. 
136 J. Karthikeyan, R. Haridharan, C. Cheng, Angew. Chem. Int. Ed. 2012, 51, 12343–12347. 
137
 F. Chen, G. Liao, X. Li, J. Wu, B. Shi, Org. Lett. 2014, 16, 5644−5647. 
138 (a) I. Petneházy, Z. M. Jászay, A. Szabó, K. Everaert, Synthesis 2011, 2490–2494; (b) L. Y. Kuo, S. K. Glazier. 
Inorg. Chem. 2012, 51, 328–335. 




8.3 General Procedures 
General Procedure A: Ruthenium-Catalyzed Oxidative Alkyne Annulation with Substituted 
1H-Pyrazoles (126) 
A suspension of 5-(4-nitrophenyl)-1H-pyrazole (126a) (95.0 mg, 0.50 mmol), diphenylacetylene 
(11a) (178.0 mg, 1.00 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), AgSbF6 (34.3 mg, 20 
mol %) and Cu(OAc)2·H2O (100 mg, 0.50 mmol) in DCE (2.0 mL) was stirred at ambient 
temperature for 5 min and then at 100 °C for 20 h under an ambient atmosphere of air. At ambient 
temperature, the reaction mixture was diluted with sat. aq. NH4Cl/NH3 (1:1, 10mL) and extracted 
with EtOAc (3  25 mL). The combined organic layers were dried over Na2SO4. After filtration 
and evaporation of the solvents in vacuo, the crude product was purified by column 
chromatography on silica gel (n-hexane/EtOAc: 20/1→8/1) to yield 127aa (139.0 mg, 77%) as a 
yellow solid. 
 
General Procedure B: Ruthenium(II)-Catalyzed Oxidative C–H Alkenylations of Sulfonic 
Acids, Chlorides and Methyl Benzenesulfonate. 
A suspension of 2,5-dimethylphenylsulfonic acid (128a) (94.0 mg, 0.50 mmol), ethyl acrylate 
(46b) (150.0 mg, 1.50 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 
mol %) and Cu(OAc)2·H2O (200 mg, 1.00 mmol) in DMA (2.0 mL) was stirred at ambient 
temperature under N2 for 5 min and then at 120 °C for 16 h. At ambient temperature, the solvent 
was removed in vacuo, and the crude product was purified by column chromatography on silica 
gel (CH2Cl2/MeOH: 15/1→10/1) to yield 129ab (131.0 mg, 91%) as an off-white solid.  
 
General ProcedureC: Ruthenium(II)-Catalyzed Oxidative C–H Alkenylations of Sulfonic 
Acids 
A suspension of 2,4-dimethylphenylsulfonic acid (128l) (92.3 mg, 0.50 mmol), 4-fluorostyrene 
(46m) (183.0 mg, 1.50 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), AgSbF6 (35.0 mg, 0.10 
mmol, 20 mol %) and Cu(OAc)2·H2O (200.0 mg, 1.00 mmol) in DMF (2.0 mL) was stirred at 
ambient temperature under N2 for 5 min and then at 100 °C for 16 h. At ambient temperature, the 
solvent was removed in vacuo, and the crude product was purified by column chromatography on 
silica gel (CH2Cl2/MeOH: 15/1→10/1) to yield 129lm (92.0 mg, 60%) as an off-white solid. 
 
General Procedure D: Ruthenium(II)-Catalyzed C–H Alkenylations of Phenols with 
Removable Directing Groups  




mg, 0.52 mmol), [RuCl2(p-cymene)]2 (7.6 mg, 2.5 mol %), AgSbF6 (18.5 mg, 10 mol %) and 
Cu(OAc)2·H2O (200 mg, 1.00 mmol) in tAmOH (2.0 mL) was stirred at ambient temperature 
under N2 for 5 min and then at 120 °C for 16 h under an ambient atmosphere of air. At ambient 
temperature, the reaction mixture was diluted with sat. aq. NH4Cl/NH3 (1:1, 10 mL) and extracted 
with EtOAc (3  25 mL). The combined organic layers were dried over Na2SO4. After filtration 
and evaporation of the solvents in vacuo, the crude product was purified by column 
chromatography on silica gel (n-hexane/EtOAc: 15/1→10/1) to yield 131ab (122.0 mg, 83%) as a 
colorless solid.  
 
General procedure E: Cobalt-Catalyzed Oxidative C–H Bond Alkenylations with Bidentate 
Directing Group: A suspension of 4-methyl-N-(quinolin-8-yl)benzamide (110a) (65.6 mg, 0.25 
mmol), ethyl acrylate (46b) (50 mg, 0.50 mmol), Co(OAc)2 (9.0 mg, 20 mol %) and AgOPiv 
(105.0 mg, 2.0 equiv) in a PEG 400 (2.0 mL) and CF3CH2OH (0.5 mL) mixture solvent was 
stirred at 100 °C for 18 h under an ambient atmosphere of air. At ambient temperature, the reaction 
mixture was diluted with H2O and extracted with tBuOMe (3  25 mL). The combined organic 
layers were dried over Na2SO4. After filtration and evaporation of the solvents in vacuo, the crude 
product was purified by column chromatography on silica gel (n-hexane/EtOAc: 2/1→1/1) to 
yield 132ab (66.0 mg, 73%) as a white solid. 
 
General procedure F: Silver-Mediated Alkyne Annulations by C−H/P−H Functionalizations: 
A suspension of ethyl phenylphosphinate (121a) (85.0 mg, 0.50 mmol), diphenylacetylene (11a) 
(178.0 mg, 1.00 mmol) and AgOAc (166.0 mg, 1.00 mmol) in DMSO (2.0 mL) was stirred under 
N2 atmosphere at ambient temperature and then at 120 °C for 12 h. At ambient temperature, the 
reaction mixture was diluted with water and extracted with EtOAc (3  25 mL). The combined 
organic layers were dried over Na2SO4. After filtration and evaporation of the solvents in vacuo, 
the crude product was purified by column chromatography on silica gel (n-hexane/EtOAc: 












8.4 Analytical Data 
8.4.1 Analytical Data for the Products of the Ruthenium-Catalyzed Alkyne 
Annulation with Substituted 1H-Pyrazoles by C–H/N–H Bond Functionalizations 
6-Nitro-3,4-diphenylpyrazolo[5,1-a]isoquinoline (127aa): 
The general procedure A was followed using 
5-(4-nitrophenyl)-1H-pyrazole (126a) (94.6 mg, 0.50 mmol) and 
diphenylacetylene (11a) (178.0 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 8/1) yielded 127aa (139.0 mg, 77%) as 
a yellow solid.  
M. p. = 182–184 °C. 
1
H NMR (300 MHz, d6-DMSO): δ = 8.66 (d, J = 8.8 Hz, 1H), 8.41 (dd, J = 8.8, 2.2 Hz, 1H), 
8.13–8.06 (m, 1H), 8.02 (d, J = 2.2 Hz, 1H), 7.67 (d, J = 1.6 Hz, 1H), 7.38–7.27 (m, 10H).  
13
C NMR (75 MHz, d6-DMSO): δ = 145.7 (Cq), 140.9 (CH), 137.3 (Cq), 136.1 (Cq), 134.0 (Cq), 
131.7 (Cq), 130.8 (CH), 130.1 (CH), 128.9 (Cq), 127.9 (CH), 127.7 (CH), 127.3 (CH), 127.1 (CH), 
127.0 (Cq), 125.1 (CH), 122.5 (Cq), 121.0 (CH), 120.7 (CH), 100.4 (CH).  
IR (neat): 3055, 1535, 1487, 1424, 1391, 751, 689, 649 cm
–1
. 




, 334 (20), 318 (40), 290 (20), 
214 (10), 158 (15), 105 (15), 77 (10).  




 365.1159, found 365.1154. 
 
6-(Trifluoromethyl)-3,4-diphenylpyrazolo[5,1-a]isoquinoline (127ba): 
The general procedure A was followed using 5-{4-(trifluoro-
methyl)phenyl}-1H-pyrazole (126b) (107.0 mg, 0.50 mmol) and 
diphenylacetylene (11a) (178.0 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 15/1) yielded 127ba (137.0 mg, 70%) as an off-white solid.  
M. p. = 137–139 °C. 
1
H NMR(300 MHz, CDCl3): δ = 8.32 (d, J = 8.3 Hz, 1H), 8.04–8.03 (m, 1H), 7.79 (d, J = 8.3 Hz, 
1H), 7.71 (s, 1H), 7.34–7.30 (m, 8H), 7.23–7.18 (m, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 141.4 (CH), 137.7 (Cq), 137.7 (Cq), 135.1 (Cq), 132.6 (Cq), 131.4 
(CH), 130.7 (CH), 129.7 (Cq), 129.5 (
2
JC-F = 33 Hz, Cq), 128.6 (CH), 128.3 (CH), 128.0 (CH), 
127.7 (CH), 126.2 (Cq), 125.8 (Cq), 124.3 (CH), 124.0 (
1
JC-F = 273 Hz, Cq), 123.9 (
3
JC-F = 4 Hz, 
CH), 123.9 (
3
JC-F = 4 Hz, CH), 98.8 (CH).  
19
F NMR (CDCl3, 283 MHz): δ = −62.3 (s). 






MS (EI) m/z (relative intensity): 388 (50) [M]
+
, 387 (100) [M–H]
+
, 360 (5), 340 (7), 333 (7), 290 
(5), 174 (4), 77 (3). 




 389.1260, found 389.1255.  
 
6-Chloro-3,4-diphenylpyrazolo[5,1-a]isoquinoline (127ca): 
The general procedure A was followed using 5-(4-chlorophenyl)-1H-pyrazole 
(126c) (90.0 mg, 0.50 mmol) and diphenylacetylene (11a) (179.0 mg, 1.00 
mmol). Purification by column chromatography (n-hexane/EtOAc: 15/1) 
yielded 127ca (124.0 mg, 69%) as an off-white solid.  
M. p. = 83–85 °C.  
1
H NMR(300 MHz, CDCl3): δ = 8.14 (d, J = 8.6 Hz, 1H), 7.99 (d, J = 2.2 Hz, 1H), 7.54 (dd, J = 8.6, 
2.0 Hz, 1H), 7.39 (d, J = 2.0 Hz, 1H), 7.37–7.27 (m, 8H), 7.20–7.17 (m, 2H), 7.10 (d, J = 2.2 Hz, 
1H). 
13
C NMR (75 MHz, CDCl3): δ = 141.3 (CH), 138.0 (Cq), 137.4 (Cq), 135.4 (Cq), 133.7 (Cq), 132.7 
(Cq), 131.4 (CH), 131.3 (Cq), 130.7 (CH), 128.5 (CH), 128.2 (CH), 128.0 (CH), 127.8 (CH), 127.5 
(CH), 126.0 (CH), 125.1 (CH), 123.1 (Cq), 122.4 (Cq), 97.8 (CH).  
IR (neat): 3058, 1443, 1411, 780, 760, 713, 693, 650 cm–1. 
MS (EI) m/z (relative intensity): 355 [M+H]+, 354 (80) [M]+, 353 (100) [M–H]+, 318 (10), 290 
(30), 214 (10), 159 (70), 144 (30), 130 (20).  




 355.0997, found 355.0993. 





The general procedure A was followed using 4-(1H-pyrazol-5-yl)benzonitrile 
(126d) (84.9 mg, 0.50 mmol) and diphenylacetylene (11a) (178.0 mg, 1.00 
mmol). Purification by column chromatography (n-hexane/EtOAc: 15/1) 
yielded 127da (114.0 mg, 66%) as a light yellow solid.  
M. p. = 207–209°C. 
1
H NMR (300 MHz, CDCl3): δ = 8.28 (d, J = 8.2 Hz, 1H), 8.05 (d, J = 2.2 Hz, 1H), 7.80–7.75 (m, 
2H), 7.36–7.30 (m, 8H), 7.23 (d, J = 2.2 Hz, 1H), 7.20–7.16 (m, 2H). 
13
C NMR (75 MHz, CDCl3): δ = 141.6 (CH), 138.1 (Cq), 137.4 (Cq), 134.7 (Cq), 132.2 (Cq), 131.6 
(CH), 131.3 (CH), 130.6 (CH), 130.0 (Cq), 129.1 (CH), 128.8 (CH), 128.4 (CH), 128.0 (CH), 127.8 
(CH), 126.5 (Cq), 124.4 (CH), 123.1 (Cq), 118.8 (Cq), 111.0 (Cq), 99.5 (CH).  






MS (EI) m/z (relative intensity): 345 (73) [M]+, 344 (100) [M–H]+, 317 (12), 290 (12), 214 (3), 171 
(5), 158 (5), 144 (5).  




 346.1339, found 346.1334.  





The general procedure A was followed using 5-(naphthalen-1-yl)-1H-pyrazole 
(126e) (98.0mg, 0.50mmol) and diphenylacetylene (11a) (179.0 mg, 1.00 
mmol). Purification by column chromatography (n-hexane/EtOAc: 15/1) 
yielded 127ea (142.0 mg, 76%) as an off-white solid.  
M. p. = 192–194°C. 
1
H NMR (300 MHz, d6-DMSO): δ = 9.15 (d, J = 8.6 Hz, 1H), 8.17 (d, J = 2.3 Hz, 1H), 8.09 (d, J = 
7.8 Hz, 1H), 7.97 (d, J = 9.0 Hz, 1H), 7.91–7.86 (m, 2H), 7.77–7.72 (m, 1H), 7.34–7.24 (m, 11H). 
13
C NMR (75 MHz, d6-DMSO): δ = 141.6 (CH), 137.0 (Cq), 136.2 (Cq), 136.1 (Cq), 133.4 (Cq), 
132.0 (Cq), 131.4 (CH), 130.7 (CH), 128.9 (CH), 128.6 (Cq), 128.6 (CH), 128.0 (Cq),128.0 (CH), 
128.0 (CH), 127.9 (CH), 127.5 (CH), 127.2 (CH), 126.7 (CH), 125.1 (CH), 123.9 (Cq), 123.7 (CH), 
119.6 (Cq), 101.3 (CH). 
IR (neat): 3045, 1437, 1375, 822, 744, 730, 681, 659 cm
–1
. 
MS (EI) m/z (relative intensity): 370 (90) [M]+, 369 (100)[M–H]+, 342 (10), 313 (5), 265 (10), 237 
(5), 184 (5), 170 (5).  




 370.1465, found 370.1468.  





The general procedure A was followed using 
5-(4-methoxyphenyl)-1H-pyrazole (126f) (84.0 mg, 0.48 mmol) and 
diphenylacetylene (11a) (180.0 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 10/1) yielded 127fa (97.0 mg, 57%) as a light yellow solid.  
M. p. = 237–239 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.13 (d, J = 8.8 Hz, 1H), 7.96 (d, J = 2.3 Hz, 1H), 7.37–7.19 (m, 
11H), 7.01 (d, J = 2.3 Hz, 1H), 6.84 (d, J = 2.3 Hz, 1H), 3.73 (s, 3H).  
13
C NMR (75 MHz, CDCl3): δ = 159.1 (Cq), 141.1 (CH), 138.6 (Cq), 136.7 (Cq), 136.2 (Cq), 133.2 
(Cq), 131.6 (Cq), 131.5 (CH), 130.8 (CH), 128.3 (CH), 128.0 (CH), 127.9 (CH), 127.2 (CH), 125.2 




IR (neat): 3028, 2966, 1610, 1481, 1418, 1217, 1025, 696 cm
–1
.  




, 306 (20), 278 (10), 175 (10), 
159 (15), 139 (15), 77 (5).  




 351.1492 found 351.1482.  





The general procedure A was followed using 5-(4-methylphe-
nyl)-1H-pyrazole (126g) (79.0 mg, 0.50 mmol) and diphenylacetylene (11a) 
(178.0 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 20/1) yielded 127ga (70.0 mg, 42%) as a yellow solid.  
M. p. = 112–114 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.11 (d, J = 8.2 Hz, 1H), 7.96 (d, J = 2.1 Hz, 1H), 7.42 (dd, J = 
8.2, 1.8 Hz, 1H), 7.36–7.16 (m, 11H), 7.07 (d, J = 2.2 Hz, 1H), 2.40 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 141.0 (CH), 138.6 (Cq), 137.7 (Cq), 136.4 (Cq), 136.2 (Cq), 133.2 
(Cq), 131.6 (CH), 130.8 (CH), 130.0 (Cq), 128.9 (CH), 128.3 (CH), 127.9 (CH), 127.9 (CH), 127.1 
(CH), 126.3 (CH), 123.8 (Cq), 123.5 (CH), 121.8 (Cq), 97.0 (CH), 21.8 (CH3). 
IR(neat): 3051, 3023, 1622, 1481, 1412, 1347, 813, 762 cm
–1
.  
MS (EI) m/z (relative intensity): 333 (100) [M−H]
+
, 306 (5), 290 (5), 279 (10), 245 (5), 202 (5), 
158 (5). 




 334.1465, found 334.1456. 




The general procedure A was followed using 
N,N-dimethyl-4-(1H-pyrazol-5-yl)aniline (126h) (93.4 mg, 0.50 mmol) and 
diphenylacetylene (11a) (179.0 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 10/1) yielded 127ha (109.0 mg, 60%) as a light yellow solid.  
M. p. = 228−230 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.06 (d, J = 8.9 Hz, 1H), 7.92 (d, J = 2.1 Hz, 1H), 7.35–7.21 (m, 
10H), 7.08 (dd, J = 8.9, 2.6 Hz, 1H), 6.92 (d, J = 2.1 Hz, 1H), 6.55 (d, J = 2.6 Hz, 1H), 2.90 (s, 
6H). 
13
C NMR (75 MHz, CDCl3): δ = 149.6 (Cq), 141.0 (CH), 138.9 (Cq), 136.5 (Cq), 136.4 (Cq), 133.5 




(CH), 123.6 (Cq), 115.2 (Cq), 114.4 (CH), 107.7 (CH), 95.5 (CH), 40.5 (CH3). 
IR (neat): 3109, 2920, 1604, 1485, 1442, 1413, 724, 696 cm
–1
. 
MS (EI) m/z (relative intensity): 363 (100) [M]
+
, 362 (75) [M–H]
+
, 346 (20), 319 (5)[M–NMe2]
+
, 
290 (7), 180 (40), 159 (25), 131 (10). 




 364.1808, found 364.1809. 
 
3,4-Diphenylbenzo[g]pyrazolo[5,1-a]isoquinoline (127ia): 
The general procedure A was followed using 
5-(naphthalen-2-yl)-1H-pyrazole (126i) (97.0 mg, 0.50 mmol) and diphenyl-
acetylene (11a) (179.0 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 127ia (129.0 mg, 70%) as an off-white solid.  
M. p. = 272−274 °C. 
1
H NMR (300 MHz, d6-DMSO): δ = 8.97 (s, 1H), 8.13 (d, J = 8.2 Hz, 1H), 7.95 (d, J = 2.0 Hz, 1H), 
7.83 (d, J = 8.2 Hz, 1H), 7.72 (s, 1H), 7.61–7.56 (m, 1H), 7.53–7.47 (m, 1H), 7.51 (d, J = 2.0 Hz, 
1H), 7.34–7.23 (m, 10H). 
13
C NMR (75 MHz, CDCl3): δ = 140.8 (CH), 138.3 (Cq), 136.3 (Cq), 136.1 (Cq), 133.1 (Cq), 132.5 
(Cq), 132.1 (Cq), 131.6 (CH), 130.9 (CH), 128.5 (Cq), 128.4 (CH), 128.3 (CH), 128.1 (CH), 127.8 
(CH), 127.7 (CH), 127.2 (CH), 126.5 (CH), 126.2 (CH), 125.9 (CH), 123.8 (Cq), 122.5 (Cq), 122.2 
(CH), 99.1 (CH). 
IR (neat): 3053, 1488, 1442, 1390, 889, 748, 723, 693 cm
–1
. 
MS (EI) m/z (relative intensity): 370 (95) [M]+, 369 (100)[M–H]+, 264 (5), 207 (10), 184 (50), 177 
(25), 170 (20), 156 (10). 




 371.1543, found 371.1535. 





The general procedure A was followed using 5-(3-nitrophenyl)-1H-pyrazole 
(126j) (94.3 mg, 0.50 mmol) and diphenylacetylene (11a) (178.0 mg, 1.00 
mmol). Purification by column chromatography (n-hexane/EtOAc: 15/1) 
yielded 127ja (78.0 mg, 43%) as a yellow solid.  
M. p. = 180−182 °C. 
1
H NMR (300 MHz, CDCl3): δ = 9.04 (d, J = 2.4 Hz, 1H), 8.19 (dd, J = 9.1, 2.4 Hz, 1H), 8.05 (d, 






C NMR (75 MHz, CDCl3): δ = 146.0(Cq), 142.0 (CH), 139.7 (Cq), 137.9 (Cq), 135.0 (Cq), 134.3 
(Cq), 132.2 (Cq), 131.4 (CH), 130.5 (CH), 128.9 (CH), 128.4 (CH), 128.1 (CH), 128.1 (CH), 127.8 
(CH), 123.9 (Cq), 123.2 (Cq), 121.6 (CH), 119.4 (CH), 99.3 (CH). 
IR (neat): 3059, 1511, 1490, 1330, 758, 736, 714, 696 cm
–1
. 




, 318 (40), 290 (10), 158 (10), 
144 (5), 77 (3). 




 365.1159, found 365.1160. 
 
1-Methyl-5,6-diphenyl-7H-pyrazolo[1',5':1,2]pyrido[4,3-b]indole (127la): 
The general procedure A was followed using 
1-methyl-3-(1H-pyrazol-5-yl)-1H-indole (126l) (97.0 mg, 0.49 mmol), and 
diphenylacetylene (11a) (182.0 mg, 1.02 mmol) and Cu(OAc)2·H2O (200 mg, 
1.00 mmol). Purification by column chromatography (n-hexane/EtOAc: 10/1) 
yielded 127la (107.0 mg, 58%) as a light yellow solid.  
M. p. = 221–223 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.19 (d, J = 7.7 Hz, 1H), 8.08 (d, J = 2.2 Hz, 1H), 7.50–7.38 (m, 
3H), 7.32–7.29 (m, 10H), 7.00 (d, J = 2.2 Hz, 1H), 3.27 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 142.2 (CH), 140.5 (Cq), 137.3 (Cq), 136.1 (Cq), 135.3 (Cq), 134.6 
(Cq), 133.1 (Cq), 131.8 (CH), 130.8 (CH), 128.3 (CH), 128.0 (CH), 127.9 (CH), 127.8 (CH), 124.6 
(CH), 121.6 (Cq), 120.6 (CH), 120.5 (CH), 115.0 (Cq), 109.4 (CH), 107.7 (Cq), 93.9 (CH), 32.1 
(CH3). 
IR (neat): 3047, 1632, 1462, 1371, 1261, 884, 714, 692 cm
–1
. 
MS (EI) m/z (relative intensity): 373 (100) [M]
+
, 357 (15), 329 (10), 179 (60), 165 (15), 151 (10), 
138 (5), 77 (5). 




 374.1652, found 374.1647. 
 
6-Nitro-5,6-di-p-tolylpyrazolo[5,1-a]isoquinoline(127ab): 
The general procedure A was followed using 
5-(4-nitrophenyl)-1H-pyrazole (126a) (95.4 mg, 0.50 mmol) and 
1,2-di-p-tolylethyne (11b) (206.0 mg, 1.00 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 15/1) yielded 127ab 
(81.0 mg, 41 %) as a yellow solid.  
M. p. = 240–242 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.48–8.23 (m, 3H), 8.04 (d, J = 2.3 Hz, 1H), 7.34–6.98 (m, 9H), 





C NMR (75 MHz, CDCl3): δ = 146.7 (Cq), 141.5 (CH), 138.6 (Cq), 138.5 (Cq), 137.5 (Cq), 137.2 
(Cq), 131.6 (Cq), 131.1 (CH), 130.4 (CH), 129.3 (Cq), 129.2 (CH), 128.8 (CH), 127.8 (Cq), 124.7 
(CH), 123.6 (Cq), 122.6 (CH), 121.3 (CH), 99.8 (CH), 21.4 (CH3), 21.3 (CH3).  
IR (neat): 3024, 1607, 1520, 1503, 1417, 1354, 1337, 1310 cm
–1
. 
MS (EI) m/z (relative intensity): 392 (100) [M–H]
+
, 346 (25), 331 (5), 304 (5), 291 (5), 165 (10), 
119 (5). 




 393.1472, found 393.1468. 
 
3,4-Bis(4-methoxyphenyl)-6-nitropyrazolo[5,1-a]isoquinoline (127ac): 
The general procedure A was followed using 
5-(4-nitrophenyl)-1H-pyrazole (126a) (94.8 mg, 0.50 mmol) and 
1,2-bis(4-methoxyphenyl)acetylene(11c) (239.0 mg, 1.00 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 10/1) 
yielded 127ac (161.0 mg, 76%) as a yellow solid.  
M. p. = 207–209 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.38–8.28 (m, 3H), 8.05 (d, J = 2.2 Hz, 1H), 7.29–7.23 (m, 3H), 
7.11 (d, J = 8.7 Hz, 2H), 6.90–6.84 (m, 4H), 3.84 (s, 3H), 3.80 (s, 3H).
 
13
C NMR (75 MHz, CDCl3): δ = 159.5 (Cq), 159.0 (Cq), 146.7 (Cq), 141.5 (CH), 138.4 (Cq), 137.2 
(Cq), 132.5 (CH), 132.0 (CH), 130.5 (Cq), 127.8 (Cq), 126.9 (Cq), 124.7 (CH), 124.5 (Cq), 123.4 
(Cq), 122.6 (CH), 121.3 (CH), 114.0 (CH), 113.6 (CH), 99.9 (CH), 55.2 (CH3), 55.1 (CH3). 
IR (neat): 2833, 1517, 1504, 1338, 1246, 1178, 1028, 783 cm
–1
.  
MS (EI) m/z (relative intensity): 425 (100) [M]
+
, 424 (90), 394 (35), 378 (20), 335 (5), 292 (5), 91 
(10). 




 426.1448, found 426.1444. 
 
3,4-Bis(4-fluorophenyl)-6-nitropyrazolo[5,1-a]isoquinoline (127ad): 
The general procedure A was followed using 
5-(4-nitrophenyl)-1H-pyrazole (126a) (95.1 mg, 0.50 mmol) and 
1,2-bis(4-fluorophenyl)acetylene (11d) (215.0 mg, 1.00 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 20/1) 
yielded 127ad (119.0 mg, 59%) as a yellow solid. 
M. p. = 184–186°C. 
1
H NMR (300 MHz, CDCl3): δ = 8.40 (dd, J = 8.8, 2.2 Hz, 1H), 8.34 (d, J = 8.8 Hz, 1H), 8.30 (d, 
J = 2.2 Hz, 1H), 8.07 (d, J = 2.2 Hz, 1H), 7.35–7.28 (m, 3H), 7.20–7.16 (m, 2H), 7.10–7.01 (m, 
4H). 
13
C NMR ( 75 MHz, CDCl3): δ = 162.7 (
1
JC-F = 250 Hz, Cq), 162.3 (
1




(Cq), 141.9 (CH), 137.7 (Cq), 137.3 (Cq), 133.1 (
3
JC-F = 8 Hz, CH), 132.6 (
3
JC-F = 8 Hz, CH), 130.4 
(
4
JC-F = 3 Hz, Cq), 130.0 (Cq), 128.0 (
4
JC-F = 3 Hz, Cq), 127.9 (Cq), 124.9 (CH), 123.0 (Cq), 122.3 
(CH), 121.8 (CH), 115.9 (
2
JC-F = 22 Hz, CH), 115.4 (
2
JC-F = 22 Hz, CH), 100.2 (CH). 
19
F NMR (283 MHz, CDCl3): δ = –111.23 (s), –112.84 (s). 
IR (neat): 1599, 1500, 1334, 1222, 1156, 840, 820, 784 cm
–1
. 
MS (EI) m/z (relative intensity): 401 (100) [M]
+
, 400 (85) [M–H]
+
, 354 (30), 326 (12), 301 (6), 
232 (6), 176 (10), 98 (5). 




 402.1049, found 402.1034. 
 
3,4-Bis(4-chlorophenyl)-6-nitropyrazolo[5,1-a]isoquinoline (127ae): 
The general procedure A was followed using 
5-(4-nitrophenyl)-1H-pyrazole (126a) (95.0 mg, 0.50 mmol) and 
1,2-bis(4-chlorophenyl)acetylene (11e) (247.0 mg, 1.00 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 10/1) 
yielded 127ae (117.0 mg, 54%) as a yellow solid.  
M. p. = 212–214 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.37 (dd, J = 8.8, 2.2 Hz, 1H), 8.29 (d, J = 8.8 Hz, 1H), 8.25 (d, 
J = 2.2 Hz, 1H), 8.02 (d, J = 2.2 Hz, 1H), 7.34–7.27 (m, 4H), 7.25–7.22 (m, 3H), 7.13–7.08 (m, 
2H).  
13
C NMR (75 MHz, CDCl3): δ = 146.9 (Cq), 141.9 (CH), 137.4 (Cq), 137.3 (Cq), 135.3 (Cq), 134.4 
(Cq), 132.8 (Cq), 132.6 (CH), 132.0 (CH), 130.3 (Cq), 129.7 (Cq), 129.1 (CH), 128.7 (CH), 128.0 
(Cq), 125.0 (CH), 122.8 (Cq), 122.2 (CH), 121.9 (CH), 100.3 (CH). 
IR (neat): 1514, 1487, 1333, 1090, 848, 835, 787, 741 cm
–1
. 
MS (EI) m/z (relative intensity): 433 (100) [M]
+
, 432 (80) [M–H]
+
, 386 (25), 351 (15), 324 (10), 
288 (10), 158 (10), 146 (10). 






 434.0458, found 434.0441. 
 
3,4-Bis(4-bromophenyl)-6-nitropyrazolo[5,1-a]isoquinoline (127af): 
The general procedure A was followed using 
5-(4-nitrophenyl)-1H-pyrazole (126a) (94.3 mg, 0.50 mmol) and 
1,2-bis(4-bromophenyl)ethyne (11f) (335.0 mg, 1.00 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 20/1) 
yielded 127af (113.0 mg, 42%) as a yellow solid. 
M. p. = 234–236 °C. 
1




J = 2.1 Hz, 1H), 8.04 (d, J = 2.1 Hz, 1H), 7.52–7.45 (m, 4H), 7.26 (d, J = 2.2 Hz, 1H), 7.26–7.17 
(m, 2H), 7.09–7.04 (m, 2H). 
13
C NMR (75 MHz, CDCl3): δ = 146.9 (Cq), 141.9 (CH), 137.4 (Cq), 137.3 (Cq), 133.3 (Cq), 132.9 
(CH), 132.2 (CH), 132.1 (CH), 131.6 (CH), 130.8 (Cq), 129.6 (Cq), 128.0 (Cq), 125.0 (CH), 123.7 
(Cq), 122.7 (Cq), 122.7 (Cq), 122.2 (CH), 121.9 (CH), 100.3 (CH). 
IR(neat): 3085, 1586, 1512, 1332, 1065, 1010, 905, 847 cm
–1
. 
MS (EI) m/z (relative intensity):521 (100) [M+H]
+
, 493 (10), 475 (15), 443 (20), 397 (15), 316 
(20), 288 (20), 158 (20). 






 521.9447, found 521.9441. 
 
Diethyl 4,4'-(6-Nitropyrazolo[5,1-a]isoquinoline-3,4-diyl)dibenzoate (127ag): 
The general procedure A was followed using 
5-(4-nitrophenyl)-1H-pyrazole (126a) (94.6 mg, 0.50 mmol) and 
diethyl 4,4'-(ethyne-1,2-diyl)dibenzoate (11g) (324.0 mg, 1.00 
mmol). Purification by column chromatography (n-hexane/EtOAc: 
6/1) yielded 127ag (150.0 mg, 59%) as a yellow solid. 
M. p. = 199–200 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.41 (dd, J = 8.8, 2.1 Hz, 1H), 8.35 (d, J = 8.8 Hz, 1H), 8.26 (d, 
J = 2.1 Hz, 1H), 8.05 (d, J = 2.3 Hz, 1H), 8.04–7.99 (m, 4H), 7.44–7.40 (m, 2H), 7.32–7.29 (m, 
3H), 4.40 (q, J = 7.1 Hz, 2H), 4.36 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H), 1.37 (t, J = 7.1 Hz, 
3H). 
13
CNMR (75 MHz, CDCl3): δ = 165.8 (Cq), 165.7 (Cq), 146.8 (Cq), 141.9 (CH), 138.9 (Cq), 137.3 
(Cq), 137.2 (Cq), 136.1 (Cq), 131.3 (CH), 130.8 (Cq), 130.6 (CH), 130.3 (Cq), 129.8 (CH), 129.3 
(CH), 129.3 (Cq), 127.9 (Cq), 124.9 (CH), 123.0 (Cq), 122.1 (CH), 121.9 (CH), 100.3 (CH), 61.2 
(CH2), 61.1 (CH2), 14.4 (CH3), 14.3 (CH3). 
IR (neat): 2982, 1715, 1523, 1420, 1343, 1272, 1103, 1021 cm
–1
. 
MS (EI) m/z (relative intensity): 509 (5) [M]
+
, 479 (3), 267 (10), 239 (8), 134 (10), 98 (25), 59 
(27), 43 (100). 




 510.1660, found 510.1643. 
 
6-Nitro-3,4-di-n-propylpyrazolo[5,1-a]isoquinoline (127ah): 
The general procedure A was followed using 5-(4-nitrophenyl)-1H-pyrazole 
(126a) (94.3 mg, 0.50 mmol) and oct-4-yne (11h) (110.0 mg, 1.00 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 20/1) yielded 




M. p. = 123−124 °C.
 
1
H NMR (300 MHz, CDCl3): δ = 8.73 (d, J = 2.2 Hz, 1H), 8.29 (dd, J = 8.8, 2.2 Hz, 1H), 8.18 (d, 
J = 8.8 Hz, 1H), 8.02 (d, J = 2.3 Hz, 1H), 7.11 (d, J = 2.3 Hz, 1H), 3.29 (t, J = 8.0 Hz, 2H), 2.99 (t, 
J = 8.0 Hz, 2H), 1.89–1.78 (m, 2H), 1.77–1.68 (m, 2H), 1.14 (t, J = 7.3 Hz, 3H), 1.13 (t, J = 7.3Hz, 
3H). 
13
C NMR (75 MHz, CDCl3): δ = 146.7 (Cq), 140.6 (CH), 139.0 (Cq), 136.3 (Cq), 129.0 (Cq), 127.7 
(Cq), 125.0 (CH), 120.4 (CH), 120.0 (CH), 119.0 (Cq), 99.5 (CH), 30.2 (CH2), 29.6 (CH2), 23.9 
(CH2), 21.2 (CH2), 14.4 (CH3), 14.3 (CH3). 




MS (EI) m/z (relative intensity): 297 (80) [M]
+
, 268 (95), 252 (55), 222 (100), 194 (30), 178 (25), 
152 (25), 127 (15). 




 298.1550, found 298.1551. 
 
3,4-Di-n-propylbenzo[g]pyrazolo[5,1-a]isoquinoline (127ih): 
The general procedure A was followed using 
5-(naphthalen-2-yl)-1H-pyrazole (126i) (97.1 mg, 0.50 mmol) and oct-4-yne 
(11h) (115.0 mg, 1.04 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 50/1) yielded 127ih (92.0 mg, 61%) as an off-white solid. 
M. p. = 130–132 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.58 (s, 1H), 8.27 (s, 1H), 8.03–7.98 (m, 2H), 7.96 (d, J = 2.1 
Hz, 1H) , 7.56–7.51 (m, 2H), 7.14 (d, J = 2.1 Hz, 1H), 3.29 (t, J = 8.0Hz, 2H), 3.04 (t, J = 8.0Hz, 
2H), 1.94–1.73 (m, 4H), 1.18 (t, J = 7.3 Hz, 3H), 1.15 (t, J = 7.3 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 139.6 (CH), 137.5 (Cq), 136.4 (Cq), 132.6 (Cq), 131.5 (Cq), 128.3 
(CH), 127.6 (CH), 127.4 (Cq), 126.1 (CH), 126.0 (CH), 122.6 (Cq), 122.6 (CH), 122.4 (CH), 118.6 
(Cq), 98.7 (CH), 30.1 (CH2), 29.9 (CH2), 23.6 (CH2), 21.7 (CH2), 14.6 (CH3), 14.4 (CH3). 
IR (neat): 2955, 2930, 2870, 1396, 1088, 922, 879, 787 cm
–1
. 
MS (EI) m/z (relative intensity): 302 (97) [M]
+
, 273 (100), 259 (35), 245 (35), 231 (28), 203 (28), 
189 (15), 151 (20). 




 303.1856, found 303.1854. 
 
3,4-Di-n-propylpyrazolo[5,1-a]isoquinoline-6-carbonitrile (127dh): 
The general procedure A was followed using 
4-(1H-pyrazol-5-yl)benzonitrile (126d) (84.5 mg, 0.50 mmol) and oct-4-yne 




(n-hexane/EtOAc: 30/1) yielded 127dh (71.0 mg, 52%) as a light yellow solid. 
M. p. = 122–124 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.16 (d, J = 8.2Hz, 1H), 8.14 (s, 1H), 8.01 (d, J = 2.2 Hz, 1H), 
7.70 (dd, J = 8.2, 1.5 Hz, 1H), 7.08 (d, J = 2.2 Hz, 1H), 3.28 (t,J = 8.1 Hz, 2H), 2.93 (t,J = 8.1 Hz, 
2H), 1.89–1.76 (m, 2H), 1.75–1.62 (m, 2H), 1.13 (t, J = 7.3 Hz, 3H), 1.12 (t, J = 7.3Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 140.4 (CH), 138.8 (Cq), 136.5 (Cq), 129.0 (CH), 128.9 (Cq), 
128.1 (CH), 126.4 (Cq), 124.8 (CH), 119.2 (Cq), 118.2 (Cq), 110.9 (Cq), 99.0 (CH), 30.1 (CH2), 
29.5 (CH2), 23.8 (CH2), 21.2 (CH2), 14.4 (CH3), 14.3 (CH3). 
IR (neat): 2962, 1258, 1088, 1050, 1017, 777, 741, 694 cm
–1
. 
MS (EI) m/z (relative intensity): 277 (55) [M]
+
, 262 (50), 248 (100), 234 (30), 221 (40), 206 (30), 
192 (10), 152 (20).  




 278.1652, found 278.1653. 
 
3,4-Di-n-propyl-6-(trifluoromethyl)pyrazolo[5,1-a]isoquinoline (127bh): 
The general procedure A was followed using 5-{4-(trifluoromethyl)-
phenyl}-1H-pyrazole (126b) (106.0 mg, 0.50 mmol)and oct-4-yne(1h) 
(113.0 mg, 1.03 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 50/1) yielded 127bh (104.0 mg, 65%) as a colorless oil. 
1
H NMR (300 MHz, CDCl3): δ = 8.19 (d, J = 8.4 Hz, 1H), 8.09 (d, J = 1.8 Hz, 1H), 8.00 (d, J = 
2.2 Hz, 1H), 7.71 (dd, J = 8.4, 1.2Hz, 1H), 7.07 (d, J = 2.2 Hz, 1H), 3.30 (t, J = 8.0 Hz 2H), 2.98 (t, 
J = 8.0 Hz 2H), 1.90–1.77 (m, 2H), 1.75–1.65 (m, 2H), 1.10 (t, J = 7.4 Hz, 6H). 
13
C NMR (75 MHz, CDCl3): δ = 140.2 (CH), 138.2 (Cq), 136.8 (Cq), 129.3 (
2
JC-F = 32 Hz, Cq), 
128.7 (Cq), 125.9 (
4
JC-F = 1 Hz, Cq), 124.6 (CH), 124,3 (
1
JC-F = 272Hz, Cq), 122.4 (
3
JC-F = 3 Hz, 
CH), 121.2 (
3
JC-F = 4 Hz, CH), 118.8 (Cq), 98.4 (CH), 30.1 (CH2), 29.5 (CH2), 23.8 (CH2), 21.2 
(CH2), 14.4 (CH3), 14.4 (CH3). 
19
F NMR (283 MHz, CDCl3): δ = –62.2 (s). 
IR(neat): 2961, 2933, 2874, 1355, 1339, 1310, 1117, 1079 cm
–1
. 
MS (EI) m/z (relative intensity): 320 (90) [M]
+
, 305 (60), 291 (100), 264 (50), 249 (20), 223 (10), 
202 (10). 




 321.1573, found: 321.1573. 
 
4-Methyl-6-nitro-3-phenylpyrazolo[5,1-a]isoquinoline (127ai): 
The general procedure was A followed using 5-(4-nitrophenyl)-1H-pyrazole 
(126a) (95.5 mg, 0.50 mmol) and (prop-1-yn-1-yl)benzene (11i) (120.0 mg, 




15/1) yielded 127ai (76.0 mg, 50%) as a yellow solid. 
M. p. = 178–180°C. 
1
H NMR (300 MHz, CDCl3): δ = 8.82 (d, J = 2.2 Hz, 1H), 8.41 (dd, J = 8.8, 2.2 Hz, 1H), 8.28 (d, 
J = 8.8 Hz, 1H), 7.97 (d, J = 2.2 Hz, 1H), 7.66–7.54 (m, 3H), 7.50–7.47 (m, 2H), 7.19 (d, J = 2.2 
Hz, 1H), 2.44 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 146.7(Cq), 141.1 (CH), 137.9 (Cq), 136.7 (Cq), 132.8 (Cq), 130.1 
(CH), 130.0 (Cq), 129.4 (CH), 128.8 (CH), 128.2 (Cq), 124.9 (CH), 121.4 (CH), 120.5 (CH), 116.2 
(Cq), 99.8 (CH), 15.1 (CH3). 
IR (neat): 3090, 3055, 1520, 1333, 798, 761, 737, 706 cm
–1
. 
MS (EI) m/z(relative intensity): 303 (90) [M]
+
, 302 (100), 256 (50), 244 (10), 229 (10), 202 (10), 
128 (15), 115 (10). 




 303.1002, found:303.1010. 
 
4-(n-Butyl)-3-(4-methoxyphenyl)-6-nitropyrazolo[5,1-a]isoquinoline (127aj): 
The general procedure A was followed using 
5-(4-nitrophenyl)-1H-pyrazole (126a) (94.7 mg, 0.50 mmol) and 
1-(hex-1-yn-1-yl)-4-methoxybenzene (11j) (193.0 mg, 1.03 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 10/1) 
yielded 127aj (135.0 mg, 72%) as a yellow solid. 
M. p. = 107–108 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.82 (d, J = 2.2 Hz, 1H), 8.38 (dd, J = 8.8, 2.2 Hz, 1H), 8.27 (d, 
J = 8.8 Hz, 1H), 7.96 (d, J = 2.2 Hz, 1H), 7.38(d, J = 8.8 Hz, 2H), 7.17 (d, J = 2.2 Hz, 1H), 7.12 (d, 
J = 8.8 Hz, 2H), 3.91 (s, 3H), 2.85–2.80 (m, 2H), 1.66–1.56 (m, 2H), 1.40–1.32 (m, 2H), 0.87 (t, J 
= 7.3 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 160.1 (Cq), 146.7 (Cq), 141.1 (CH), 137.9 (Cq), 136.7 (Cq), 131.1 
(CH), 129.1 (Cq), 128.5 (Cq), 125.1 (CH), 124.9 (Cq), 121.4 (Cq), 121.1 (CH), 120.6 (CH), 
114.3(CH), 99.6 (CH), 55.3 (CH3), 32.9 (CH2), 28.0 (CH2), 22.7 (CH2), 13.7 (CH3). 
IR (neat): 2957, 2930, 2871, 1518, 1507, 1336, 1288, 1246 cm
–1
. 
MS (EI) m/z (relative intensity) 375 (25) [M]
+
, 333 (100), 286 (18), 242 (15), 214 (12), 143 (10), 
101 (5), 77 (5). 




 376.1656, found 376.1654. 
 
3-(n-Hexyl)-4-(4-methoxyphenyl)-6-nitropyrazolo[5,1-a]isoquinoline (127ak): 
The general procedure A was followed using 




1-methoxy-4-(oct-1-yn-1-yl)benzene (11k) (218.0 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 10/1) yielded 127ak (127.0 mg, 63%) as a brownsolid. 
M. p. = 98–100 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.82 (d, J = 2.2 Hz, 1H), 8.39 (dd, J = 8.8, 2.2 Hz, 1H), 8.28 (d, 
J = 8.8 Hz, 1H), 7.96 (d, J = 2.2 Hz, 1H), 7.53–7.30 (m, 2H), 7.17 (d, J = 2.2 Hz, 1H), 7.15–7.06 
(m, 2H), 3.91 (s, 3H), 2.84–2.79 (m, 2H), 1.67–1.56 (m, 2H),1.38–1.21 (m, 6H), 0.86 (t, J = 6.6 
Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 160.2 (Cq), 146.8 (Cq), 141.2 (CH), 137.9 (Cq), 136.7 (Cq), 131.1 
(CH), 129.2 (Cq), 128.6 (Cq), 125.2 (CH), 125.0 (Cq), 121.5 (Cq), 121.2 (CH), 120.6 (CH), 114.4 
(CH), 99.6 (CH), 55.3 (CH3), 31.3 (CH2), 30.7 (CH2), 29.3 (CH2), 28.3 (CH2), 22.5 (CH2), 14.0 
(CH3). 
IR (neat): 2954, 2927, 2855, 1712, 1520, 1508, 1338, 1292 cm
–1
. 
MS (EI) m/z (relative intensity): 403 (60) [M]
+
, 332 (100), 286 (45), 271 (10), 259 (10), 242 (20), 
216 (10), 189 (3). 




 404.1969, found 404.1978. 
 
4-(n-Butyl)-6-cycno-3-(4-methoxyphenyl)pyrazolo[5,1-a]isoquinoline (127dj) 
The general procedure A was followed using 
4-(1H-pyrazol-5-yl)benzonitrile (126d) (85.1 mg, 0.50 mmol) and 
1-(hex-1-yn-1-yl)-4-methoxybenzene (11j) (192.0 mg, 1.02 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 
15/1→10/1) yielded 127dj (121.0 mg, 68%) as a light yellow solid. 
M. p. = 174–175 °C.  
1
H NMR (300 MHz, CDCl3): δ = 8.23 (d, J = 8.4 Hz, 1H), 8.21 (d, J = 1.5 Hz 1H), 7.94 (d, J = 
2.2 Hz, 1H), 7.78 (dd, J = 8.4, 1.5 Hz, 1H), 7.37 (d, J = 8.7 Hz, 2H), 7.13 (d, J = 2.2 Hz, 1H), 7.10 
(d, J = 8.7 Hz, 2H), 3.91 (s, 3H), 2.78–2.71 (m, 2H), 1.62–1.52 (m, 2H), 1.40–1.24 (m, 2H), 0.85 
(t, J = 7.3 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 160.1 (Cq), 141.1 (CH), 137.7 (Cq), 136.8 (Cq), 131.1 (CH), 
129.6 (CH), 129.0 (Cq), 128.8 (CH), 127.1 (Cq), 125.0 (Cq), 124.9 (CH), 120.6 (Cq), 119.1 (Cq), 
114.4 (CH), 111.0 (Cq), 99.1 (CH), 55.3 (CH3), 32.9 (CH2), 28.0 (CH2), 22.8 (CH2), 13.7 (CH3). 
IR (neat): 2955, 2932, 2224, 1507, 1462, 1417, 1242, 1178 cm
–1
. 
MS (EI) m/z (relative intensity): 355 (50) [M]
+
, 326 (10), 312 (100), 285 (15), 268 (20), 242 (20), 
214 (10), 177 (5). 









Intermolecular Competition Experiment between Substrates 126f and 126a 
 
 
A mixture of 5-(4-methoxyphenyl)-1H-pyrazole (126f) (87.5 mg, 0.50 mmol), 
5-(4-nitrophenyl)-1H-pyrazole (126a) (95.7 mg, 0.50 mmol), diphenylacetylene (11a) (89.4 mg, 
0.50 mmol), [RuCl2(p-cymene)]2 (30.7 mg, 10 mol %), AgSbF6 (69 mg, 40 mol %) and 
Cu(OAc)2·H2O (200 mg, 1.00 mmol) in DCE (2.0 mL) was stirred at ambient temperature for 5 
min and then at 100 °C for 20 h under an ambient atmosphere of air. At ambient temperature, the 
reaction mixture was diluted with sat. aq. NH4Cl/NH3 (1:1, 10 mL) and extracted with EtOAc (3  
25 mL). The combined organic layers were dried over Na2SO4. After filtration and evaporation of 
the solvents in vacuo, the crude products were purified by column chromatography on silica gel 
(n-hexane/EtOAc: 15/1→8/1) to yield 127fa (34.0 mg, 19%) and 127aa (49.0 mg, 27%).Their 
spectral data were identical to those reported above. 
 
Intermolecular Competition Experiment between Alkynes 11a and 11h 
 
 
A mixture of 5-(4-nitrophenyl)-1H-pyrazole (126a) (95.0 mg, 0.50 mmol), diphenylacetylene (11a) 
(271.0 mg, 1.52 mmol), oct-4-yne(11h) (175.0 mg, 1.59 mmol), [RuCl2(p-cymene)]2 (15.4 mg, 5.0 
mol %), AgSbF6 (36.2 mg, 20 mol %) and Cu(OAc)2·H2O (102.0 mg, 0.51 mmol) in DCE (2.0 
mL) was stirred at ambient temperature for 5 min and then at 100 °C for 20 h under an ambient 




NH4Cl/NH3 (1:1, 10 mL) and extracted with EtOAc (3  25 mL). The combined organic layers 
were dried over Na2SO4. After filtration and evaporation of the solvents in vacuo, the crude 
product was purified by column chromatography on silica gel (n-hexane/EtOAc: 20/1→8/1) to 
yield 127aa (35.0 mg, 19%) and 127ah (17.0 mg, 11%) as yellow solids. Their spectral data were 
identical to those reported above. 
 




A mixture of 5-(4-nitrophenyl)-1H-pyrazole (126a) (95.3 mg, 0.50 mmol), 1,2-bis(4-methoxy-
phenyl)acetylene (11c) (356.0 mg, 1.50 mmol), 1,2-bis(4-fluorophenyl)acetylene(11d) (320 mg, 
1.50 mmol), [RuCl2(p-cymene)]2 (15.7 mg, 5.0 mol %), AgSbF6 (36.2 mg, 20 mol %) and 
Cu(OAc)2·H2O (102 mg, 0.50 mmol) in DCE (2.0 mL) was stirred at ambient temperature for 5 
min, and then at 100 °C for 20 h under an ambient atmosphere of air. At ambient temperature, the 
reaction mixture was diluted with sat. aq. NH4Cl/NH3 (1:1, 10 mL) and extracted with EtOAc (3  
25 mL). The combined organic layers were dried over Na2SO4. After filtration and evaporation of 
the solvents in vacuo, the crude products were purified by column chromatography on silica gel 
(n-hexane/EtOAc: 20/1→10/1) to yield 127ac (69.0 mg, 32%) and 127ad (29.0mg, 14%) as 












Ruthenium(II)-Catalyzed H/D Exchange with Arylpyrazole 126a Employing D2O as the 
Cosolvent 
 
The general procedure A was followed using 5-(4-nitrophenyl)-1H-pyrazole (126a) (95.0 mg, 0.50 
mmol), diphenylacetylene (11a) (179 mg, 1.00 mmol), [RuCl2(p-cymene)]2 (15.4 mg, 5.0 mol %), 
AgSbF6 (35.1 mg, 20 mol %) and Cu(OAc)2 (91.7 mg, 0.50 mmol) in a solvent mixture of DCE 
and D2O (1.8/0.2 mL). Purification by column chromatography (n-hexane/EtOAc: 10/1→2/1) 
yielded reisolated partially deuterated starting material [D]n-126a (27 mg, 28%) and product 
[D]n-127aa (44 mg, 24%) as yellow solids. The deuterium incorporations in [D]n-127aa and 





8.4.2 Analytical Data for the Products of the Ruthenium(II)-Catalyzed Oxidative 
C–H Alkenylations of Sulfonic Acids, Chloride and Benzenesulfonate. 
 
(E)-2-(3-Ethoxy-3-oxoprop-1-en-1-yl)-3,6-dimethylbenzenesulfonic Acid (129ab): 
The general procedure B was followed using 2,5-dimethylbenzenesulfonic 
acid (128a) (94.0 mg, 0.50 mmol) and ethyl acrylate (46b) (150.0 mg, 
1.50 mmol). Purification by column chromatography (CH2Cl2/MeOH: 
10/1) yielded 129ab (131.0 mg, 91%) as an off-white solid. 
M. p. = 222−224 °C. 
1
H NMR (300 MHz, d6-DMSO): δ = 8.15 (d, J = 16.4 Hz, 1H), 7.09 (d, J = 7.8 Hz, 1H), 7.01 (d, 
J= 7.8 Hz, 1H), 5.63 (d, J = 16.4 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 2.52 (s, 3H), 2.16 (s, 3H), 1.23 
(t, J = 7.1 Hz, 3H). 
13
C NMR (100 MHz, d6-DMSO): δ = 166.0 (Cq), 147.6 (CH), 145.3 (Cq), 133.9 (Cq), 132.9 (Cq), 
132.3 (Cq), 130.9 (CH), 130.0 (CH), 119.7 (CH), 59.5 (CH2), 21.7 (CH3), 21.2 (CH3), 14.2 (CH3). 
IR (neat): 3446 (br), 2982, 1699, 1640, 1310, 1179, 1059, 654 cm
–1
. 
MS (EI) m/z (relative intensity): 267 (5) [M–OH]
+
, 237 (5), 203 (65), 175 (100), 157 (25), 129 
(30), 115 (30), 91 (20). 




] 283.0646, found 283.0649. 
 




The general procedure B was followed using 2-methylbenzenesulfonic 
acid (128b) (87.0 mg, 0.50 mmol) and ethyl acrylate (46b) (150.0 mg, 
1.50mmol). Purification by column chromatography (CH2Cl2/MeOH: 
15/1→10/1) yielded 129bb (126.0 mg, 92%) as an off-white solid. 
M. p. = 285−287°C. 
1
H NMR (300 MHz, d6-DMSO): δ = 8.85 (d, J = 15.9 Hz, 1H), 7.50–7.31 (m, 1H), 7.20 (m, 2H), 
6.10 (d, J = 15.9 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 2.58 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 166.1 (Cq), 147.7 (CH), 145.4 (Cq), 136.4 (Cq), 133.0 (Cq), 
132.8 (CH), 127.8 (CH), 125.6 (CH), 117.0 (CH), 59.5 (CH2), 22.3 (CH3), 14.2 (CH3). 
IR (neat): 3504 (br), 1698, 1632, 1364, 1308, 1186, 1167, 664 cm
–1
. 
MS (EI) m/z (relative intensity): 253 (5) [M–OH]
+
, 230 (15), 223 (10), 196 (15), 189 (50), 161 
(100), 143 (10), 115 (40). 
HR-MS (ESI) m/zcalcd for C12H13O5S [M–H
+
] 269.0489, found 269.0490.  
 
(E)-2-(3-Ethoxy-3-oxoprop-1-en-1-yl)-6-fluorobenzenesulfonic Acid (129cb): 
The general procedure B was followed using 2-fluorobenzenesulfonic acid 
(128c) (88.0 mg, 0.50 mmol) and ethyl acrylate (46b) (150.0 mg, 1.50 
mmol). Purification by column chromatography (CH2Cl2/MeOH: 
15/1→10/1) yielded 129cb (126.0 mg, 92%) as an off-white solid. 
M. p. = 217−219 °C. 
1
H NMR (300 MHz, d6-DMSO): δ = 8.78 (d, J = 16.0 Hz, 1H), 7.45–7.42 (m, 1H), 7.36–7.29 (m, 
1H), 7.19–7.12 (m, 1H), 6.27 (d, J = 16.0 Hz, 1H), 4.16 (dq, J = 7.1, 1.1 Hz, 2H), 1.23 (dt, J = 7.1, 
1.1 Hz, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 165.8 (Cq), 158.5 (d, 
1
JC-F = 249.4 Hz, Cq), 144.6 (d, 
4
JC-F = 
3.6 Hz, CH), 134.7 (d, 
3
JC-F = 2.6 Hz, Cq), 134.3 (d, 
2
JC-F = 14.5 Hz, Cq), 129.7 (d, 
3
JC-F = 9.6 Hz, 
CH), 123.2 (d, 
4
JC-F = 3.2 Hz, CH), 118.9 (CH) , 117.6 (d, 
2
JC-F = 25.3 Hz, CH), 59.8 (CH2), 14.2 
(CH3). 
19
F NMR (283 MHz, d6-DMSO): δ = –108.6 (ddd, J = 10.7, 5.2, 1.4 Hz). 
IR (neat): 3470 (br), 2984, 1698, 1634, 1462, 1231, 1189, 655 cm
–1
. 
MS (EI) m/z (relative intensity): 257 (5) [M–OH]
+
, 229 (5), 193 (35), 165 (100), 120 (15), 109 
(15), 83 (10), 43 (15). 
HR-MS (ESI) m/z calcd for C11H10FO5S [M–H
+
] 273.0238, found 273.0329. 
 
(E)-2-(3-Ethoxy-3-oxoprop-1-en-1-yl)-4-fluoro-6-methylbenzenesulfonic Acid (129db): 




methylbenzenesulfonic acid (128d) (95.0 mg, 0.50 mmol) and ethyl acrylate (46b) (150.0 mg, 
1.50 mmol). Purification by column chromatography (CH2Cl2/MeOH: 10/1) yielded 129db (136.0 
mg, 94%) as a white solid. 
M. p. = 261−263 °C. 
1
H NMR (300 MHz, d6-DMSO): δ = 8.79 (d, J = 16.0 Hz, 1H), 7.23–7.19 (m, 1H), 7.07–7.02 (m, 
1H), 6.19 (d, J = 16.0 Hz, 1H), 4.15 (q, J = 7.4. Hz, 2H), 2.56 (s, 3H), 1.22 (t, J = 7.4 Hz, 3H). 
13
C NMR (75 MHz, d6-DMSO): δ = 166.1 (Cq), 160.5 (d, 
1
JC-F = 244.6 Hz, Cq), 146.3 (d, 
4
JC-F = 
2.1 Hz, CH), 142.4 (d, 
4
JC-F = 3.0 Hz, Cq), 140.0 (d, 
3
JC-F = 7.9 Hz, Cq), 135.6 (d, 
3
JC-F = 8.0 Hz, 
Cq), 118.9 (d, 
2
JC-F = 20.6 Hz, CH), 118.4(CH), 111.8 (d, 
2
JC-F = 21.7 Hz, CH), 59.7 (CH2), 22.2 (d, 
4
JC-F = 1.5 Hz, CH3), 14.2 (CH3). 
19
F NMR (283 MHz, d6-DMSO): δ = –115.0. 
IR (neat): 3489 (br), 2984, 1694, 1588, 1322, 1214, 1184, 1095 cm
–1
. 
MS (EI) m/z (relative intensity): 271 (5) [M–OH]
+
, 207 (50), 179 (100), 133 (25), 123 (15), 109 
(10), 83 (10), 43 (15). 
HR-MS (ESI) m/z calcd for C12H12FO5S [M–H
+
] 287.0395, found 287.0396. 
 
(E)-2-(3-Ethoxy-3-oxoprop-1-en-1-yl)naphthalene-1-sulfonic Acid (129eb): 
The general procedure B was followed using naphthalene-1-sulfonic acid 
(129e) (105.0 mg, 0.50 mmol) and ethyl acrylate (46b) (150.0 mg, 1.50 
mmol). Purification by column chromatography (CH2Cl2/MeOH: 
15/1→10/1) yielded 3ea (141.0 mg, 91%) as a white solid.  
M. p. = 281−283 °C. 
1
H NMR (300 MHz, d6-DMSO): δ = 9.28–9.25 (m, 1H), 9.18 (d, J = 16.1Hz, 1H), 7.87–7.82 (m, 
2H), 7.65–7.61 (m, 1H), 7.50–7.45 (m, 2H), 6.28 (d, J = 16.1 Hz, 1H), 4.22–4.14 (m, 2H), 1.29–
1.23 (m, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 166.1 (Cq), 147.0 (CH), 143.6 (Cq), 133.9 (Cq), 129.9 (Cq), 
129.5 (Cq), 129.1 (CH), 128.9 (CH), 127.3 (CH), 126.0 (CH), 125.6 (CH), 124.8 (CH), 118.3 (CH), 
59.7 (CH2), 14.3 (CH3). 
IR (neat): 3481 (br), 2984, 1695, 1628, 1267, 1183, 1053, 612 cm
–1
.  
MS (EI) m/z(relative intensity): 304 (15) [M–2H]
+
, 267 (5), 225 (55), 197 (100), 161 (50), 139 
(50), 115 (40), 43 (95). 
HR-MS (ESI) m/z calcd for C15H13O5S [M–H
+
] 305.0489, found 305.0500. 
 
2-(3-Ethoxy-3-oxoprop-1-en-1-yl)-3,6-dimethoxybenzenesulfonic Acid (129fb): (E:Z = 2.3:1). 




benzenesulfonic acid (128f) (109.5 mg, 0.50 mmol) and ethyl acrylate (46b) (150.0 mg, 1.50 
mmol). Purification by column chromatography (CH2Cl2/MeOH: 15/1→10/1) yielded 129fb 
(114.0 mg, 72%) as an off-white solid.  
M. p. = 212−214 °C. 
(E-isomer): 
1
H NMR (300 MHz, d6-DMSO): δ = 8.30 (d, J = 16.2 Hz, 1H), 7.00 (s, 2H), 6.09 (d, 
J = 16.2 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.70 (s, 3H), 3.68 (s, 3H), 1.23(t, J = 7.1 Hz, 3H).
13
C 
NMR (100 MHz, d6-DMSO): δ = 166.7 (Cq), 151.6 (Cq), 151.2 (Cq), 142.0 (CH), 137.3 (Cq), 
122.7 (Cq), 120.6 (CH), 116.3 (CH), 113.2 (CH), 59.4 (CH2), 57.7 (CH3), 56.3 (CH3), 14.2 (CH3). 
(Z-isomer): 
1
H NMR (300 MHz, d6-DMSO): δ = 7.19 (d, J = 12.2 Hz, 1H), 6.88 (s, 1H), 6.87 (s, 
1H), 5.74 (d, J = 12.2 Hz, 1H), 3.89 (q, J = 7.1 Hz, 2H), 3.68 (s, 3H), 3.55 (s, 3H), 1.01 (t, J = 7.1 
Hz, 3H).
13
CNMR (100 MHz, d6-DMSO): δ = 165.4 (Cq), 151.0 (Cq), 149.7 (Cq), 140.4 (CH), 
136.7 (Cq), 124.4 (Cq), 118.4 (CH), 113.5 (CH), 112.0 (CH), 58.6 (CH2), 57.1 (CH3), 55.9 (CH3), 
13.8 (CH3). 
IR (neat): 3457 (br), 2979, 2838, 1697, 1636, 1466, 1248, 1173 cm
–1
. 
MS (EI) m/z (relative intensity): 315 (5) [M–H]
+
, 235 (55), 207 (100), 192 (20), 177 (20), 165 (15), 
43 (18). 
HR-MS (ESI) m/zcalcd for C13H15O7S [M–H
+
] 315.0544, found 315.0548. 
 
(E)-2-(3-Ethoxy-3-oxoprop-1-en-1-yl)-4,6-difluorobenzenesulfonic Acid (129hb) 
The general procedure B was followed using 2,4-difluorobenzenesulfonic 
acid (128h) (98.0 mg, 0.50 mmol) and ethyl acrylate (46b) (150.0 mg, 1.50 
mmol). Purification by column chromatography (CH2Cl2/MeOH: 
20/1→10/1) yielded 129hb (110.0 mg, 75%) as an off-white solid. 
M. p. = 292−294 °C. 
1
H NMR (300 MHz, d6-DMSO): δ = 8.77 (d, J = 16.0 Hz, 1H), 7.42–7.37 (m, 1H), 7.25–7.16 (m, 
1H), 6.41 (d, J = 16.0 Hz, 1H), 4.18 (q, J = 7.0 Hz, 2H), 1.25 (t, J = 7.0 Hz, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 165.9 (Cq), 161.2 (dd, J = 247.0, 14.0 Hz, Cq), 159.3 (dd, J 
= 252.0, 13.0 Hz, Cq), 143.3 (m, CH), 136.4 (dd, J = 9.3, 3.9 Hz, Cq), 131.6 (dd, J = 15.0, 4.0 Hz, 
Cq), 120.3 (CH), 110.0 (dd, J = 22.2, 3.6 Hz, CH), 105.5 (dd, J = 29.8, 25.1 Hz, CH), 59.9 (CH2), 
14.1 (CH3). 
19
F NMR (283 MHz, d6-DMSO): δ = –103.9 (t), –110.4 (q). 
IR (neat): 3463 (br), 2982, 1702, 1603, 1584, 1309, 1186, 1098 cm
–1
. 
MS (EI) m/z (relative intensity): 275 (5) [M–OH]
+
, 247 (5), 211 (35), 183 (100), 167 (20), 138 
(15), 101 (10), 43 (28). 
HR-MS (ESI) m/z calcd for C11H9F2O5S [M–H
+





(E)-2-(3-Ethoxy-3-oxoprop-1-en-1-yl)benzenesulfonic Acid (129ib)  
The general procedure B was followed using benzenesulfonic acid (128i) 
(163.0 mg, 1.03 mmol) and ethyl acrylate (46b) (51.0 mg, 0.51 mmol). 
Purification by column chromatography (CH2Cl2/MeOH: 12/1→10/1) yielded 
129ib (71.0 mg, 54%) as a white solid. 
M. p. = 259−261 °C. 
1
H NMR (300 MHz, d6-DMSO): δ = 8.70 (d, J = 16.2 Hz, 1H), 7.82–7.72 (m, 2H), 7.35–7.32 (m, 
2H), 6.42 (d, J = 16.2 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 1.23 (t, J = 7.1 Hz, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 166.0 (Cq), 147.0 (Cq), 144.0 (CH), 131.3 (Cq), 128.9 (CH), 
128.8 (CH), 126.8 (CH), 126.5 (CH), 118.0 (CH), 59.7 (CH2), 14.2 (CH3). 
IR (neat): 3455 (br), 1692, 1633, 1316, 1183, 1024, 611 cm
–1
. 
MS (EI) m/z (relative intensity): 239 (5) [M–OH]
+
, 211 (5), 175 (50), 147 (100), 137 (5), 103 (10), 
91 (10), 43 (10). 




] 255.0333, found 255.0334. 
 
(E)-2-(3-Ethoxy-3-oxoprop-1-en-1-yl)-4-methylbenzenesulfonic Acid (129jb): 
The general procedure B was followed using 4-methylbenzenesulfonic acid 
(129j) (172.3 mg, 1.00 mmol) and ethyl acrylate (46b) (51.1 mg, 0.51 mmol). 
Purification by column chromatography (CH2Cl2/MeOH: 20/1→15/1) yielded 
129jb (120.0 mg, 87%) as a pale white solid. 
M. p. = 289−291 °C. 
1
H NMR (300 MHz, d6-DMSO): δ = 8.67 (d, J = 16.2 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.58 (s, 
1H), 7.15 (d, J = 7.8 Hz, 1H), 6.42 (d, J = 16.2 Hz, 1H), 4.16 (q, J = 7.2 Hz, 2H), 2.29 (s, 3H), 
1.24 (t, J = 7.2 Hz, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 166.0 (Cq), 144.4 (Cq), 144.0 (CH), 138.3 (Cq), 131.1 (Cq), 
129.4 (CH), 127.0 (CH), 126.9 (CH), 117.9 (CH), 59.7 (CH2), 20.5 (CH3), 14.2 (CH3). 
IR (neat): 3448 (br), 2979, 1696, 1634, 1318, 1182, 1023, 680 cm
–1
. 
MS (EI) m/z (relative intensity): 253 (5) [M–OH]
+
, 243 (10), 189 (35), 161 (80), 115 (30), 83 (20), 
55 (45), 43 (100). 




269.0489, found 269.0501. 
 
(E)-2-(3-Ethoxy-3-oxoprop-1-en-1-yl)-5-methylbenzenesulfonic Acid (129kb): 




acid (128k) (80.0 mg, 0.45 mmol) and ethyl acrylate (46b) (150.0 mg, 1.50 mmol). Purification by 
column chromatography (CH2Cl2/MeOH: 15/1→10/1) yielded 129kb (105.0 mg, 83%) as a white 
solid. 
M. p. = 123−125 °C. 
1
H NMR (300 MHz, D2O): δ = 8.28 (d, J = 15.9 Hz, 1H), 7.57 (s, 1H), 7.43 (d, J = 7.9 Hz, 1H), 
7.17 (d, J = 7.9 Hz, 1H), 6.22 (d, J = 15.9 Hz, 1H), 4.09 (q, J = 7.2 Hz, 2H), 2.20 (s, 3H), 1.16 (t, J 
= 7.2 Hz, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 166.1 (Cq), 146.9 (Cq), 144.0 (CH), 138.8 (Cq), 129.3 (CH), 
128.5 (Cq), 127.4 (CH), 126.5 (CH), 117.0 (CH), 59.6 (CH2), 20.9 (CH3), 14.2 (CH3). 
IR (neat): 3452 (br), 2935, 1706, 1636, 1319, 1189, 1027, 623 cm
–1
. 
MS (EI) m/z (relative intensity): 253 (10) [M–OH]
+
, 225 (5), 213 (15), 189 (70), 161 (100), 113 
(15), 115 (35), 64 (20). 
HR-MS (ESI) m/z calcd for C12H13O5S [M–H
+
] 269.0489, found 269.0500. 
 
(E)-2-(3-Ethoxy-3-oxoprop-1-en-1-yl)-4,6-dimethylbenzenesulfonic Acid (129lb): 
The general procedure B was followed using 2,4-dimethylbenzenesulfonic 
acid (128l) (93.0 mg, 0.50 mmol) and ethyl acrylate (46b) (150.0 mg, 1.50 
mmol). Purification by column chromatography (CH2Cl2/MeOH: 10/1) 
yielded 129lb (120.0 mg, 85%) as a white solid. 
M. p. = 189−191 °C. 
1
H NMR (300 MHz, d6-DMSO): δ = 8.86 (d, J = 15.9 Hz, 1H), 7.18 (d, J = 2.0 Hz, 1H), 7.01 (d, J 
= 2.0 Hz, 1H), 6.09 (d, J = 15.9 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 2.55 (s, 3H), 2.25 (s, 3H), 1.25 
(t, J = 7.1 Hz, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 166.1 (Cq), 147.7 (CH), 142.9 (Cq), 136.9 (Cq), 136.3 (Cq), 
133.4 (CH), 132.8 (Cq), 126.0 (CH), 116.8 (CH), 59.5 (CH2), 22.0 (CH3), 20.2 (CH3), 14.2 (CH3). 
IR (neat): 3387 (br), 2978, 1697, 1633, 1176, 1093, 1025, 680 cm
–1
. 
MS (EI) m/z (relative intensity): 267 (5) [M–OH]
+
, 239 (5), 161 (5), 134 (15), 112 (10), 98 (20), 
57 (30), 43 (100). 
HR-MS (ESI) m/z calcd for C13H15O5S [M–H
+
] 283.0646, found 283.0645.  
The spectral data were in accordance with those reported in the literature.
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 (E)-2-(3-n-Butoxy-3-oxoprop-1-en-1-yl)-4,6-dimethylbenzenesulfonic Acid (129lc): 
The general procedure B was followed using 
2,4-dimethylbenzenesulfonic acid (128l) (93.5 mg, 0.50 mmol) and butyl 




chromatography (CH2Cl2/MeOH: 15/1→10/1) yielded 129lc (123.0 mg, 78%) as a white solid. 
M. p. = 208−210 °C. 
1
H NMR (400 MHz, d6-DMSO) ): δ = 8.86 (d, J = 15.9 Hz, 1H), 7.17 (s, 1H), 7.00 (s, 1H), 6.08 
(d, J = 15.9 Hz, 1H), 4.11 (t, J = 6.6 Hz, 2H), 2.54 (s, 3H), 2.24 (s, 3H), 1.64–1.57 (m, 2H), 1.42–
1.33 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 166.2 (Cq), 147.7 (CH), 142.9 (Cq), 136.9 (Cq), 136.3 (Cq), 
133.4 (CH), 132.8 (Cq), 126.0 (CH), 116.7 CH), 63.2 (CH2), 30.3 (CH2), 22.0 (CH3), 20.2 (CH3), 
18.6 (CH2), 13.5 (CH3). 
IR (neat): 3417 (br), 2959, 2932, 2874, 1695, 1633, 1172, 1091, 1020 cm
–1
. 
MS (EI) m/z (relative intensity): 310 (1) [M–2H]
+
, 234 (5), 202 (5), 146 (20), 134 (24), 118 (25), 
89 (10), 64 (20), 44 (100). 
HR-MS (ESI) m/z calcd for C15H19O5S [M–H
+
] 311.0959, found 311.0960. 




(E)-2-{3-(Benzyloxy)-3-oxoprop-1-en-1-yl}-4,6-dimethylbenzenesulfonic Acid (129ld): 
The general procedure B was followed using 
2,4-dimethylbenzenesulfonic acid (128l) (93.0 mg, 0.50 mmol) and 
benzyl acrylate (46d) (237.0 mg, 1.46 mmol). Purification by column 
chromatography (CH2Cl2/MeOH: 10/1) yielded 129ld (145.0 mg, 84%) as an off-white solid. 
M. p. = 241−243 °C. 
1
H NMR (400 MHz, d6-DMSO): δ = 8.94 (d, J = 15.9 Hz, 1H), 7.41–7.31 (m, 5H), 7.19 (s, 1H), 
7.00 (s, 1H), 6.16 (d, J = 15.9 Hz, 1H), 5.20 (s, 2H), 2.54 (s, 3H), 2.24 (s, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 166.0 (Cq), 148.3 (CH), 143.0 (Cq), 137.0 (Cq), 136.3 (Cq), 
136.2 (Cq), 133.6 (CH), 132.7 (Cq), 128.2 (CH), 127.7 (CH), 127.6 (CH), 126.0 (CH), 116.4 (CH), 
65.0 (CH2), 22.0 (CH3), 20.2 (CH3). 
IR (neat): 3425 (br), 1695, 1631, 1167, 1090, 1020, 680, 656 cm
–1
. 
MS (EI) m/z (relative intensity): 345 (5) [M–H]
+
, 299 (3), 265 (5), 219 (5), 206 (10), 197 (20), 180 
(5), 91 (100). 
HR-MS (ESI) m/zcalcd for C18H17O5S [M–H
+
] 345.0802, found 345.0804.  
 
(E)-2,4-Dimethyl-6-(3-oxobut-1-en-1-yl)benzenesulfonic Acid (129lf): 
The general procedure B was followed using 2,4-dimethylbenzenesulfonic 
acid (128l) (92.5 mg, 0.50 mmol)and methyl vinylketone (46f) (110.0 mg, 




15/1→10/1) yielded 129lf (120.0 mg, 95%) as a pale solid. 
M. p. = 260−262 °C. 
1
H NMR (400 MHz, d6-DMSO): δ = 8.88 (d, J = 16.3 Hz, 1H), 7.18 (s, 1H), 7.02 (s, 1H), 6.28 (d, 
J = 16.3 Hz, 1H), 2.56 (s, 3H), 2.27 (s, 3H), 2.26 (s, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 198.1 (Cq), 147.0 (CH), 143.1 (Cq), 137.0 (Cq), 136.5 (Cq), 
133.6 (CH), 132.9 (Cq), 126.6 (CH), 125.7 (CH), 26.6 (CH3), 22.0 (CH3), 20.2 (CH3). 
IR (neat): 3492 (br), 1669, 1594, 1387, 1178, 1088, 1019, 690 cm
–1
. 
MS (EI) m/z (relative intensity): 239 (3) [M–CH3]
+
, 134 (5), 112 (5), 101 (10), 84 (10), 66 (10), 58 
(40), 43 (100). 
HR-MS (ESI) m/z calcd for C12H13O4S [M–H
+
] 253.0540, found 253.0542. 
 
(E)-2,4-Dimethyl-6-{2-(phenylsulfonyl)vinyl}benzenesulfonic Acid (129lg): 
The general procedure B was followed using 
2,4-dimethylbenzenesulfonic acid (128l) (93.3 mg, 0.50 mmol) and 
(vinylsulfonyl)benzene (46g) (254.0 mg, 1.51 mmol). Purification by 
column chromatography (CH2Cl2/MeOH: 15/1→10/1) yielded 129lg 
(163.0 mg, 92%) as a pale yellow solid.  
M. p. = 214−216 °C. 
1
H NMR (300 MHz, d6-DMSO): δ = 8.90 (d, J = 15.3 Hz, 1H), 7.95–7.92 (m, 2H), 7.72–7.59 (m, 
3H), 7.15 (s, 1H), 7.04 (s, 1H), 6.95 (d, J = 15.3 Hz, 1H), 2.55 (s, 3H), 2.23 (s, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 146.1 (CH), 143.3 (Cq), 141.2 (Cq), 137.2 (Cq), 136.6 (Cq), 
134.2 (CH), 133.1 (CH), 130.9 (Cq), 129.2 (CH), 126.9 (CH), 126.4 (CH), 125.9 (CH), 21.8 (CH3), 
20.1 (CH3). 
IR (neat): 3417 (br), 1614, 1596, 1303, 1142, 1083, 684, 651 cm
–1
. 
MS (EI) m/z (relative intensity): 299 (3), 284 (5), 271 (10), 239 (40), 211 (100), 183 (20), 165 (30), 
119 (25). 
HR-MS (ESI) m/z calcd for C16H15O5S2 [M–H
+
] 351.0366, found 351.0368. 
 
2-(2-Cyanovinyl)-4,6-dimethylbenzenesulfonic Acid (E:Z = 5:1) (129lh): 
The general procedure B was followed using 2,4-dimethylbenzenesulfonic 
acid (128l) (92.7 mg, 0.50 mmol) and acrylonitrile (46h) (84.0 mg, 1.58 
mmol). Purification by column chromatography (CH2Cl2/MeOH: 10/1) 
yielded 129lh (88.0 mg, 75%) as a pale yellow solid.The ratio of the two isomers was 5:1, as 
estimated by 
1




M. p. = 293−295°C 
(E-isomer):
1
H NMR (300 MHz, d6-DMSO): δ = 8.67 (d, J = 16.7 Hz, 1H), 7.18 (s, 1H), 7.04 (s, 
1H), 5.98 (d, J = 16.7 Hz, 1H), 2.51 (s, 3H), 2.23 (s, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 153.1 (CH), 142.6 (Cq), 137.1 (Cq), 136.4 (Cq), 134.2 (CH), 
131.9 (Cq), 125.3 (CH), 119.1 (Cq), 95.2 (CH), 21.9 (CH3), 20.2 (CH3). 
(Z-isomer):
1
H NMR (300 MHz, d6-DMSO): δ = 8.14 (d, J = 11.7 Hz, 1H), 7.21 (s, 1H), 7.06 (s, 
1H), 5.62 (d, J = 11.7 Hz, 1H), 2.53 (s, 3H), 2.25 (s, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 153.8 (CH), 142.3 (Cq), 137.0 (Cq), 136.6 (Cq), 133.5 (CH), 
131.9 (Cq), 125.1 (CH), 117.7 (Cq), 94.0 (CH), 21.5 (CH3), 20.3 (CH3). 
IR (neat): 3459 (br), 2228, 1616, 1595, 1181, 696, 570, 526 cm
–1
. 
MS (EI) m/z (relative intensity): 237 (5) [M]
+
, 197 (25), 170 (20), 157 (20), 142 (15), 129 (15), 97 
(55), 83 (100). 
HR-MS (ESI) m/z calcd for C11H10NO3S [M–H
+
] 236.0387, found 236.0392. 




(E)-2-{2-(Diethoxyphosphoryl)vinyl}-4,6-dimethylbenzenesulfonic Acid (129li): 
The general procedure B was followed using 
2,4-dimethylbenzenesulfonic acid (128l) (93.8 mg, 0.50 mmol) and 
diethyl vinylphosphonate (46i) (259.0 mg, 1.58 mmol). Purification by 
column chromatography (CH2Cl2/MeOH: 10/1) yielded 129li (165.0 mg, 94%) as an off-white 
solid. 
M. p. = 137−139 °C. 
1
H NMR (300 MHz, d6-DMSO): δ = 8.57 (dd, J = 22.7, 17.5 Hz, 1H), 7.15 (s, 1H), 7.00 (s, 1H), 
5.95 (dd, J = 20.5, 17.5 Hz, 1H), 4.07–3.98 (m, 4H), 2.55 (s, 3H), 2.25 (s, 3H), 1.26 (t, J = 7.0 Hz, 
6H). 
13
C NMR (125 MHz, d6-DMSO): δ = 150.7 (d, J = 8.7 Hz, CH), 142.7 (d, J = 1.7 Hz, Cq), 137.1 
(Cq), 136.4 (d, J = 1.4 Hz, Cq), 134.0 (d, J = 24.1 Hz, Cq), 133.4 (CH), 125.9(d, J = 1.9 Hz, CH), 




P NMR (122 MHz, d6-DMSO): δ = 19.4. 
IR (neat): 3394 (br), 2979, 1615, 1597, 1194, 1014, 969, 684 cm
–1
. 
MS (EI) m/z (relative intensity): 331 (3) [M–OH]
+
, 284 (3), 267 (70), 239 (30), 211 (100), 193 (15), 
177 (5), 115 (10). 
HR-MS (ESI) m/z calcd forC14H20O6PS [M–H
+
] 347.0724, found 347.0726. 







The general procedure C was followed using 
2,4-dimethylbenzenesulfonic acid (128l) (91.5 mg, 0.49 mmol) and 
2-vinylnaphthalene (46k) (230.0 mg, 1.49 mmol), AgSbF6 (69.0 mg, 
0.20 mmol, 41 mol %). Purification by column chromatography 
(CH2Cl2/MeOH: 10/1) yielded 129lk (86.0 mg, 51%) as a pale yellow solid. 
M. p. = 223−225 °C. 
1
H NMR (300 MHz, d6-DMSO): δ = 8.57 (d, J = 16.3 Hz, 1H), 7.90–7.85 (m, 4H), 7.72 (d, J = 
8.0 Hz,1H), 7.51–7.41 (m, 2H), 7.32 (d, J = 2.0 Hz, 1H), 6.96 (d, J = 16.3 Hz, 1H), 6.90 (d, J = 
2.0 Hz, 1H), 2.54 (s, 3H), 2.26 (s, 3H). 
13
C NMR (100 MHz, d6-DMSO): δ = 142.1 (Cq), 136.7 (Cq), 136.3 (Cq), 135.9 (Cq), 135.5 (Cq), 
133.3 (Cq), 132.2 (Cq), 131.9 (CH), 131.7 (CH), 127.9 (CH), 127.6 (CH), 127.5 (CH), 126.9 CH), 
126.2 (CH), 125.6 (CH), 125.6 (CH), 125.1 (CH), 123.9 (CH), 22.5 (CH3), 20.4 (CH3). 
IR (neat): 3413 (br), 1594, 1177, 1093, 1024, 961, 719, 687 cm
–1
. 
MS (EI) m/z (relative intensity): 338 (15) [M]
+
, 323 (10), 288 (45), 259 (45), 239 (15), 155 (75), 
127 (70), 43 (100). 
HR-MS (EI) m/z calcd for C20H18O3S [M]
+
 338.0971, found 338.0978. 
 
(E)-2,4-Dimethyl-6-{2-(2,3,4,5,6-pentafluorophenyl)vinyl}benzenesulfonic Acid (129ll): 
The general procedure C was followed using 
2,4-dimethylbenzenesulfonic acid (128l) (93.0 mg, 0.50 mmol) and 
1,2,3,4,5-pentafluoro-6-vinylbenzene (46l) (291.0 mg, 1.65 mmol, but 
with twofold amount of AgSbF6 (69.0 mg, 0.20 mmol, 40 mol%). 
Purification by column chromatography (CH2Cl2/MeOH: 15/1→10/1) yielded 129ll (101.0 mg, 
53%) as an off-white solid. 
1
H NMR (500 MHz, d6-DMSO): δ = 8.68 (d, J = 16.6 Hz, 1H), 7.22 (d, J = 2.2 Hz, 1H), 6.98 (d, J 
= 2.2 Hz, 1H), 6.55 (d, J = 16.6 Hz, 1H), 2.57 (s, 3H), 2.28 (s, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 143.8 (m, Cq), 142.3 (Cq), 140.8 (t, J = 7.5 Hz, CH), 138.5 
(m, Cq), 137.1 (m, Cq), 137.0 (Cq), 136.3 (Cq), 134.8 (Cq), 132.6 (CH), 125.3 (CH), 113.0 (m, Cq), 
110.5 (CH), 22.2 (CH3), 20.3 (CH3). 
19
F NMR (283 MHz, d6-DMSO): δ = –(143.9−144.0) (m), –158.28 (t, J = 22.0 Hz), –
(163.8−164.0) (m). 
IR (neat): 3422(br), 1518, 1497, 1179, 1087, 956, 577 cm
–1
. 
MS (EI) m/z (relative intensity): 378 (5) [M]
+





HR-MS (ESI) m/z calcd for C16H10F5O3S [M–H
+
] 377.0276, found 377.0270.  
 
(E)-2-(4-Fluorostyryl)-4,6-dimethylbenzenesulfonic Acid (129lm): 
The general procedure C was followed using 2,4-dimethyl-
benzenesulfonic acid (128l) (92.3 mg, 0.50 mmol) and 
1-fluoro-4-vinylbenzene (46m) (183.0 mg, 1.50 mmol). Purification by 
column chromatography (CH2Cl2/MeOH: 10/1) yielded 129lm (92.0 
mg, 60%) as an off-white solid. 
M. p. = 237−239 °C. 
1
H NMR (300 MHz, d6-DMSO): δ = 8.36 (d, J = 16.2 Hz, 1H), 7.53–7.47 (m,2H), 7.24–7.18 (m, 
3H), 6.88 (s, 1H), 6.78 (d, J = 16.3 Hz, 1H), 2.53 (s, 3H), 2.24 (s, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 161.0 (d, 
1
JC-F = 243 Hz, Cq), 141.9 (d, 
4
JC-F = 3.0 Hz, Cq), 
136.5 (Cq), 136.1 (Cq), 135.3 (Cq), 134.7 (d, J = 3.1 Hz, Cq), 131.5 (CH), 131.2 (CH), 127.8 (d, 
3
JC-F = 7.9 Hz, CH), 125.5 (CH), 124.9 (CH), 115.2 (d, 
2
JC-F = 21.4 Hz, CH), 22.5 (CH3), 20.4 
(CH3). 
19
F NMR (283 MHz, d6-DMSO): δ = –110.6 (s). 
IR (neat): 3395 (br), 2924, 1597, 1507, 1219, 1172, 1091, 1022 cm
–1
. 
MS (EI) m/z (relative intensity): 299 (5), 285 (10), 267 (30), 239 (25), 154 (10), 134 (35), 98 (75). 
HR-MS (ESI) m/z calcd for C16H14FO3S [M–H
+
] 305.0653, found 305.0652.  
 
(E)-2-(2-Fluorostyryl)-4,6-dimethylbenzenesulfonic Acid (129ln): 
 
The general procedure C was followed using 2,4-dimethylbenzenesulfonic 
acid (128l) (93.0. mg, 0.5 mmol), 1-fluoro-2-vinylbenzene (11n) (183.0 
mg, 1.50 mmol), and AgSbF6 (69.0 mg, 40 mol%). Purification by column 
chromatography (CH2Cl2 /MeOH: 15:1→10:1) yielded 129ln (105.6 mg, 
69%) as an off-white solid. 
M. p. = 289–291 °C.
 
1
H NMR (300 MHz, d6-DMSO): δ = 8.48 (d, J = 16.4 Hz, 1H), 7.70–7.59 (m, 1H), 7.35–7.15 (m, 
4H), 6.93 (s, 1H), 6.84 (d, J = 16.4 Hz, 1H), 2.56 (s, 3H), 2.27 (s, 3H). 
13
C NMR (125 MHz, d6-DMSO): δ = 159.2 (d, 
1
JC-F = 246.2 Hz, Cq), 142.0 (Cq), 136.8 (Cq), 
136.2 (Cq), 135.3 (Cq), 134.0 (d, 
3
JC-F = 3.5 Hz, CH), 131.9 (CH), 128.4 (d, 
3
JC-F = 8.2 Hz, CH), 
126.9 (d, 
3
JC-F = 3.9 Hz, CH), 125.6 (d, 
2
JC-F = 12.2 Hz, Cq), 125.1 (CH), 124.3 (CH), 118.2 (CH), 
115.4 (d, 
2





F NMR (283 MHz, d6-DMSO): δ = –(119.2−119.3) (m). 
IR (neat): 3438 (br), 2957, 2920, 1605, 1486, 1455, 1194, 1091, 686 cm
–1
. 
MS (EI) m/z (relative intensity): 304 (12) [M–2H]
+
, 291 (4), 226 (80), 211 (20), 197 (48), 180 (12), 
158 (13), 64 (100). 
HR-MS: (ESI) m/z calcd for C16H14FO3S [M–H
+
] 305.0653, found 305.0652. 
 
Ruthenium(II)-Catalyzed Oxidative Alkenylation of 4-Methylbenzenesulfonyl Chloride 136. 
 
The general procedure B was followed using 4-methylbenzenesulfonyl chloride 136 (96.0 mg, 
0.50mmol), ethyl acrylate (46b) (157.0 mg, 1.57 mmol), [RuCl2(p-cymene)]2 (15.5 mg, 5.0 
mol %), AgSbF6 (36.0 mg, 20 mol %) and Cu(OAc)2∙H2O (200.0 mg, 1.00 mmol) in DMA. 
Purification by column chromatography (CH2Cl2/MeOH: 20/1→15/1) yielded product 129jb (96.2 
mg, 71%) as a paleyellow solid. Its spectral data were identical to those reported above. 
 
Ruthenium(II)-Catalyzed Oxidative Alkenylation of Methyl Benzenesulfonate (137) 
 
 
The general procedure B was followed using methyl benzenesulfonate (137) (86.0 mg, 0.50mmol), 
ethyl acrylate (46b) (157.0 mg, 1.57 mmol), [RuCl2(p-cymene)]2 (15.5 mg, 5.0 mol %), AgSbF6 
(36.0 mg, 20 mol %) and Cu(OAc)2∙H2O (200.0 mg, 1.00 mmol) in DMA. Purification by column 
chromatography (CH2Cl2/MeOH: 20/1→15/1) yielded monoalkenylated benzenesulfonic acid 
129ib (70 mg, 55%) and dialkenylated product 129ib' (27 mg, 15%) as pale yellow solids. The 
spectral data of 129ib were identical to those reported above. 
2,6-Bis{(E)-3-ethoxy-3-oxoprop-1-en-1-yl}benzenesulfonic Acid (129ib'): 
1
H NMR (400 MHz, d6-DMSO): δ = 8.83 (d, J = 15.9 Hz, 2H), 7.62 (d, J = 7.7 Hz, 2H), 7.35 (t, J = 
7.7 Hz, 1H), 6.20 (d, J = 15.9 Hz, 2H), 4.18 (q, J = 7.1 Hz, 4H), 1.26 (t, J = 7.1 Hz, 6H). 
13
C NMR (125 MHz, d6-DMSO): δ = 166.0 (Cq), 146.2 (CH), 145.7 (Cq), 133.3 (Cq), 129.2 (CH), 




IR (neat): 3497, 2982, 1697, 1632, 1309, 1162, 1026, 670, 595 cm
-1
. 
HR-MS: (ESI) m/z calcd for C16H17O7S [M–H
+
] 353.0700, found 353.0700. 
 
Intermolecular Competition Experiment between Substrates128l and 128h 
 
 
A suspension of 2,4-dimethylphenylsulfonic acid 128l (187.0 mg, 1.00 mmol), 
2,4-difluorobenzenesulfonic acid 128h (194.0 mg, 1.00 mmol), ethyl acrylate (46b) (51.5 mg, 
0.51mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), AgSbF6 (35.0 mg, 20 mol %) and 
Cu(OAc)2·H2O (200 mg, 1.00 mmol) in DMA (2.0 mL) was stirred at ambient temperature under 
N2 for 5 min and then at 120 °C for 16 h under N2. At ambient temperature, the solvent was 
removed in vacuo, and the crude products were purified by column chromatography on silica gel 
(CH2Cl2/MeOH: 10/1) to yield 142 mg of the acids 129lb (78%) and 129hb (19%) as an 
inseparable mixture. The ratio of product 129lb/129hb was estimated by 
1
H NMR spectroscopy 
applying their spectral data reported above. 
 
Ruthenium(II)-Catalyzed H/D Exchange in Alkenylation of Substrate 128j Employing D2O 
as the Cosolvent 
 
The general procedure B was followed using 4-methylbenzenesulfonic acid 128j (174.0 mg, 1.00 
mmol), ethyl acrylate (46b) (50.2 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (15.5 mg, 5.0 mol %), 
AgSbF6 (36.0 mg, 20mol %) and Cu(OAc)2 (183.0 mg, 1.00 mmol) in a solvent mixture of DMA 




yielded [D]n-129jb (105.0 mg, 78%) as an off-white solid and reisolated starting material 
[D]n-128j (80.0 mg, 46%). The deuterium incorporation in [D]n-129jb and [D]n-128j were 
estimated by 
1
H NMR spectroscopy. 
 
8.4.3 Ruthenium(II)-Catalyzed C–H Bond Alkenylation of Arenes Bearing 
Removable Directing Groups. 
(E)-Ethyl 3-{3-Methyl-2-(pyridin-2-yloxy)phenyl}acrylate (131ab): 
The general procedure D was followed using 2-(o-tolyloxy)pyridine(130a) 
(185.4 mg, 1.00 mmol), ethyl acrylate (46b) (52.0 mg, 0.52 mmol), 
[RuCl2(p-cymene)]2 (7.6 mg, 2.5 mol %), AgSbF6 (18.5 mg, 10 mol %) 
and Cu(OAc)2·H2O (207.6 mg, 1.04 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 12/1→10/1) yielded 131ab (122.0 mg, 83%) as a colorless 
solid. 




H NMR (300 MHz, CDCl3): δ = 8.08 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.76 (d, J = 16.1 Hz, 1H), 
7.70−7.63 (m, 1H), 7.52−7.49 (m, 1H), 7.29–7.24 (m, 1H), 7.16 (dd, J = 7.7, 7.6 Hz, 1H), 6.95–6.90 
(m, 2H), 6.40 (d, J = 16.1 Hz, 1H), 4.16 (q, J = 7.1Hz, 2H), 2.08 (s, 3H), 1.24 (t, J = 7.1Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.8 (Cq), 163.2 (Cq), 150.7 (Cq), 147.8 (CH), 139.6 CH), 139.2 
(CH), 133.1(CH), 132.3 (Cq), 128.3 (Cq), 125.6 (CH), 125.3 (CH), 119.7 (CH), 118.1 (CH), 110.3 
(CH), 60.3 (CH2), 16.6 (CH3), 14.2 (CH3). 
IR (neat): 2974, 2928, 1699, 1629, 1422, 1242, 1165, 772 cm–1. 
MS (EI) m/z (relative intensity): 283 (15) [M]
+
, 254 (10), 238 (15), 210 (100), 180 (10), 167 (15), 
131 (10), 78 (20). 
HR-MS (EI) m/z calcd for C17H17NO3 [M]
+
 283.1208, found 283.1211. 
 
(E)-tert-Butyl 3-{3-methyl-2-(pyridin-2-yloxy)phenyl}acrylate (131ap): 
The general procedure D was followed using 
2-(o-tolyloxy)pyridine(130a) (185.1 mg, 1.00 mmol), tert-butyl acrylate 
(46p) (62.2 mg, 0.49 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %), 
and AgSbF6 (17.9 mg, 11 mol %) Purification by column chromatography 
(n-hexane/EtOAc: 15/1) yielded 131ap (123.0 mg, 81%) as a colorless solid. 




H NMR (300 MHz, CDCl3): δ = 8.09–8.06 (m,1H), 7.69 (d, J = 16.1 Hz, 1H), 7.68–7.62 (m, 1H), 
7.51 (dd, J = 7.7, 1.6 Hz, 1H), 7.34–7.21 (m, 1H), 7.15 (dd, J = 7.7, 7.6 Hz, 1H), 6.99–6.83 (m, 2H), 





C NMR (75 MHz, CDCl3): δ = 166.1 (Cq), 163.2 (Cq), 150.6 (Cq), 147.7 (CH), 139.5 (CH), 138.0 
(CH), 132.8 (CH), 132.2 (Cq), 128.3 (Cq), 125.5 (CH), 125.0 (CH), 121.4 (CH), 118.0 (CH), 110.2 
(CH), 80.2 (Cq), 28.1 (CH3), 16.6 (CH3). 
IR (neat): 2986, 1695, 1421, 1325, 1265, 1238, 1161, 779 cm–1. 
MS (EI) m/z (relative intensity): 311 (30) [M]
+
, 254 (20), 238 (45), 318 (40), 194 (15), 180 (20), 
167 (22), 78 (27). 




 311.1516, found 311.1529. 
 
(E)-Benzyl 3-{3-Methyl-2-(pyridin-2-yloxy)phenyl}acrylate (131ad): 
The general procedure D was followed using 2-(o-tolyloxy)pyridine(130a) 
(186.2 mg, 1.00 mmol), benzyl acrylate (46d) (79.2 mg, 0.49 mmol), 
[RuCl2(p-cymene)]2 (7.7 mg, 12.5 μmol, 2.5 mol %), and AgSbF6 (18.2 
mg, 11 mol %). Purification by column chromatography (n-hexane/EtOAc: 
20/1→15/1) yielded 131ad (127.0 mg, 75%) as a light yellow oil. 
1
H NMR (300 MHz, CDCl3): δ = 8.16−8.13 (m, 1H), 7.91 (d, J = 16.1 Hz, 1H), 7.67 (td, J = 7.8, 2.0 
Hz, 1H), 7.47 (d, J = 2.2 Hz, 1H), 7.36−7.32 (m, 5H), 7.21 (dd, J = 8.3, 2.2 Hz, 1H), 7.02−6.94 (m, 
3H), 6.52 (d, J = 16.1 Hz, 1H), 5.19 (s, 2H), 2.36 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.6 (Cq), 163.5 (Cq), 150.6 (Cq), 147.60 (CH), 139.5 (CH), 
139.4 (CH), 136.0 (Cq), 134.7 (Cq), 132.1 (CH), 128.4 (CH), 128.2 (CH), 128.0 (CH), 128.0 (CH), 
126.9 (Cq), 122.4 (CH), 118.9 (CH), 118.5 (CH), 111.4 (CH), 66.1 (CH2), 20.8 (CH3). 
IR (neat): 3031, 2948, 1709, 1464, 1426, 1239, 1161, 696 cm–1. 
MS (EI) m/z (relative intensity): 345 (30) [M]
+
, 254 (22), 238 (15), 210 (100), 194 (45), 182 (50), 
167 (30), 91 (70). 




 345.1359, found 345.1362. 
 
(E)-Ethyl-3-{3-isopropyl-2-(pyridin-2-yloxy)phenyl}acrylate (131bb): 
The general procedure D was followed using 
2-(2-isopropylphenoxy)pyridine (130b) (215.0 mg, 1.00 mmol), ethyl 
acrylate (46b) (49.3 mg, 0.49 mmol), [RuCl2(p-cymene)]2 (7.9 mg, 2.6 mol 
%), AgSbF6 (19.1 mg, 11 mol %). Purification by column chromatography 
(n-hexane/EtOAc: 15/1→12/1) yielded 131bb (134.0 mg, 87%) as a colorless oil. 
1
H NMR (300 MHz, CDCl3): δ = 8.10 (ddd, J = 5.0, 2.0, 0.6 Hz, 1H), 7.74 (d, J = 16.1 Hz, 1H), 7.65 
(ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.51 (dd, J = 7.7, 1.7 Hz, 1H), 7.40 (dd, J = 7.8, 1.7 Hz, 1H), 7.25 (dd, 
J = 7.7, 7.8 Hz, 1H), 7.01–6.83 (m, 2H), 6.39 (d, J = 16.1 Hz, 1H), 4.15 (q, J = 7.1 Hz, 2H), 3.02 





C NMR (75 MHz, CDCl3): δ = 166.7 (Cq), 163.7 (Cq), 149.4 (Cq), 147.7 (CH), 142.4 (Cq), 139.5 
(CH), 139.4 (CH), 128.8 (Cq), 128.3 (CH), 126.0 (CH), 125.1 (CH), 119.6 (CH), 118.1 (CH), 110.1 
(CH), 60.2 (CH2), 27.0 (CH), 22.9 (CH3), 14.1 (CH3). 
IR (neat): 2963, 1709, 1424, 1260, 1237, 1168, 1135, 774 cm–1. 
MS (EI) m/z (relative intensity): 311 (30) [M]
+
, 294 (10), 268 (70), 238 (100), 222 (20), 196 (20), 
120 (30), 78 (35). 




 311.1516, found 311.1524. 
 
(E)-tert-Butyl 3-{3-isopropyl-2-(pyridin-2-yloxy)phenyl}acrylate (131bp) 
The general procedure D was followed using 2-(2-isopropylphenoxy)-
pyridine (1b) (212.0 mg, 0.99 mmol), tert-butyl acrylate (46p) (62.7 mg, 
0.49 mmol), [RuCl2(p-cymene)]2 (7.9 mg, 2.6 mol %), and AgSbF6 (18.1 
mg, 11 mol%). Purification by column chromatography (n-hexane/EtOAc: 
15/1) yielded 131bp (155.0 mg, 93%) as a colorless solid. 




H NMR (300 MHz, CDCl3):δ = 8.11 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.70–7.65 (m, 1H), 7.65 (d, J 
= 16.0 Hz, 1H), 7.52 (dd, J =7.7, 1.6 Hz, 1H), 7.40 (dd, J = 7.8, 1.6 Hz, 1H), 7.25 (dd, J = 7.8, 7.7 
Hz, 1H), 6.96–6.91 (m, 2H), 6.31 (d, J = 16.0 Hz, 1H), 3.03 (hept, J = 6.9 Hz, 1H), 1.44 (s, 9H), 
1.14 (d, J = 6.9 Hz, 6H). 
13
C NMR (75 MHz, CDCl3): δ = 166.1 (Cq), 163.8 (Cq), 149.3 (Cq), 147.8 (CH), 142.4 (Cq), 139.5 
(CH), 138.4 (CH), 128.6 (CH), 128.5 (Cq), 126.0 (CH), 124.9 (CH), 121.5 (CH), 118.0 (CH), 110.1 
(CH), 80.2 (Cq), 28.1 (CH3), 27.1 (CH), 23.0 (CH3). 
IR (neat): 2969, 1698, 1421, 1325, 1262, 1233, 1157, 779 cm
–1
. 
MS (EI) m/z (relative intensity): 339 (20) [M]
+
, 296 (10), 266 (33), 238 (100), 222 (20), 196 (22), 
120 (10), 78 (12). 
HR-MS (EI) m/z calcd for C21H25NO3 [M]
+
 339.1829, found 339.1840. 
 
(E)-Ethyl 3-{3-fluoro-2-(pyridin-2-yloxy)phenyl}acrylate (131cb): 
The general procedure D was followed using 2-(2-fluorophenoxy)pyridine 
(130c) (189.0 mg, 1.00 mmol), ethyl acrylate (46b) (54.9 mg, 0.55 mmol), 
[RuCl2(p-cymene)]2 (7.9 mg, 2.5 mol %), and AgSbF6 (18.7 mg, 11 mol %). 
Purification by column chromatography (n-hexane/EtOAc: 12/1→10/1) 
yielded 131cb(128 mg, 81%) as a yellow solid. 
M. p. = 74–76 °C. 
1




7.73 (ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.47–7.43 (m, 1H), 7.26–7.15 (m, 2H), 7.08 (dt, J = 8.3, 0.9 
Hz, 1H), 7.01 (ddd, J = 7.2, 5.0, 0.9 Hz, 1H), 6.49 (d, J = 16.2 Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 
1.29 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.6 (Cq), 162.6 (Cq), 155.5 (
1
JC-F = 251 Hz, Cq), 147.4 (CH), 
140.0 (
2
JC-F = 13 Hz, Cq), 139.6 (CH), 137.8 (
4
JC-F = 4 Hz, CH), 130.3 (
3
JC-F = 2 Hz, Cq), 125.8 
(
3
JC-F = 8 Hz, CH), 122.9 (
4
JC-F = 4 Hz, CH), 121.0 (CH), 118.9 (CH), 117.8 (
2
JC-F = 19 Hz, CH), 
110.7 (CH), 60.6 (CH2), 14.2 (CH3). 
19
F NMR (283 MHz, CDCl3): δ = –126.21 (s). 
IR (neat): 2987, 1710, 1426, 1265, 1226, 1170, 981, 772 cm
–1
. 
MS (EI) m/z (relative intensity): 287(10) [M]
+
, 258 (15), 242 (15), 214 (100), 185 (20), 136 (10), 
107 (15), 78 (55). 




 287.0952, found 287.0953. 
 
(E)-tert-Butyl 3-{3-fluoro-2-(pyridin-2-yloxy)phenyl}acrylate (131cp): 
The general procedure D was followed using 2-(2-fluorophenoxy) pyridine 
(131c) (188.0 mg, 0.99 mmol), tert-butyl acrylate (46p) (63.3 mg, 0.49 
mmol), [RuCl2(p-cymene)]2 (7.9 mg, 2.6 mol %), and AgSbF6 (18.6 mg, 
11 mol %). Purification by column chromatography (n-hexane/EtOAc: 
15/1→12/1) yielded 131cp (136.0 mg, 87%) as a colorless solid. 
M. p. = 108–110 °C.  
1
H NMR (300 MHz, CDCl3): δ = 8.09 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.74 (d, J = 16.1 Hz, 1H), 
7.72 (ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.47–7.43 (m, 1H), 7.23–7.14 (m, 2H), 7.07 (dt, J = 8.3, 0.9 
Hz, 1H), 7.00 (ddd, J = 7.2, 5.0, 0.9 Hz, 1H), 6.42 (d, J = 16.1 Hz, 1H), 1.48 (s, 9H). 
13
C NMR (125 MHz, CDCl3): δ = 165.9 (Cq), 162.6 (Cq), 156.4 (
1
JC-F = 249 Hz, Cq), 147.4 (CH), 
139.9 (
2
JC-F = 13 Hz, Cq), 139.6 (CH), 136.7 (
4
JC-F = 3 Hz, CH), 130.5 (
3
JC-F = 2.0 Hz, Cq), 125.8 
(
3
JC-F = 8 Hz, CH), 122.8 (CH), 122.7 (
4
JC-F = 3 Hz, CH), 118.8 (CH), 117.6 (
2
JC-F = 19 Hz, CH), 
110.7 (CH), 80.7 (Cq), 28.1 (CH3). 
19
F NMR (283 MHz, CDCl3): δ = –126.36. 




MS (EI) m/z (relative intensity): 315 (5) [M]
+
, 259 (10), 242 (25), 214 (100), 198 (10), 185 (15), 
136 (7), 78 (18). 
HR-MS (EI) m/z calcd for C18H18FNO3 [M]
+
 315.1265, found 315.1286. 
 
(E)-Benzyl 3-{3-Fluoro-2-(pyridin-2-yloxy)phenyl}acrylate (131cd): 




(131c) (188.0 mg, 0.99 mmol), benzyl acrylate (46d) (69.3 mg, 0.43 mmol), [RuCl2(p-cymene)]2 
(7.8 mg, 2.5 mol %), and AgSbF6 (18.1 mg, 10 mol %). Purification by column chromatography 
(n-hexane/EtOAc: 20/1→15/1) yielded 131cd (137.0 mg, 92%) as a brown oil. 
1
H NMR (300 MHz, CDCl3): δ = 8.10 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.91 (d, J = 16.1 Hz, 1H), 
7.73 (ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.48–7.44 (m, 1H), 7.40–7.33 (m, 5H), 7.27–7.14 (m, 2H), 
7.09 (dt, J = 8.3, 0.9 Hz, 1H), 7.01 (ddd, J = 7.2, 5.0, 0.9, 1H), 6.57 (d, J = 16.1, 1H), 5.23 (s, 2H). 
13
C NMR (75 MHz, CDCl3): δ = 166.3 (Cq), 162.5 (Cq), 155.4 (
1
JC-F = 249 Hz, Cq), 147.3 (CH), 
140.0 (
2
JC-F = 13 Hz, Cq), 139.6 (CH), 138.3 (
4
JC-F = 3 Hz, CH), 135.8 (Cq), 130.1 (
3
JC-F = 2.0 Hz, 
Cq), 128.5 (CH), 128.1 (CH), 128.1 (CH), 125.8 (
3
JC-F = 8 Hz, CH), 122.8 (
4
JC-F = 3 Hz, CH), 
120.5 (CH), 118.8 (CH), 117.9 (
2
JC-F = 19 Hz, CH), 110.6 (CH), 66.3 (CH2). 
19
F NMR (283 MHz, CDCl3): δ = –126.13 (s). 
IR (neat): 3064, 2952, 1712, 1460, 1427, 1266, 1232, 773 cm
–1
. 
MS (EI) m/z (relative intensity): 349(40) [M]
+
, 330 (10), 258 (15), 242 (13), 214 (100), 198 (40), 
186 (40), 91 (65). 




 349.1109, found 349.1111. 
 
(E)-Ethyl 3-{3-Chloro-2-(pyridin-2-yloxy)phenyl}acrylate (131db): 
The general procedure D was followed using 2-(2-chlorophenoxy)pyridine 
(130d) (205.5 mg, 1.00 mmol), ethyl acrylate (46b) (52.8 mg, 0.53 mmol), 
[RuCl2(p-cymene)]2 (7.8 mg, 2.5 mol %), and AgSbF6 (18.1 mg, 10 mol %). 
Purification by column chromatography (n-hexane/EtOAc: 15/1) yielded 
131db (111.0 mg, 69%) as a colorless solid. 





H NMR (300 MHz, CDCl3): δ = 8.08 (ddd, J = 5.0, 1.9, 0.8 Hz, 1H), 7.77 (d, J = 16.2 Hz, 1H), 
7.76−7.70 (m, 1H), 7.64–7.54 (m, 1H), 7.48 (dd, J = 8.0, 1.5 Hz, 1H), 7.22 (dd, J = 7.9, 8.0 Hz, 1H), 
7.06 (dd, J = 8.3, 0.9 Hz, 1H), 6.99 (ddd, J = 7.2, 5.0, 0.9 Hz, 1H), 6.46 (d, J = 16.2 Hz, 1H), 4.19 (q, 
J = 7.2 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.5 (Cq), 162.6 (Cq), 148.5 (Cq), 147.4 (CH), 139.7 (CH), 138.2 
(CH), 131.8 (CH), 130.6 (Cq), 129.1 (Cq), 126.2 (CH), 126.0 (CH), 121.0 (CH), 118.7 (CH), 110.8 
(CH), 60.5 (CH2), 14.2 (CH3). 
IR (neat): 2975, 1699, 1423, 1322, 1262, 1239, 1190, 770 cm–1. 
MS (EI) m/z (relative intensity): 303 (20) [M]
+
, 268 (65), 258 (25), 240 (60), 230 (100), 209 (13), 
196 (20), 167 (25). 









(E)-Ethyl 3-{2-(Pyridin-2-yloxy)-3-(trifluoromethyl)phenyl}acrylate (131eb): 
The general procedure D was followed using 
2-{2-(trifluoromethyl)phenoxy}pyridine (130e) (236.0 mg, 0.99 mmol), 
ethyl acrylate (46b) (50.1 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (7.8 mg, 
2.5 mol %), and AgSbF6 (18.3 mg, 11 mol %). Purification by column 
chromatography (n-hexane/EtOAc: 12/1→10/1) yielded 131eb (136.0 mg, 81%) as a colorless 
solid. 
M. p. = 44−46 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.01 (ddd, J = 5.0, 2.0, 0.8, 1H), 7.84 (dd, J = 7.9, 1.6 Hz, 1H), 
7.71 (m, 1H), 7.70 (ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.61 (d, J = 16.1 Hz, 1H), 7.44–7.30 (m, 1H), 
7.05 (dt, J = 8.3, 0.9Hz, 1H), 6.95 (ddd, J = 7.2, 5.0, 0.9 Hz, 1H), 6.40 (d, J = 16.1 Hz, 1H), 4.14 (q, 
J = 7.1 Hz, 2H), 1.22 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.2 (Cq), 163.5 (Cq), 149.8 (
3
JC-F = 2.0 Hz, Cq), 147.3 (CH), 
139.7 (CH), 137.5 (CH), 131.1 (CH), 130.9 (Cq), 128.6 (
3
JC-F = 5.0 Hz, CH), 125.6 (CH), 125.0 
(
2
JC-F = 32 Hz, Cq), 124.9 (
1
JC-F = 272 Hz, Cq), 121.2 (CH), 118.7 (CH), 110.7 (CH), 60.5 (CH2), 
14.1 (CH3). 
19
F NMR (283 MHz, CDCl3): δ = –61.7 (s). 
IR (neat): 2987, 1708, 1425, 1328, 1231, 1136, 1104, 777 cm–1. 
MS (EI) m/z (relative intensity):337 (20) [M]
+
, 292 (20), 264 (100), 244 (25), 196 (15), 167 (10), 51 
(15). 




 337.0920, found 337.0919. 
 
(E)-tert-Butyl 3-{2-(pyridin-2-yloxy)-3-(trifluoromethyl)phenyl}acrylate (131ep): 
The general procedure D was followed using 2-{2-(trifluoromethyl)-
phenoxy}pyridine (131e) (233.0 mg, 0.97 mmol), tert-butyl acrylate 
(46p) (63.8 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %), 
and AgSbF6 (18.7 mg, 11 mol %). Purification by column 
chromatography (n-hexane/EtOAc: 15/1) yielded 131ep (144.0 mg, 79%) as an off-white solid. 
M. p. = 78−80 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.05–8.02 (m, 1H), 7.87–7.83 (m, 1H), 7.73–7.71 (m, 2H), 7.52 
(d, J = 16.0 Hz, 1H), 7.36 (dd, J = 7.9, 7.8 Hz, 1H), 7.06 (d, J = 8.3, 1H), 6.97 (ddd, J = 7.2, 5.0, 1.0 
Hz, 1H), 6.34 (d, J = 16.0 Hz, 1H), 1.43 (s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 165.4 (Cq), 163.5 (Cq), 149.7 (Cq), 147.3 (CH), 139.7 (CH), 136.4 
(CH), 131 (Cq), 130.9 (CH), 128.4 (
3
JC-F = 5.0 Hz, CH), 125.6 (CH), 125.4 (
2
JC-F = 33 Hz, Cq), 123.1 
(CH), 123.0 (
1





F NMR (283 MHz, CDCl3): δ = –61.7. 
IR (neat): 2970, 1699, 1427, 1334, 1261, 1235, 1129, 783cm–1. 
MS (EI) m/z (relative intensity): 365 (5) [M]
+
, 309 (6), 292 (17), 264 (100), 244 (17), 196 (10), 167 
(7), 78 (20). 
HR-MS (EI) m/z calcd for C19H18F3NO3 [M]
+
 365.1239, found 365.1246. 
 
(E)-Ethyl 3-{3,5-dimethyl-2-(pyridin-2-yloxy)phenyl}acrylate (131fb): 
The general procedure D was followed using 2-(2,4-dimethylphenoxy)-
pyridine (130f) (195.0 mg, 0.98 mmol), ethyl acrylate(46b) (53.4 mg, 0.53 
mmol), [RuCl2(p-cymene)]2 (7.9 mg, 2.5 mol %), and AgSbF6 (18.7 mg, 10 
mol %). Purification by column chromatography (n-hexane/EtOAc: 
15/1→12/1) yielded 131fb (130.0 mg, 82%) as a colorless solid. 
M. p. = 73−75 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.10 (ddd, J = 4.9, 2.0, 1.0 Hz, 1H), 7.75 (d, J = 16.1 Hz, 1H), 
7.67 (ddd, J = 8.2, 7.2, 2.0 Hz, 1H), 7.33 (d, J = 2.0 Hz, 1H), 7.11 (d, J = 2.0 Hz, 1H), 6.96–6.91 (m, 
2H), 6.41 (d, J = 16.1 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 2.34 (s, 3H), 2.06 (s, 3H), 1.26 (t, J = 7.1 
Hz, 3H). 
13
C NMR (75 MHz, CDCl3):δ = 166.9 (Cq), 163.3 (Cq), 148.5 (Cq), 147.7 (CH), 139.5 (CH), 139.3 
(CH), 135.0 (Cq), 134.0 (CH), 131.8 (Cq), 127.7 (Cq), 125.7 (CH), 119.5 (CH), 118.0 (CH), 110.3 
(CH), 60.2 (CH2), 20.9 (CH3), 16.5 (CH3), 14.2 (CH3). 
IR (neat): 2982, 1698, 1428, 1281, 1234, 1202, 1040, 774 cm–1. 
MS (EI) m/z (relative intensity): 297 (30) [M]
+
, 280 (10), 268 (15), 252 (25), 224 (100), 203 (30), 
175 (25), 78(40). 
HR-MS (EI) m/z calcd for C18H19NO3 [M]
+
 297.1365, found 297.1369. 
 
(E)-tert-Butyl 3-{3,5-Dimethyl-2-(pyridin-2-yloxy)phenyl}acrylate (131fp): 
The general procedure D was followed using 2-(2,4-dimethylphenoxy)-
pyridine (130f) (199.0 mg, 1.00 mmol), tert-butyl acrylate (46p) (65.2 mg, 
0.51 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %), and AgSbF6 (17.9 
mg, 10 mol %). Purification by column chromatography 
(n-hexane/EtOAc: 15/1) yielded 131fp (120.0 mg, 73%) as a colorless solid. 





H NMR (300 MHz, CDCl3): δ = 8.10 (ddd, J = 4.7, 2.0, 1.0, 1H), 7.67 (ddd, J =8.2, 7.3, 2.0 Hz, 
1H) 7.66 (d, J = 16.0 Hz, 1H), 7.38–7.29 (m,1H), 7.10–7.09 (m, 1H), 6.95–6.91 (m, 2H), 6.33 (d, 
J=16.0 Hz, 1H), 2.34 (s, 3H), 2.07 (s, 3H), 1.46 (s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 166.2 (Cq), 163.4 (Cq), 148.5 (Cq), 147.8 (CH), 139.5 (CH), 138.2 
(CH), 134.9 (Cq), 133.8 (CH), 131.8 (Cq), 127.9 (Cq), 125.5 (CH), 121.2 (CH), 117.9 (CH), 110.3 
(CH), 80.2 (Cq), 28.1 (CH3), 20.9 (CH3), 16.6 (CH3). 
IR (neat): 2971, 1694, 1425, 1239, 1153, 1131, 870, 781 cm–1. 
MS (EI) m/z (relative intensity): 325 (10) [M]
+
, 268 (10), 252 (32), 224 (100), 206 (13), 194 (7), 175 
(20), 78 (10). 
HR-MS (EI) m/z calcd for C20H23NO3 [M]
+
 325.1672, found 325.1683. 
(E)-Ethyl 3-{3,4-Dimethyl-2-(pyridin-2-yloxy)phenyl}acrylate (131gb): 
The general procedure D was followed using 
2-(2,3-dimethylphenoxy)pyridine (130g) (200.0 mg, 1.00 mmol), ethyl 
acrylate (46b) (47.7 mg, 0.48 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 2.6 mol 
%), and AgSbF6 (18.2 mg, 11 mol %). Purification by column 
chromatography (n-hexane/EtOAc: 15/1→10/1) yielded 131gb (108.0 mg, 76%) as a colorless 
solid. 
M. p. = 128−130 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.12–8.09 (m, 1H), 7.74 (d, J = 16.1 Hz, 1H), 7.68 (ddd, J = 8.3, 
7.2, 2.0 Hz, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.09 (d, J = 8.0 Hz, 1H), 6.96–6.92 (m, 2H), 6.38 (d, J = 
16.1 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 2.33 (s, 3H), 2.02 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H). 
13
C NMR (75MHz, CDCl3): δ = 167.0 (Cq), 163.4 (Cq), 150.5 (Cq), 147.8 (CH), 141.1 (Cq), 139.6 
(CH), 139.5 (CH), 130.8 (Cq), 127.4 (CH), 125.8 (Cq), 124.5 (CH), 118.6 (CH), 118.0 (CH), 110.3 
(CH), 60.2 (CH2) 20.4 (CH3), 14.2 (CH3), 12.9 (CH3). 
IR (neat): 2982, 1711, 1254, 1236, 1200, 1168, 1141, 782 cm
–1
. 
MS (EI) m/z (relative intensity): 297 (30) [M]
+
, 268 (15), 252 (20), 224 (100), 203 (15), 181 (15), 
115 (10), 78 (20). 




 297.1359, found 297.1360. 
(E)-tert-Butyl 3-{3,4-Dimethyl-2-(pyridin-2-yloxy)phenyl}acrylate (131gp): 
The general procedure D was followed using 2-(2,3-dimethylphenoxy)-
pyridine (130g) (200.8 mg, 1.01 mmol), tert-butyl acrylate (46p) (64.5 
mg, 0.50 mmol), [RuCl2(p-cymene)]2 (7.9 mg, 2.6 mol %), and AgSbF6 
(18.2 mg, 11 mol %). Purification by column chromatography 




M. p. = 115−117 °C. 
1
H NMR (300 MHz, CDCl3):δ = 8.12–8.08 (m, 1H), 7.65 (d, J = 16.0 Hz, 1H), 7.71–7.65 (m, 1H), 
7.44 (d, J=8.1 Hz, 1H), 7.07(d, J= 8.1 Hz, 1H), 6.99–6.85 (m, 2H), 6.31 (d, J=16.0 Hz, 1H), 2.02 (s, 
3H), 2.02 (s, 3H), 1.45 (s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 166.3(Cq), 163.5 (Cq) 150.4 (Cq), 147.8 (CH), 140.8 (Cq), 139.5 
(CH), 138.4 (CH), 130.7 (Cq), 127.3 (CH), 125.9 (Cq), 124.3 (CH), 120.4 (CH), 117.9 (CH), 110.3 
(CH), 80.1 (Cq), 28.1 (CH3), 20.4 (CH3), 12.9 (CH3). 
IR (neat): 2974, 1698, 1256, 1234, 1150, 987, 824, 782 cm
–1
. 
MS (EI) m/z(relative intensity): 325 (10) [M]
+
, 268 (10), 252 (20), 224 (100), 208 (10), 194 (5), 175, 
(15), 115 (7). 




 325.1672, found 325.1685. 
 
(E)-Benzyl 3-{3,4-Dimethyl-2-(pyridin-2-yloxy)phenyl}acrylate (131gd): 
The general procedure D was followed using 2-(2,3-dimethylphenoxy)-
pyridine (130g) (199.0 mg, 1.00 mmol), benzyl acrylate (2d) (84.9 mg, 
0.52 mmol), [RuCl2(p-cymene)]2 (7.9 mg, 2.6 mol %), and AgSbF6 (17.6 
mg, 10 mol %). Purification by column chromatography (n-hexane/EtOAc: 
20/1→15/1) yielded 131gd (153.0 mg, 82%) as a brown oil. 
1
H NMR (300 MHz, CDCl3): δ = 8.15–8.11 (m, 1H), 7.85 (d, J = 16.1 Hz, 1H), 7.72–7.66 (m, 1H), 
7.47 (d, J = 8.0 Hz, 1H), 7.37–7.35 (m, 5H), 7.11 (d, J = 8.0 Hz, 1H), 6.96 (m, 2H), 6.47 (d, J = 16.1 
Hz, 1H), 5.19 (s, 2H), 2.34 (s, 3H), 2.05 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.7 (Cq) 163.3 (Cq), 150.5 (Cq), 147.7 (CH), 141.2 (Cq), 140.0 
(CH), 139.5 (CH), 136.0 (Cq), 130.7 (Cq), 128.4 (CH), 128.0 (CH), 127.9 (CH), 127.3 (CH), 125.6 
(Cq), 124.4 (CH), 118.0 (CH), 117.9 (CH), 110.2 (CH), 65.9 (CH2), 20.3 (CH3), 12.8 (CH3). 
IR (neat): 3032, 2946, 1708, 1427, 1237, 1195, 1152, 777 cm
–1
. 
MS (EI) m/z (relative intensity): 359 (40) [M]
+
, 344 (10), 268 (25), 252 (15), 224 (100), 208 (30), 
181 (25), 91 (70). 




 359.1516, found 359.1535. 
 
(E)-Ethyl 3-{1-(pyridin-2-yloxy)naphthalen-2-yl}acrylate (131hb): 
The general procedure D was followed using 2-(naphthalen-1-yloxy)-
pyridine (130h) (221.0 mg, 1.00 mmol), ethyl acrylate (46b) (50.3 mg, 
0.50 mmol), [RuCl2(p-cymene)]2 (7.9 mg, 2.6 mol %), and AgSbF6 (18.6 
mg, 11 mol %). Purification by column chromatography (n-hexane/EtOAc: 




M. p. = 156−158 °C 
1
H NMR (300 MHz, CDCl3): δ = 8.06 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 8.00 (d, J = 16.1 Hz, 1H), 
7.91–7.79 (m, 2H), 7.75 (s, 2H), 7.71 (ddd, J =8.3, 7.2, 2.0 Hz, 1H), 7.50 (ddd, J = 8.2, 6.8, 1.3 Hz, 
1H), 7.42 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.03 (dt, J = 8.3, 0.8 Hz, 1H), 6.96 (ddd, J = 7.2, 5.0, 0.9 
Hz, 1H), 6.54 (d, J = 16.1 Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.8(Cq), 164.2 (Cq), 148.8 (Cq), 147.9 (CH), 139.7 (CH), 138.6 
(CH), 135.6 (Cq), 128.0 (CH), 128.0 (Cq), 127.4 (CH), 126.8 (CH), 126.0 (CH), 124.2 (Cq), 123.3 
(CH), 123.2 (CH), 119.8 (CH), 118.4 (CH), 110.2 (CH), 60.4 (CH2), 14.2 (CH3). 
IR (neat): 2987, 1712, 1292, 1256, 1234, 1174, 1138, 783 cm
–1
. 
MS (EI) m/z (relative intensity): 319 (10) [M], 290 (25), 274 (15), 246 (65), 225 (100), 197 (80), 
168 (20), 139 (30). 
HR-MS (EI) m/z calcd for C20H17NO3 [M]
+
 319.1208, found 319.1217. 
 
(E)-tert-Butyl 3-{1-(Pyridin-2-yloxy)naphthalen-2-yl}acrylate (131hp): 
The general procedure D was followed using 2-(naphthalen-1-yloxy)-
pyridine (130h) (222.0 mg, 1.00 mmol), tert-butyl acrylate (46p) (65.2 
mg, 0.51 mmol), [RuCl2(p-cymene)]2 (7.8 mg, 2.5 mol %), and AgSbF6 
(18.3 mg, 11 mol %). Purification by column chromatography 
(n-hexane/EtOAc: 15/1) yielded 131hp (145.0 mg, 82%) as an off-white solid. 
M. p. = 126−128 °C 
1
H NMR (300 MHz, CDCl3): δ = 8.06 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.92 (d, J = 16.2 Hz, 1H), 
7.85 (m, 2H), 7.78–7.75 (m, 2H), 7.71 (ddd, J = 8.4, 7.2, 2.0 Hz, 1H), 7.50 (ddd, J = 8.3, 6.9, 1.3 Hz, 
1H), 7.41 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.09–7.00 (m, 1H), 6.96 (ddd, J = 7.2, 5.0, 1.0 Hz, 1H), 
6.48 (d, J = 16.2 Hz, 1H), 1.49 (s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 166.1 (Cq), 164.3(Cq), 148.6 (Cq), 147.9 (CH), 139.7 (CH), 137.5 
(CH), 135.5 (Cq), 128.1(Cq), 128.0 (CH), 127.3 (CH), 126.8 (CH), 125.9(CH), 124.2(Cq), 
123.2(CH), 123.1(CH), 121.5(CH), 118.4 (CH), 110.2 (CH), 80.4 (Cq), 28.1 (CH3). 
IR (neat): 2974, 1698, 1257, 1232, 1160, 1072, 985, 779 cm
–1
. 
MS (EI) m/z (relative intensity): 347 (15) [M]
+
, 290 (15), 274 (30), 246 (90), 217 (50), 196 (100), 
168 (42), 139 (28). 
HR-MS (EI) m/z calcd C22H21NO3 [M]
+









The general procedure D was followed using 2-(naphthalen-1-yloxy)-
pyridine (130h) (222.0 mg, 1.00 mmol), benzyl acrylate(46d) (82.2 mg, 
0.51 mmol), [RuCl2(p-cymene)]2 (7.8 mg, 2.5 mol %), AgSbF6 (18.6 mg, 
11 mol %). Purification by column chromatography (n-hexane/EtOAc: 
20/1→15/1) yielded 131hd (169.0 mg, 88%) as an off-white solid. 
M. p. = 128−130 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.06 (d, J = 16.1 Hz, 1H), 8.06 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 
7.87–7.84 (m, 2H), 7.75 (m, 2H), 7.72 (ddd, J = 8.4, 7.2, 2.0 Hz, 1H), 7.51 (ddd, J = 8.3, 6.9, 1.3 Hz, 
1H), 7.43 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.38–7.34 (m, 5H), 7.04 (ddd, J = 8.3, 0.9, 0.8 Hz, 1H), 
6.97 (ddd, J = 7.2, 5.0, 0.9 Hz, 1H), 6.60 (d, J = 16.1 Hz, 1H), 5.21 (s, 2H). 
13
C NMR (75 MHz, CDCl3): δ = 166.6 (Cq), 164.2 (Cq), 148.9(Cq), 147.9 (CH), 139.7 (CH), 139.2 
(CH), 136.1 (Cq), 135.7 (Cq), 128.5 (CH), 128.1 (CH), 128.1 (CH), 128.0 (CH), 128.0 (Cq), 127.5 
(CH), 126.9 (CH), 126.0 (CH), 124.0 (Cq), 123.2 (CH), 123.2 (CH), 119.3 (CH), 118.5 (CH), 
110.2(CH), 66.2 (CH2). 
IR (neat): 2960, 1708, 1427, 1256, 1230, 1163, 1136, 772 cm
–1
. 
MS (EI) m/z (relative intensity): 381 (5) [M]
+
, 287 (20), 246 (50), 217 (35), 196 (10), 139 (15), 91 
(100). 
HR-MS (EI) m/z calcd C25H19NO3 [M]
+
 381.1359, found 381.1367.
 
 
(E)-Ethyl 3-{3-(Pyridin-2-yloxy)naphthalen-2-yl}acrylate (131ib): 
The general procedure D was followed using 2-(naphthalen-2-yloxy)pyridine 
(130i) (221.0 mg, 1.00 mmol), ethyl acrylate (46b) (50.6 mg, 0.51 mmol), 
[RuCl2(p-cymene)]2 (15.5 mg, 5.0 mol %), and AgSbF6 (35.7 mg, 20 mol %). 
Purification by column chromatography (n-hexane/EtOAc: 15/1) yielded 131ib (126.0 mg, 78%) as 
a colorless solid. 
M. p. = 124−126 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.19−8.16 (m, 1H), 8.16 (s, 1H), 7.96 (d, J = 16.1 Hz, 1H), 7.87–
7.84 (m, 1H), 7.80–7.66 (m, 2H), 7.52 (s, 1H), 7.54–7.38 (m, 2H), 7.05–7.00 (m, 2H), 6.64 (d, J = 
16.1 Hz, 1H), 4.23 (q, J = 7.1 Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.9 (Cq), 163.6 (Cq), 150.4 (Cq), 147.9 (CH), 139.7 (CH), 139.5 
(CH), 134.7 (Cq), 130.8 (Cq), 129.0 (CH), 128.3 (CH), 127.4 (CH), 127.3(Cq), 127.2 (CH), 125.8 
(CH), 120.4 (CH), 118.9 (CH), 118.8(CH), 111.7 (CH), 60.4 (CH2), 14.3 (CH3). 
IR (neat): 2986, 1702, 1426, 1313, 1264, 1246, 1176, 781 cm
–1
. 
MS (EI) m/z (relative intensity): 319 (15) [M]
+
, 290 (50), 274 (15), 246 (100), 217 (45), 197 (20), 








 319.1203, found 319.1217. 
 
(E)-tert-Butyl 3-{3-(pyridin-2-yloxy)naphthalen-2-yl}acrylate (131ip): 
The general procedure D was followed using 2-(naphthalen-2-yloxy)-
pyridine (130i) (220.0 mg, 0.99 mmol), tert-butyl acrylate (46p) (66.0 mg, 
0.52 mmol), [RuCl2(p-cymene)]2 (15.7 mg, 5.1 mol %), AgSbF6 (35.7 mg, 
20 mol %). Purification by column chromatography (n-hexane/EtOAc: 20/1→15/1) yielded 131ip 
(133.0 mg, 74%) as a colorless solid. 
M. p. = 138−140°C. 
1
H NMR (300 MHz, CDCl3): δ = 8.25–8.10 (m, 2H), 7.87 (d, J = 16.0 Hz, 1H), 7.86–7.83 (m, 1H), 
7.76–7.70 (m, 2H), 7.52–7.43 (m, 3H), 7.04–7.00 (m, 2H), 6.56 (d, J = 16.0 Hz, 1H), 1.50 (s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 166.1 (Cq), 163.7 (Cq), 150.3 (Cq), 147.8 (CH), 139.6 (CH), 138.3 
(CH), 134.6 (Cq), 130.9 (Cq), 128.5 (CH), 128.3 (CH), 127.5 (Cq), 127.3 (CH), 127.2 (CH), 125.8 
(CH), 122.2 (CH), 118.8 (CH), 118.8 (CH), 111.7 (CH), 80.4(Cq), 28.1 (CH3). 
IR (neat): 2972, 1701, 1423, 1231, 1134, 1091, 863, 780 cm
–1
. 
MS (EI) m/z (relative intensity): 347 (30) [M]
+
, 290 (30), 274 (40), 246 (100), 230 (35), 217 (40), 
196 (33), 139 (20). 
HR-MS (EI) m/z calcd for C22H21NO3 [M]
+
 347.1516, found 347.1510.
 
 
(E)-Ethyl 3-{5-methoxy-2-(pyridin-2-yloxy)phenyl}acrylate (131kb): 
The general procedure D was followed using 2-(4-methoxyphenoxy)pyridine 
(131k) (201.0 mg, 1.00 mmol), ethyl acrylate (46b) (49.0 mg, 0.49 mmol), 
[RuCl2(p-cymene)]2 (7.8 mg, 2.6 mol %), and AgSbF6 (17.8 mg, 11 mol %). 
Purification by column chromatography (n-hexane/EtOAc: 15/1→10/1) yielded 
131kb (99.0 mg, 68%) as a light yellow oil. 
1
H NMR (300 MHz, CDCl3): δ = 8.13 (ddd, J = 4.9, 2.0, 0.8, 1H), 7.81 (d, J = 16.1 Hz, 1H), 7.67 
(ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.14 (d, J = 3.0 Hz, 1H), 7.04 (d, J = 8.9 Hz, 1H), 6.98–6.92 (m, 3H), 
6.44 (d, J = 16.1 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.82 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.7 (Cq), 163.8 (Cq), 156.5 (Cq), 147.6 (CH), 146.3 (Cq), 139.4 
(CH), 138.7 (CH), 128.1 (Cq), 123.8 (CH), 119.8 (CH), 118.4 (CH), 117.5 (CH), 111.5 (CH), 111.1 
(CH), 60.4 (CH2), 55.5 (CH3), 14.2 (CH3). 
IR (neat): 2980, 1706, 1464, 1425, 1232, 1173, 1031, 775 cm
–1
. 
MS (EI) m/z (relative intensity): 299 (20) [M]
+
, 270 (45), 254 (20), 226 (100), 205 (45), 177 (43), 
154 (30), 133 (20). 
HR-MS (EI) m/z calcd for C17H17NO4 [M]
+





(E)-tert-Butyl 3-{5-methoxy-2-(pyridin-2-yloxy)phenyl}acrylate (131kp): 
The general procedure D was followed using 2-(4-methoxyphenoxy)pyridine 
(130k) (202.0 mg, 1.00 mmol), tert-butyl acrylate (46p) (64.0 mg, 0.50 mmol), 
[RuCl2(p-cymene)]2 (7.9 mg, 2.6 mol %), and AgSbF6 (18.5 mg, 11 mol %). 
Purification by column chromatography (n-hexane/EtOAc: 10/1→7/1) yielded 
131kp (107.0 mg, 65%) as a light yellow oil. 
1
H NMR (300 MHz, CDCl3): δ = 8.14 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.72 (d, J = 16.1 Hz, 1H), 7.67 
(ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.14 (d, J = 3.0 Hz, 1H), 7.04 (d, J = 8.9 Hz, 1H), 6.99–6.92 (m, 3H), 
6.36 (d, J = 16.1 Hz, 1H), 3.83 (s, 3H), 1.47 (s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 166.1 (Cq), 163.9 (Cq), 156.6 (Cq), 147.6 (CH), 146.2 (Cq), 139.5 
(CH), 137.7 (CH), 128.3 (Cq), 123.8 (CH), 121.6 (CH), 118.3 (CH), 117.4 (CH), 111.3 (CH), 111.2 
(CH), 80.4 (Cq), 55.6 (CH3), 28.1 (CH3). 
IR (neat): 2976, 1703, 1464, 1425, 1233, 1198, 1142, 776 cm
–1
. 
MS (EI) m/z (relative intensity): 327 (20) [M]
+
, 270 (30), 254 (40), 226 (100), 198 (20), 176 (65), 
154 (15), 78 (27). 
HR-MS (EI) m/z calcd for C19H21NO4 [M]
+
 327.1465, found 327.1472. 
 
(E)-Ethyl 3-{5-chloro-2-(pyridin-2-yloxy)phenyl}acrylate (131lb): 
The general procedure D was followed using 2-(4-chlorophenoxy)pyridine 
(130l) (204.0 mg, 0.99 mmol), ethyl acrylate (46b) (47.0 mg, 0.47 mmol), 
[RuCl2(p-cymene)]2 (7.8 mg, 2.5 mol %), AgSbF6 (18.1 mg, 11 mol %). 
Purification by column chromatography (n-hexane/EtOAc: 15/1) yielded 131lb 
(96.0 mg, 68%) as a colorless oil. 
1
H NMR (300 MHz, CDCl3): δ = 8.14–8.12 (m, 1H), 7.79 (d, J = 16.1 Hz, 1H), 7.72 (ddd, J = 8.3, 
7.2, 2.0 Hz, 1H), 7.62 (d, J = 2.6 Hz, 1H), 7.34 (dd, J = 8.7, 2.6 Hz, 1H), 7.05 (d, J = 8.7Hz, 1H), 
7.04–6.99 (m, 2H), 6.45 (d, J = 16.1 Hz, 1H), 4.20 (q, J = 7.1 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.5 (Cq), 163.1 (Cq), 151.2 (Cq), 147.6(CH), 139.8 (CH), 137.5 
(CH), 130.9 (CH), 130.4 (Cq), 128.9 (Cq), 127.5 (CH), 123.9 (CH), 120.9 (CH), 119.0 (CH), 111.7 
(CH), 60.6 (CH2), 14.2 (CH3). 
IR (neat): 2981, 1708, 1463, 1426, 1235, 1172, 1109, 773 cm
–1
. 
MS (EI) m/z (relative intensity): 303 (30) [M]
+
, 274 (35), 258 (33), 230 (100), 209 (30), 202 (25), 
167 (40), 78 (50). 









(E)-tert-Butyl 3-{5-chloro-2-(pyridin-2-yloxy)phenyl}acrylate (131lp): 
The general procedure D was followed using 2-(4-chlorophenoxy)pyridine 
(131l) (208.0 mg, 1.01 mmol), tert-butyl acrylate (46p) (62.5 mg, 0.49 mmol), 
[RuCl2(p-cymene)]2 (7.8 mg, 2.5 mol %), and AgSbF6 (17.9 mg, 11 mol %). 
Purification by column chromatography (n-hexane/EtOAc: 15/1) yielded 
131lp (123.0 mg, 76%) as a colorless solid. 
M. p. = 102−104 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.14 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.72 (ddd, J = 8.3, 7.2, 2.0 Hz, 
1H), 7.70 (d, J = 16.1Hz, 1H), 7.63 (d, J = 2.6 Hz, 1H), 7.33 (dd, J = 8.7, 2.6 Hz, 1H), 7.06 (d, J = 8.7 
Hz, 1H), 7.03–6.98 (m, 2H), 6.38 (d, J = 16.1 Hz, 1H), 1.48 (s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 165.8 (Cq), 163.1 (Cq), 151.0 (Cq), 147.6 (CH), 139.7 (CH), 136.4 
(CH), 130.7 (CH), 130.4 (Cq), 129.1 (Cq), 127.4 (CH), 123.9 (CH), 122.7 (CH), 118.9 (CH), 111.7 
(CH), 80.7 (Cq), 28.1 (CH3). 
IR (neat): 2978, 1699, 1425, 1295, 1238, 1156, 1140, 974 cm
–1
. 
MS (EI) m/z (relative intensity): 331 (10) [M]
+
, 274 (10), 258 (30), 230 (100), 214 (15), 201(15), 
167 (20), 78 (40). 




 331.0970, found 331.0978. 
 
(E)-Ethyl 3-{4-(pyridin-2-yloxy)-[1,1'-biphenyl]-3-yl}acrylate (131mb): 
The general procedure D was followed using ethyl 2-([1,1'-biphenyl]-4-yloxy)-
pyridine (130m) (253.0 mg, 1.02 mmol), ethyl acrylate (46b) (48.3 mg, 0.48 
mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), AgSbF6 (36.2 mg, 22 mol 
%). Purification by column chromatography (n-hexane/EtOAc: 30/1→20/1) 
yielded 131mb (106.0 mg, 64%) as a colorless oil. 
1
H NMR (300 MHz, CDCl3): δ = 8.20 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.95 (d, J = 16.2 Hz, 1H), 7.88 
(d, J = 2.3 Hz, 1H), 7.74 (ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.61–7.58 (m, 3H), 7.49–7.42 (m, 2H), 
7.40–7.34 (m, 1H), 7.19 (d, J = 8.5 Hz, 1H), 7.06–7.01 (m, 2H), 6.57 (d, J = 16.2 Hz, 1H), 4.23 (q, J 
= 7.1 Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.8 (Cq), 163.3 (Cq), 152.2 (Cq), 147.7 (CH), 140.0 (Cq), 139.7 
(CH), 138.8 (CH), 138.2 (Cq), 129.9 (CH), 128.8 (CH), 127.5 (Cq), 127.4 (CH), 127.0 (CH), 126.6 
(CH), 122.7 (CH), 120.0 (CH), 118.8 (CH), 111.8 (CH), 60.4 (CH2), 14.2 (CH3). 
IR (neat): 2980, 1706, 1464, 1426, 1235, 1165, 757, 695 cm
–1
. 
MS (EI) m/z (relative intensity): 345 (35) [M]
+
, 316 (60), 300 (25), 272 (100), 251 (50), 244 (35), 
223 (40), 165 (25). 









(E)-Ethyl 3-{2-(Pyridin-2-yloxy)-5-(trifluoromethyl)phenyl}acrylate (131nb): 
The general procedure D was followed using ethyl 2-{4-(trifluoromethyl)-
phenoxy}pyridine (130n) (236.0 mg, 0.99 mmol), ethyl acrylate (46b) (48.0 
mg, 0.48 mmol), [RuCl2(p-cymene)]2 (15.6 mg, 5.1 mol %), and AgSbF6 (36.7 
mg, 22 mol %). Purification by column chromatography (n-hexane/EtOAc: 
15/1) yielded 131nb (128.0 mg, 79%) as a colorless oil. 
1
H NMR (300 MHz, CDCl3): δ = 8.18–8.16 (m, 1H), 7.91 (d, J = 2.2 Hz, 1H), 7.90 (d, J = 16.1 Hz, 
1H), 7.77 (ddd, J = 8.2, 7.3, 2.0 Hz, 1H), 7.62 (dd, J = 8.6, 2.2 Hz, 1H), 7.21 (d, J = 8.6 Hz, 1H), 
7.14–6.94 (m, 2H), 6.55 (d, J = 16.1 Hz, 1H), 4.23 (q, J = 7.1 Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H). 
13
C 
NMR (75 MHz, CDCl3): δ = 166.4 (Cq), 162.6 (Cq), 155.3 (Cq), 147.7 (CH), 140.0 (CH), 137.4 
(CH), 127.7 (Cq), 127.6 (
3
JC-F = 4 Hz, CH), 127.1 (
2
JC-F =33 Hz, Cq), 125.3 (
3
JC-F = 4 Hz, CH), 123.7 
(
1
JC-F = 272 Hz, Cq), 122.5 (CH), 121.4 (CH), 119.6 (CH), 112.3 (CH), 60.7 (CH2), 14.2 (CH3).  
19
F NMR (283 MHz, CDCl3): δ = –62.35 (s). 
IR (neat): 2983, 1716, 1641, 1267, 1162, 1123, 1073, 773 cm
–1
. 
MS (EI) m/z (relative intensity): 337 (10) [M]
+
, 308 (15), 292 (17), 264 (100), 248 (7), 236 (15), 215 
(10), 167 (13). 




 337.0920, found 337.0917. 
 
(E)-Ethyl 3-{(3-ethoxy-3-oxoprop-1-en-1-yl)}-4-(pyridin-2-yloxy)benzoate (131ob): 
The general procedure D was followed using ethyl 4-(pyridin-2-yloxy)benzoate 
(130o) (241.0 mg, 0.99 mmol), ethyl acrylate (46b) (48.0 mg, 0.48 mmol), 
[RuCl2(p-cymene)]2 (15.8 mg, 5.4 mol %), and AgSbF6 (36.5 mg, 22 mol %). 
Purification by column chromatography (n-hexane/EtOAc: 10/1) yielded 131ob 
(110 mg, 67%) as a colorless oil. 
1
H NMR (300 MHz, CDCl3): δ = 8.37 (d, J = 2.1 Hz, 1H), 8.17 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 8.04 
(dd, J = 8.6, 2.1 Hz, 1H), 7.91 (d, J = 16.1 Hz, 1H), 7.75 (ddd, J = 8.3, 7.3, 2.0 Hz, 1H), 7.13 (d, J = 
8.6 Hz, 1H), 7.05 (m, 2H), 6.58 (d, J = 16.1 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H), 4.22 (q, J = 7.1 Hz, 
2H), 1.39 (t, J = 7.1 Hz, 3H), 1.30 (t, J = 7.1 Hz, 3H).
 
13
C NMR (75 MHz, CDCl3): δ = 166.6 (Cq), 165.5 (Cq), 162.7 (Cq), 156.4 (Cq), 147.8 (CH), 139.9 
(CH), 137.9 (CH), 132.1 (CH), 129.7 (CH), 127.0 (Cq), 126.9 (Cq), 121.6 (CH), 120.8 (CH), 119.5 
(CH), 112.3 (CH), 61.1(CH2), 60.5 (CH2), 14.3 (CH3), 14.2 (CH3). 
IR (neat): 2980, 1708, 1591, 1427, 1232, 1172, 1108, 763 cm
–1
. 
MS (EI) m/z (relative intensity): 341 (15) [M]
+
, 312 (15), 296 (20), 268 (100), 247 (10), 240 (50), 








 341.1258, found 341.1256. 
 
(E)-Ethyl 3-{5-acetyl-2-(pyridin-2-yloxy)phenyl}acrylate (131pb): 
The general procedure D was followed using 1-{4-(pyridin-2-yloxy)phenyl}-
ethanone (130p) (213.2 mg, 1.00 mmol), ethyl acrylate (46b) (53.0 mg, 0.53 
mmol), [RuCl2(p-cymene)]2 (15.7 mg, 4.8 mol %), and AgSbF6 (35.9 mg, 20 
mol %). Purification by column chromatography (n-hexane/EtOAc: 6/1) 
yielded 131pb (115.0 mg, 70%) as a colorless solid. 
M. p. = 99−101 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.28 (d, J = 2.2 Hz, 1H), 8.19–8.17 (m, 1H), 7.97 (dd, J = 8.6, 2.2 
Hz, 1H), 7.92 (d, J = 16.2 Hz, 1H), 7.78 (ddd,J = 8.3, 7.2, 2.0 Hz, 1H), 7.17 (d, J = 8.6 Hz, 1H), 
7.11–7.04 (m, 2H), 6.59 (d, J = 16.2 Hz, 1H), 4.24 (q, J = 7.1 Hz, 2H), 2.62 (s, 3H), 1.31 (t, J = 7.1 
Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 196.4 (Cq), 166.6 (Cq), 162.6 (Cq), 156.63 (Cq), 147.8 (CH), 140.0 
(CH), 138.0 (CH), 133.6 (Cq), 130.9 (CH), 128.6 (CH), 127.2 (Cq), 121.8 (CH), 121.0 (CH), 119.6 
(CH), 112.4 (CH), 60.6 (CH2), 26.5 (CH3), 14.2 (CH3). 
IR (neat): 2985, 1713, 1677, 1594, 1241, 1173, 975, 855 cm
–1
. 
MS (EI) m/z (relative intensity): 311 (25) [M]
+
, 282 (30), 266 (30), 238 (100), 222 (15), 196 (25), 
167 (17), 78 (35). 




 311.1152, found 311.1159. 
 
(E)-Ethyl 3-{5-nitro-2-(pyridin-2-yloxy)phenyl}acrylate (131qb): 
The general procedure D was followed using 2-(4-nitrophenoxy)pyridine 
(130q) (215.3 mg, 1.00 mmol), ethyl acrylate (46b) (49.0 mg, 0.49 mmol), 
[RuCl2(p-cymene)]2 (15.6 mg, 5.2 mol %), and AgSbF6 (35.1 mg, 21 mol %). 
Purification by column chromatography (n-hexane/EtOAc: 15/1) yielded 131qb 
(100.0 mg, 65%) as an off-white solid. 
M. p. = 72−74 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.53 (d, J = 2.8 Hz, 1H), 8.22 (dd, J = 9.0, 2.8 Hz, 1H), 8.18 (ddd, 
J = 4.9, 2.0, 0.9 Hz, 1H), 7.89 (d, J = 16.2 Hz, 1H), 7.82 (ddd, J = 8.2, 7.2, 2.0 Hz, 1H), 7.22 (d, J = 
9.0 Hz, 1H), 7.15–7.10 (m, 2H), 6.59 (d, J = 16.2 Hz, 1H), 4.23 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 
Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.2 (Cq), 162.1 (Cq), 157.6 (Cq), 147.8 (CH), 144.2 (Cq), 140.3 
(CH), 136.6(CH), 127.9 (Cq), 125.7 (CH), 123.5 (CH), 122.4 (CH), 122.1 (CH), 120.2 (CH), 112.7 




IR (neat): 2987, 1704, 1426, 1341, 1230, 1193, 770, 740 cm
–1
. 
MS (EI) m/z (relative intensity): 314 (20) [M]
+
, 285 (20), 269 (25), 241(100), 213 (22), 195 (55), 
167 (20), 78 (45). 




 314.0897, found 314.0911. 
 
(E)-Ethyl 3-{3-methyl-2-[(5-methylpyridin-2-yl)oxy]phenyl}acrylate (131sb): 
The general procedure D was followed using 5-methyl-2-(o-tolyloxy)-
pyridine (130s) (197.7 mg, 0.99 mmol), ethyl acrylate (46b) (49.7 mg, 0.50 
mmol), [RuCl2(p-cymene)]2 (7.8 mg, 2.5 mol %), AgSbF6 (18.3 mg, 11 mol 
%). Purification by column chromatography (n-hexane/EtOAc: 15/1) 
yielded 130sb (114.0 mg, 77%) as a light yellow oil.
 
1
H NMR (300 MHz, CDCl3): δ = 7.90 (d, J = 1.3 Hz, 1H), 7.79 (d, J = 16.1 Hz, 1H), 7.54–7.47 (m, 
2H), 7.28 (d, J = 7.4 Hz, 1H), 7.17 (dd, J = 7.7, 7.6 Hz, 1H), 6.82 (d, J = 8.4 Hz, 1H), 6.42 (d, J = 
16.1 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 2.24 (s, 3H), 2.10 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.8 (Cq), 161.5 (Cq), 150.9 (Cq), 147.3 (CH), 140.4 (CH), 139.3 
(CH), 133.0 (CH), 132.4 (Cq), 128.3 (Cq), 127.2 (Cq), 125.5 (CH), 125.3 (CH), 119.6 (CH), 109.5 
(CH), 60.3 (CH3), 17.4 (CH3), 16.6 (CH3), 14.2 (CH3). 
IR (neat): 2980, 2926, 1708, 1479, 1459, 1265, 1237, 1161 cm
–1
. 
MS (EI) m/z (relative intensity): 297 (40) [M], 268 (15), 252 (35), 224 (100), 208 (18), 194 (17), 
181 (27), 161 (17). 




 297.1359, found 297.1358.
 
 
(E)-tert-Butyl 3-{3-methyl-2-[(5-methylpyridin-2-yl)oxy]phenyl}acrylate (131sp): 
The general procedure D was followed using 5-methyl-2-(o-tolyloxy)-
pyridine (130s) (198.7 mg, 1.00 mmol), tert-butyl acrylate (46p) (62.5 mg, 
0.49 mmol), [RuCl2(p-cymene)]2 (7.9 mg, 2.6 mol %), AgSbF6 (17.8 mg, 
11 mol %). Purification by column chromatography (n-hexane/EtOAc: 
15/1) yielded 131sp (120.0 mg, 75%) as a colorless oil. 
1
H NMR (300 MHz, CDCl3): δ = 7.91–7.89 (m, 1H), 7.69 (d, J = 16.1 Hz, 1H), 7.53–7.46 (m, 2H), 
7.29–7.25 (m, 1H), 7.15 (dd, J = 7.7, 7.6 Hz, 1H), 6.82 (d, J = 8.3 Hz, 1H), 6.34 (d, J = 16.1 Hz, 1H), 
2.24 (s, 3H), 2.10 (s, 3H), 1.46 (s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 166.1 (Cq), 161.5 (Cq), 150.8 (Cq), 147.2 (CH), 140.4 (CH), 138.1 
(CH), 132.7 (CH), 132.3 (Cq), 128.4 (Cq), 127.1 (Cq), 125.4 (CH), 125.0 (CH), 121.3 (CH), 109.5 
(CH), 80.2 (Cq), 28.1 (CH3), 17.3 (CH3), 16.6 (CH3). 






MS (EI) m/z (relative intensity): 325 (40) [M]
+
, 268 (15), 252 (45), 224 (100), 208 (18), 194 (13), 
181 (20), 161 (10). 




 325.1672, found 325.1681. 
 
(E)-Ethyl 3-{1-Methyl-3-(pyridin-2-yloxy)-1H-indol-2-yl}acrylate (131tb): 
The general procedure D was followed using ethyl 1-methyl-3-(pyridin-2-
yloxy)-1H-indole (130t) (228.0 mg, 1.02 mmol), ethyl acrylate (46b) (51.7 
mg, 0.52 mmol), [RuCl2(p-cymene)]2 (15.4 mg, 4.8 mol %), and AgSbF6 
(36.1 mg, 21 mol %). Purification by column chromatography (n-hexane/EtOAc: 1/1) yielded 131tb 
(137.0 mg, 83%) as an off-white solid. 
M. p. = 218−220 °C. 
1
H NMR (300 MHz, CDCl3): δ= 7.66 (d, J = 16.2 Hz, 1H), 7.47 (ddd, J = 9.4, 6.5, 2.1 Hz, 1H), 
7.40–7.26 (m, 3H), 7.26–7.22 (m, 1H), 7.13 (ddd, J = 8.0, 6.7, 1.3 Hz, 1H), 6.76–6.73 (m, 1H), 6.28 
(dt, J = 6.7, 1.3 Hz, 1H), 6.02 (d, J = 16.2 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.85 (s, 3H), 1.27 (t, J = 
7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.5 (Cq), 162.6 (Cq), 140.3 (CH), 139.3 (CH), 136.9 (Cq), 129.7 
(CH), 129.0 (Cq), 124.7 (CH), 123.7 (Cq), 122.1 (CH), 121.4 (CH), 120.8 (CH), 118.8 (Cq), 118.3 
(CH), 110.0 (CH), 106.6 (CH), 60.7 (CH2), 30.7 (CH3), 14.2 (CH3). 
IR (neat): 2981, 2941, 1724, 1665, 1594, 1529, 1177, 750 cm
–1
. 
MS (EI) m/z (relative intensity): 322 (100) [M]
+
, 293(15), 249 (90), 228 (80), 221 (25), 205 (30), 
200 (60), 170 (15). 




 322.1312, found 322.1311. 
 
(E)-Ethyl 3-{2-(pyridin-2-yloxy)thiophen-3-yl}acrylate (131ub): 
The general procedure D was followed using ethyl 2-(thiophen-2-yloxy)pyridine 
(130u) (177.0 mg, 1.00 mmol), ethyl acrylate (46b) (48.0 mg, 0.48 mmol), 
[RuCl2(p-cymene)]2 (15.5 mg, 5.3 mol %), AgSbF6 (36.1 mg, 22 mol %). 
Purification by column chromatography (n-hexane/EtOAc: 1/1) yielded 131ub (92.0 mg, 70%) as 
an off-white solid. 
M. p. = 110−112°C. 
1
H NMR (300 MHz, CDCl3): δ = 7.42 (ddd, J = 9.0, 6.5, 2.1 Hz, 1H), 7.33 (d, J = 5.8 Hz, 1H), 7.27 
(d, J = 16.1 Hz, 1H), 7.26−7.22 (m, 2H), 6.66 (d, J = 9.4 Hz, 1H), 6.27 (d, J = 16.1 Hz, 1H), 6.26.(dt, 





C NMR (75 MHz, CDCl3): δ = 166.6 (Cq), 162.3 (Cq), 141.2 (Cq), 140.5 (CH), 138.8 (CH), 133.6 
(CH), 132.7 (Cq), 125.0 (CH), 124.0 (CH), 122.1 (CH), 120.5 (CH), 106.4 (CH), 60.6 (CH2), 14.2 
(CH3). 
IR (neat): 3069, 2977, 1701, 1665, 1592, 1306, 1280, 1172 cm
–1
. 
MS (EI) m/z (relative intensity): 275 (55) [M]
+
, 246 (50), 230 (10), 202 (100), 186 (13), 181 (45), 
173 (50), 153 (25). 




 275.0611, found 275.0616.
 
 
(E)-Ethyl 3-{4-Methyl-2-(pyridin-2-yloxy)phenyl}acrylate (131wb): 
The general procedure D was followed using 2-(m-tolyloxy)pyridine 
(130w) (185.4 mg, 1.00 mmol), ethyl acrylate (46b) (50.7 mg, 0.51 mmol), 
[RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %), and AgSbF6 (18.3 mg, 10 mol %). 
Purification by column chromatography (n-hexane/EtOAc: 15/1→12/1) 
yielded 131wb (121.0 mg, 83%) as a colorless solid. 
M. p. = 45−47°C 
1
H NMR (300 MHz, CDCl3): δ = 8.17 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.85 (d, J = 16.1 Hz, 1H), 7.70 
(ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.05−6.89 (m, 4H), 6.43 (d, J = 16.1 Hz, 
1H), 4.19 (q, J = 7.1 Hz, 2H), 2.35 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 167.0 (Cq), 163.4 (Cq), 152.8 (Cq), 147.8 (CH), 142.0 (Cq), 139.5 
(CH), 138.8 (CH), 127.8 (CH), 126.2 (CH), 124.5 (Cq), 122.8 (CH), 118.6 (CH), 118.6 (CH), 111.6 
(CH), 60.3 (CH2), 21.4 (CH3), 14.2 (CH3). 
IR (neat): 2980, 1709, 1316, 1234, 1172, 1103, 1029, 781 cm
–1
. 
MS (EI) m/z (relative intensity): 283 (40) [M]
+
, 254 (45), 238 (35), 210 (100), 194 (20), 182 (25), 
167 (35), 78 (35). 




 283.1203, found 283.1214. 
 
(E)-tert-Butyl 3-{4-methyl-2-(pyridin-2-yloxy)phenyl}acrylate (131wp): 
The general procedure D was followed using 2-(m-tolyloxy)pyridine 
(130w) (186.0 mg, 1.0 mmol), tert-butyl acrylate (46p) (67.0 mg, 0.52 
mmol), [RuCl2(p-cymene)]2 (7.9 mg, 2.5 mol %), AgSbF6 (17.9 mg, 10 mol 
%). Purification by column chromatography (n-hexane/EtOAc: 15/1) 
yielded 131wp (113.0 mg, 70%) as a colorless solid. 





H NMR (300 MHz, CDCl3): δ = 8.15 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.73 (d, J = 16.1 Hz, 1H), 7.67 
(ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.02−6.92 ( m, 3H), 6.88 (d, J = 1.7 Hz, 1H), 
6.33 (d, J = 16.1 Hz, 1H), 2.33 (s, 3H), 1.46 (s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 166.4 (Cq), 163.5 (Cq), 152.6 (Cq), 147.8 (CH), 141.8 (Cq), 139.5 
(CH), 137.7 (CH), 127.6 (CH), 126.2 (CH), 124.7 (Cq), 122.8 (CH), 120.4 (CH), 118.6 (CH), 111.6 
(CH), 80.2 (Cq), 28.1 (CH2), 21.5 (CH3). 
IR (neat): 2977, 1702, 1266, 1235, 1140, 1098, 984, 782 cm
–1
. 
MS (EI) m/z (relative intensity): 311 (7) [M]
+
, 254 (7), 238 (16), 210 (100), 194 (12), 167 (15), 115 
(5), 78 (15). 




 311.1516, found 311.1522.
 
 
(E)-Ethyl 3-{2-(pyridin-2-yloxy)-4-(trifluoromethyl)phenyl}acrylate (131xb): 
The general procedure D was followed using 
2-{3-(trifluoromethyl)phenoxy}pyridine (130x) (241.0 mg, 1.00 mmol), 
ethyl acrylate(46b) (50.1 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (7.6 mg, 
2.5 mol %), AgSbF6 (17.9 mg, 10 mol %). Purification by column 
chromatography (n-hexane/EtOAc: 30/1→20/1) yielded 131xb (146.0 mg, 87%) as a colorless oil. 
1
H NMR (300 MHz, CDCl3): δ = 8.15 (dd, J = 5.2, 1.9 Hz, 1H), 7.87 (d, J = 16.2 Hz, 1H), 7.78–
7.72 (m, 1H), 7.76 (d, J = 8.3Hz, 1H), 7.46 (dd, J = 8.3, 1.8 Hz, 1H), 7.37 (d, J = 1.8 Hz, 1H), 7.07–
7.03 (m, 2H), 6.54 (d, J = 16.2 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.4 (Cq), 162.7 (Cq), 152.7 (Cq), 147.7 (CH), 139.9 (CH), 137.4 
(CH), 132.6 (
2
JC-F = 33 Hz, Cq), 130.8(Cq), 128.4 (CH), 123.3 (
1
JC-F = 273 Hz, Cq), 121.9 (CH), 
121.6(
3
JC-F = 4 Hz, CH), 119.60 (
3
JC-F = 4 Hz, CH), 119.4 (CH), 111.9 (CH), 60.7 (CH2), 14.2 
(CH3). 
19
F NMR (283 MHz, CDCl3): δ = –62.9 (s). 
IR (neat): 2983, 1713, 1415, 1325, 1236, 1165, 1109, 777 cm
–1
. 
MS (EI) m/z (relative intensity): 337 (15) [M]
+
, 308 (15), 292 (20), 264 (100), 248 (7), 236 (16), 215 
(12), 167(15). 




 337.0920, found 337.0927.
 
(E)-Ethyl 3-{5-(pyridin-2-yloxy)benzo[d][1,3]dioxol-4-yl}acrylate (131yb): 
The general procedure D was followed using 2-(benzo[d][1,3]dioxol-5-yloxy)-
pyridine (130y) (217.0 mg, 1.00 mmol), ethyl acrylate (46b) (48.2 mg, 0.48 
mmol), [RuCl2(p-cymene)]2 (7.9 mg, 2.7 mol %), and AgSbF6 (19.3 mg, 12 mol 
%). Purification by column chromatography (n-hexane/EtOAc: 15/1→8/1) 




M. p. = 90−92 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.15 (ddd, J = 5.0, 2.0, 1.0 Hz, 1H), 7.69 (ddd, J = 8.2, 7.2, 2.0 Hz, 
1H) 7.67 (d, J = 16.2 Hz, 1H), 7.04–6.91 (m, 2H), 6.82 (d, J = 8.4 Hz, 1H), 6.77 (d, J = 16.2 Hz, 1H), 
6.58 (d, J = 8.4 Hz, 1H), 6.10 (s, 2H), 4.18 (q, J = 7.1 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 167.2 (Cq), 164.0 (Cq), 147.7 (CH), 147.4 (Cq), 146.9 (Cq), 144.8 
(Cq), 139.6 (CH), 133.9 (CH), 122.7 (CH), 118.5 (CH), 114.7 (CH), 112.7 (Cq), 111.2 (CH), 109.3 
(CH), 102.2 (CH2), 60.4 (CH2), 14.2 (CH3). 
IR (neat): 2976, 2900, 1695, 1455, 1425, 1304, 1234, 1185 cm
–1
. 
MS (EI) m/z (relative intensity): 313 (22) [M]
+
, 284 (70), 268 (25), 240 (100), 219 (45), 190 (40), 
182 (22), 154 (33). 




 313.0945, found 313.0955. 
 
(E)-tert-Butyl 3-{5-(pyridin-2-yloxy)benzo[d][1,3]dioxol-4-yl}acrylate (131yp): 
The general procedure D was followed using 2-(benzo[d][1,3]dioxol-5-
yloxy)pyridine (130y) (220.0 mg, 1.02 mmol), tert-butyl acrylate (46p) (63.4 
mg, 0.49 mmol), [RuCl2(p-cymene)]2 (7.8 mg, 2.6 mol %), and AgSbF6 (18.2 
mg, 11 mol %). Purification by column chromatography (n-hexane/EtOAc: 
15/1) yielded 131yp (135.0 mg, 79%) as a colorless solid. 




H NMR (300 MHz, CDCl3): δ = 8.14 (ddd, J = 4.9, 2.0, 1.0 Hz, 1H), 7.68 (m, 1H), 7.58 (d, J = 16.2 
Hz, 1H), 6.99–6.94 (m, 2H), 6.81 (d, J = 8.4 Hz, 1H), 6.69 (d, J = 16.2 Hz, 1H), 6.59 (d, J = 8.4 Hz, 
1H), 6.10 (s, 2H), 1.46 (s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 166.5 (Cq), 164.0 (Cq), 147.6(CH), 147.2 (Cq), 146.8 (Cq), 144.8 
(Cq), 139.5 (CH), 132.9 (CH), 124.5 (CH), 118.4 (CH), 114.7 (CH), 112.8 (Cq), 111.2 (CH), 109.1 
(CH), 102.1 (CH2), 80.3 (Cq), 28.1 (CH3). 
IR (neat): 2984, 2916, 1698, 1451, 1420, 1232, 1065, 857 cm
–1
. 
MS (EI) m/z (relative intensity): 341 (25) [M]
+
, 284 (40), 268 (50), 240 (100), 224 (20), 212 (27), 
190 (65), 154 (25). 




 341.1258, found 341.1263. 
Removal of the directing group 
To a solution of (E)-ethyl 3-{3-methyl-2-(pyridin-2-yloxy)phenyl}acrylate (131ab) (142.0 mg, 
0.50 mmol) in PhMe (20 mL) under N2 was added MeOTf (144.4 mg, 96μL, 0.88 mmol). The 
reaction mixture was stirred under N2 at 100 °C for 2 h and then allowed to cool down to ambient 




purification. Under N2, the solution of this solid in anhydrous EtOH (5.0 mL) was carefully added to 
a solution of sodium ethanolate prepared from Na (300 mg, 13.0 mmol) in anhydrous ethanol (15 
mL). The reaction mixture was stirred at 90 °C for 45 min, then allowed to cool down to ambient 
temperature, and the solvent was evaporated in vacuo. H2O (75 mL) was added, and the resulting 
mixture was extracted with EtOAc (3  50 mL). The combined organic layers were dried over 
Na2SO4. After filtration and evaporation of the solvent in vacuo, the residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc: 15/1) to yield 78a (78.0 mg, 75%) as a colorless 
solid. 
 
(E)-Ethyl 3-(2-hydroxy-3-methylphenyl)acrylate (71a): 
M. p. = 119−121°C. 
1
H NMR (300 MHz, CDCl3): δ = 8.18 (d, J = 16.1 Hz, 1H), 7.36 (dd, J = 
7.7, 1.8 Hz, 1H), 7.16−7.13 (m, 1H), 6.84 (t, J = 7.7 Hz, 1H), 6.53 (d, J = 
16.1 Hz, 1H), 6.22 (s, 1H), 4.28 (q, J = 7.1 Hz, 2H), 2.31 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 168.1 (Cq), 153.6 (Cq), 140.6 (CH), 132.7 (CH), 126.2 (CH), 124.1 
(Cq), 121.6 (Cq), 120.4 (CH), 118.1 (CH), 60.5 (CH2), 15.9 (CH3), 14.3 (CH3). 
IR (neat): 3318, 2982, 1681, 1316, 1220, 1183, 1029, 778 cm
–1
. 
MS (EI) m/z (relative intensity): 206 (15) [M]
+
, 160 (85), 132 (100), 115 (7), 105 (35), 91 (10), 77 
(25), 43 (30). 




 206.0937, found 206.0948. 




Intermolecular Competition Experiment between Substrates 130a and 130c 
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A mixture of 2-(o-tolyloxy)pyridine (130a) (274.0 mg, 1.48 mmol), 
2-(2-fluorophenoxy)pyridine(130c) (279.0 mg, 1.47 mmol), ethyl acrylate (46b) (49.2 mg, 0.49 
mmol), [RuCl2(p-cymene)]2 (7.9 mg, 2.6 mol %), AgSbF6 (18.5 mg, 11 mol %) and 
Cu(OAc)2·H2O (200 mg, 1.00 mmol) in tAmOH (2.0 mL) was stirred at ambient temperature for 5 
min under N2 and then stirred at 120 °C for 16 h under an ambient atmosphere of air. At ambient 
temperature, the reaction mixture was diluted with sat. aq. NH4Cl/NH3 (1:1, 10 mL) and extracted 
with EtOAc (3  25 mL). The combined organic layers were dried over Na2SO4. After filtration 
and evaporation of the solvent in vacuo, the crude products were purified by column 
chromatography on silica gel (n-hexane/EtOAc: 15/1→10/1) to yield 131ab (51.0 mg, 37%) and 
131cb (6.0 mg, 4%). The spectral data of compounds 131ab and 131cbwere identical to those 
reported above. 
 
Intermolecular Competition Experiment between Substrates 130k and 130n 
 
The general procedure D was followed using 2-(4-methoxyphenoxy)pyridine (130k) (299.0 mg, 
1.49 mmol), 2-{4-(trifluoromethyl)phenoxy}pyridine (130n) (358.0 mg, 1.50 mmol), ethyl 
acrylate (46b) (50.5 mg, 0.51 mmol), [RuCl2(p-cymene)]2(15.5 mg, 5.0 mol %), AgSbF6 (35.1 mg, 
20 mol %) and Cu(OAc)2·H2O (200 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 20/1→15/1) yielded 131kb (44.0 mg, 29%) and 131nb (6.0 mg, 3%).Their 








Ruthenium-Catalyzed H/D Exchange in Substrate130k with D2O as the Cosolvent 
 
The general procedure D was followed using 2-(4-methoxyphenoxy)pyridine (130k) (213.0 mg, 
1.06 mmol), ethyl acrylate (46b) (49.6 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (7.8 mg, 5.0 mol %), 
AgSbF6 (18.5 mg, 10 mol %) and Cu(OAc)2 (186.0 mg, 1.02 mmol) in a solvent mixture of 
tAmOH and D2O (1.8/0.2 mL). Purification by column chromatography (n-hexane /EtOAc: 
15/1→8/1) yielded [D]n-131kb (27.0 mg, 18%) as a colorless oil and reisolated partially 
deuterated starting material [D]n-130k (167.0 mg, 78%). The deuterium incorporation in 
[D]n-131kb and [D]n-130k were estimated by 
1
H NMR spectroscopy. 
 
8.4.4 Cobalt(II)-Catalyzed Oxidative Annulation through C–H Bond 
Alkenylations: Regio- and Site- Selective Access to Isoindolin-1-one 
 
Ethyl 2-{3-Oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate (132bb): 
The general procedure E was followed using N-(quinolin-8-yl)benzamide 
(110b) (62.0 mg, 0.25 mmol) and ethyl acrylate (46b) (50.0 mg, 0.50 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 
132bb (74.0 mg, 85 %) as a colorless solid. 
M. p. = 145−147 °C. 
1
H NMR (400 MHz, CDCl3): δ = 8.85 (dd, J = 4.2, 1.8 Hz, 1H), 8.18 (ddd, J = 8.3, 1.8, 0.4 Hz, 
1H), 7.98–7.96 (m, 1H), 7.86 (dd, J = 7.3, 1.4 Hz, 1H), 7.83 (dd, J = 8.3, 1.4 Hz, 1H), 7.63–7.58 
(m, 2H), 7.56–7.49 (m, 2H), 7.40 (dd, J = 8.3, 4.2 Hz, 1H), 6.30 (t, J = 6.3 Hz, 1H), 3.79 (q, J = 
7.2 Hz, 2H), 2.72 (dd, J = 15.9, 5.6 Hz, 1H), 2.60 (dd, J = 15.9, 6.9 Hz, 1H), 0.96 (t, J = 7.2 Hz, 
3H). 
13
C NMR (100 MHz, CDCl3): δ = 170.0 (Cq), 168.2 (Cq), 150.2 (CH), 145.4 (Cq), 144.7 (Cq), 
136.3 (CH), 133.4(Cq), 132.1 (Cq), 131.9 (CH), 130.4 (CH), 129.3 (Cq), 128.4 (CH), 128.0 (CH), 
126.3 (CH), 124.3 (CH), 122.5 (CH), 121.5 (CH), 60.5 (CH2), 59.5 (CH), 38.0 (CH2), 13.8 (CH3). 




MS (EI) m/z (relative intensity): 346 (25) [M]
+
, 301 (10), 273 (100), 259 (10), 231 (10), 204 (10), 








 346.1312, found 346.1314. 
 
Benzyl 2-{3-Oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate (132bd): 
The general procedure E was followed using N-(quinolin-8-yl)benzamide 
(110b) (62.0 mg, 0.25 mmol) and benzyl acrylate (46d) (82.0 mg, 0.51 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 
132bd (79.0 mg, 77%) as a colorless solid. 
M. p. = 67−69 °C. 
1
H NMR (500 MHz, CDCl3): δ = 8.84 (dd, J = 4.2, 1.8 Hz, 1H), 8.17 (dd, J = 8.3, 1.8 Hz, 1H), 7.97–
7.96 (m, 1H), 7.82 (d, J = 7.8 Hz, 2H), 7.57 (t, J = 7.8 Hz, 1H), 7.55 ( dt, J = 1.3, 7.4 Hz, 1H), 7.52–
7.46 (m, 2H), 7.39 (dd, J = 8.3, 4.2 Hz, 1H), 7.29–7.27 (m, 3H), 7.12–7.10 (m, 2H), 6.32 (dd, J = 
7.2, 5.3 Hz, 1H), 4.97–4.60 (m, 2H), 2.80 (dd, J = 16.0, 5.3 Hz, 1H), 2.65 (dd, J = 16.0, 7.2 Hz, 1H). 
13
C NMR (125 MHz, CDCl3): δ = 169.9 (Cq), 168.2 (Cq), 150.1 (CH), 145.3 (Cq), 144.5 (Cq), 136.4 
(CH), 135.1 (Cq), 133.3 (Cq), 132.0 (Cq), 131.9 (CH), 130.4 (CH), 129.3 (Cq), 128.5 (CH), 128.4 
(CH), 128.2 (CH), 128.2 (CH), 128.0 (CH), 126.3 (CH), 124.3 (CH), 122.5 (CH), 121.5 (CH), 66.4 
(CH2), 59.5 (CH), 37.9 (CH2). 
IR (neat): 3038, 2950, 1731, 1692, 1395, 1145, 730, 694 cm
–1
. 
MS (EI) m/z (relative intensity): 408 (20) [M]
+
, 273 (100), 230 (10), 181 (40), 169 (10), 131 (15), 
91 (20). 




408.1468, found 408.1456. 
 
2-{3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetonitrile (132bh): 
The general procedure E was followed using N-(quinolin-8-yl)benzamide 
(110b) (62.5 mg, 0.25 mmol) and acrylonitrile (46h) (50.0 mg, 0.94 
mmol).Purification by column chromatography (n-hexane/EtOAc: 2/1→1/1) 
yielded 132bh (56.0 mg, 75%) as a colorless solid. 
M. p. = 196−198 °C. 
1
H NMR (500 MHz, CDCl3): δ = 8.84 (dd, J = 4.2, 1.7 Hz, 1H), 8.23 (dd, J = 8.3, 1.7 Hz, 1H), 8.02 
(d, J = 7.6 Hz, 1H), 7.98 (dd, J = 7.3, 1.3 Hz, 1H), 7.87 (dd, J = 8.4, 1.3 Hz, 1H), 7.70–7.65 (m, 3H), 
7.61–7.58 (m, 1H), 7.44 (dd, J = 8.3, 4.2 Hz, 1H), 6.35 (dd, J = 6.9, 4.0 Hz, 1H), 2.82 (dd, J = 16.9, 
4.0 Hz, 1H), 2.60 (dd, J = 16.9, 6.9 Hz, 1H). 
13
C NMR (125 MHz, CDCl3): δ = 167.8 (Cq), 150.2 (CH), 144.2 (Cq), 143.2 (Cq), 136.7 (CH), 
132.6 (CH), 132.2 (Cq), 132.1 (Cq), 130.4 (CH), 129.4 (Cq), 129.3 (CH), 128.3 (CH), 126.7 (CH), 
124.7 (CH), 122.3 (CH), 121.7 (CH), 115.7 (Cq), 58.0 (CH), 22.1 (CH2). 






MS (EI) m/z (relative intensity): 299 (100) [M]
+
, 270 (40), 259 (40), 231 (40), 130 (60), 101 (25), 
43 (25). 




299.1053, found 299.1060. 
 
3-(2-oxopropyl)-2-(quinolin-8-yl)isoindolin-1-one (132bf): 
The general procedure E was followed using N-(quinolin-8-yl)benzamide 
(110b) (62.0 mg, 0.25 mmol) and methyl vinyl ketone (46f) (36.0 mg, 0.51 
mmol). Purification by column chromatography (n-hexane/EtOAc: 2/1→1/1) 
yielded 132bf (48.0 mg, 61%) as a colorless solid. 
M. p. = 136−138 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.86 (dd, J = 4.2, 1.8 Hz, 1H), 8.18 (dd, J = 8.3, 1.8 Hz, 1H), 7.97–
7.94 (m, 1H), 7.83 (td, J = 7.6, 1.5 Hz, 2H), 7.61 (t, J = 7.3 Hz, 1H), 7.60–7.47 (m, 3H), 7.41 (dd, J 
= 8.3, 4.2 Hz, 1H), 6.33 (dd, J = 8.2, 4.7 Hz, 1H), 2.85 (dd, J = 17.4, 4.7 Hz, 1H), 2.68 (dd, J = 17.4, 
8.2 Hz, 1H), 1.87 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 205.6 (Cq), 168.2 (Cq), 150.4 (CH), 146.2 (Cq), 144.6 (Cq), 136.3 
(CH), 133.6 (Cq), 132.0 (CH), 131.9 (Cq), 130.1 (CH), 129.4 (Cq), 128.3 (CH), 128.2 (CH), 126.3 
(CH), 124.3 (CH), 122.8 (CH), 121.6 (CH), 59.0 (CH), 46.7 (CH2), 30.5 (CH3). 
IR (neat): 3042, 2922, 1688, 1499, 1470, 1394, 1362, 1150 cm
–1
. 
MS (EI) m/z (relative intensity): 316 (5) [M]
+
, 274 (30), 273 (100)[M–Ac]
+
, 229 (10), 129 (10), 
101 (10), 43 (20). 




 316.1206, found 316.1215. 
 
Ethyl 2-{6-methyl-3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate (132ab): 
The general procedure E was followed using 4-methyl-N-(quinolin-
8-yl)benzamide (110a) (65.5 mg, 0.25 mmol) and ethyl acrylate (46b) 
(50.0 mg, 0.5 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 2/1→1/1) yielded 132ab (66.0 mg, 73%) as a 
colorless solid. 
M. p. = 132−134 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.85 (dd, J = 4.3, 1.8 Hz, 1H), 8.19 (dd, J = 8.4, 1.8 Hz, 1H), 
7.86−7.81 (m, 3H), 7.61 (dd, J = 8.3, 7.3 Hz, 1H), 7.41 (dd, J = 8.3, 4.3 Hz, 1H), 7.34–7.30 (m, 
2H), 6.24 (t, J = 6.3 Hz, 1H), 3.79 (qd, J = 7.1, 2.3 Hz, 2H). 2.70 (dd, J = 15.9, 5.7 Hz, 1H), 2.58 
(dd, J = 15.9, 6.9 Hz, 1H), 2.48 (s, 3H), 0.97 (t, J = 7.1 Hz, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 170.0 (Cq), 168.3 (Cq), 150.1 (CH), 145.8 (Cq), 144.6 (Cq), 




126.3 (CH), 124.0 (CH), 122.9 (CH), 121.4 (CH), 60.5 (CH2), 59.4 (CH), 38.2 (CH2), 22.1 (CH3), 
13.9 (CH3). 
IR (neat): 2975, 2944, 2902, 1696, 1587, 1475, 1404, 1243, 1209 cm
–1
. 
MS (EI) m/z (relative intensity): 360 (25) [M]
+
, 287 (100), 273 (10), 207 (10), 143 (10); 115 (5), 
44 (5). 




 361.1547, found 361.1548. 
 
5-Methyl-3-(2-oxopropyl)-2-(quinolin-8-yl)isoindolin-1-one (132af): 
The general procedure E was followed using 4-methyl-N-(quinolin-
8-yl)benzamide (110a) (65.2 mg, 0.25 mmol) and methyl vinyl ketone 
(46f) (35.0 mg, 0.5 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 2/1→1/1) yielded 132af (52.0 mg, 63%) as a 
colorless solid. 
M. p. = 166−167 °C. 
1
H NMR (500 MHz, CDCl3): δ = 8.85 (dd, J = 4.2, 1.8 Hz, 1H), 8.18 (dd, J = 8.3, 1.8 Hz, 1H), 7.84–
7.80 (m, 3H), 7.60 (dd, J = 8.2, 7.4 Hz, 1H), 7.40 (dd, J = 8.3, 4.2 Hz, 1H), 7.32–7.29 (m, 2H), 6.29 
(dd, J = 8.3, 4.6 Hz, 1H), 2.83 (dd, J = 17.5, 4.6 Hz, 1H), 2.67 (dd, J = 17.5, 8.3 Hz, 1H), 2.46 (s, 
3H), 1.88 (s, 3H). 
13
CNMR (125 MHz, CDCl3): δ = 205.8 (Cq), 168.2 (Cq), 150.3 (CH), 146.6 (Cq), 144.7 (Cq), 142.7 
(Cq), 136.3 (CH), 133.8 (Cq), 130.1 (CH), 129.4 (Cq, 2C), 129.3 (CH), 128.0 (CH), 126.3 (CH), 
124.1 (CH), 123.3 (CH), 121.5 (CH), 58.8 (CH), 46.8 (CH2), 30.5 (CH3), 22.0 (CH3). 
IR (neat): 3041, 2957, 2905, 1688, 1616, 1393, 1144, 795, 772 cm
–1
. 
MS (EI) m/z (relative intensity): 330 (5) [M]
+
, 288 (30), 287 (100), 272 (5), 143 (10), 115 (10), 43 
(5). 




 330.1363; found 330.1369. 
 
 
Ethyl 2-{6-Methoxy-3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate (132cb): 
The general procedure E was followed using 4-methoxy-N-(quinolin-
8-yl)benzamide (110c) (69.5 mg, 0.25 mmol) and ethyl acrylate (46b) 
(50.0 mg, 0.5 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 2/1→1/1) yielded 132cb (53.0 mg, 56%) as a 
colorless solid. 
M. p. = 131−133 °C. 
1




7.87 (dd, J = 8.1, 0.7 Hz, 1H), 7.84 (dd, J = 7.3, 1.4 Hz, 1H), 7.81 (dd, J = 8.3, 1.4 Hz, 1H). 7.60 
(dd, J = 8.2, 7.3 Hz, 1H), 7.39 (dd, J = 8.3, 4.2 Hz, 1H), 7.09–6.96 (m, 2H), 6.37–6.17 (m, 1H), 
3.87 (s, 3H), 3.80 (q, J = 7.1 Hz, 2H), 2.70 (dd, J = 16.0, 5.5 Hz, 1H), 2.57 (dd, J = 16.0, 7.1 Hz, 
1H), 0.97 (t, J = 7.1 Hz, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 170.0 (Cq), 167.9 (Cq), 163.0 (Cq), 150.0 (CH), 147.7 (Cq), 
144.6 (Cq), 136.1 (CH), 133.5 (Cq), 130.3 (CH), 129.2 (Cq), 127.8 (CH), 126.2 (CH), 125.5 (CH), 
124.6 (Cq), 121.4 (CH), 114.9 (CH), 107.4 (CH), 60.5 (CH2), 59.2 (CH), 55.6 (CH3), 38.2 (CH2), 
13.9 (CH3). 
IR (neat): 2968, 2937, 1683, 1605, 1250, 788, 693 cm
–1
. 
MS (EI) m/z (relative intensity): 376 (30) [M]
+
, 331 (5), 304 (30), 303 (100), 289 (10), 231 (5), 
129 (5). 




 376.1418, found 376.1429. 
 
Ethyl 2-{6-chloro-3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate (132db): 
The general procedure E was followed using 4-chloro-N-(quinolin-
8-yl)benzamide (110d) (70.0 mg, 0.25 mmol) and ethyl acrylate (46b) 
(50.0 mg, 0.50 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 2/1→1/1) yielded 132db (73.0 mg, 77 %) as a 
colorless solid. 
M. p. = 121−123 °C. 
1
H NMR (500 MHz, CDCl3): δ = 8.84 (dd, J = 4.2, 1.8 Hz, 1H), 8.19 (dd, J = 8.3, 1.8 Hz, 1H), 7.89 
(dd, J = 8.1, 0.5 Hz, 1H), 7.84 (d, J = 7.8 Hz, 2H), 7.61 (dd, J = 8.2, 7.4 Hz, 1H), 7.58–7.57 (m, 1H), 
7.49 (ddd, J = 8.1, 1.8, 0.6 Hz, 1H), 7.41 (dd, J = 8.3, 4.2 Hz, 1H), 6.29–6.27 (m, 1H), 3.85 (q, J = 
7.2Hz, 2H), 2.73 (dd, J = 16.2, 5.2 Hz, 1H), 2.57 (dd, J = 16.2, 7.3 Hz, 1H), 1.00 (t, J = 7.2 Hz, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 169.6 (Cq), 167.1 (Cq), 150.2 (CH), 147.0 (Cq), 144.4 (Cq), 138.2 
(Cq), 136.2 (CH), 133.0 (Cq), 130.6 (Cq), 130.2 (CH), 129.3 (Cq), 128.9 (CH), 128.2 (CH), 126.2 
(CH), 125.4 (CH), 123.1 (CH), 121.5 (CH), 60.7 (CH2), 59.1 (CH), 37.7 (CH2), 13.9 (CH3). 
IR (neat):2975, 2952, 1730, 1692, 1398, 1228, 1148, 788 cm
–1
. 
MS (EI) m/z (relative intensity): 380 (20) [M]
+
, 335 (5), 307 (100), 293 (10), 229 (10), 163 (10), 
43 (15). 




 380.0922; found 380.0931. 
 
Ethyl 2-{6-bromo-3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate (132eb): 




8-yl)benzamide (110e) (81.6 mg, 0.25 mmol) and ethyl acrylate (46b) (50.0 mg, 0.50 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 132eb (89.0 mg, 
84%) as a colorless solid. 
M. p. = 155−156 °C. 
1
H NMR (500 MHz, CDCl3): δ = 8.85 (dd, J = 4.2, 1.7 Hz, 1H), 8.20 (dd, J = 8.3, 1.7 Hz, 1H), 7.86–
7.82 (m, 3H), 7.75–7.74 (m, 1H), 7.66 (ddd, J = 8.1, 1.7, 0.6 Hz, 1H), 7.62 (t, J = 7.8 Hz, 1H), 7.42 
(dd, J = 8.3, 4.2 Hz, 1H), 6.28 (dd, J = 7.3, 5.2 Hz, 1H), 3.85 (q, J = 7.1Hz, 2H), 2.73 (dd, J = 16.2, 
5.2 Hz, 1H), 2.58 (dd, J = 16.2, 7.3 Hz, 1H), 1.00 (t, J = 7.1 Hz, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 169.8 (Cq), 167.4 (Cq), 150.3 (CH), 147.3 (Cq), 144.5 (Cq), 136.4 
(CH), 133.0 (Cq), 131.9 (CH), 131.1 (Cq), 130.4 (CH), 129.4 (Cq), 128.3 (CH), 126.7 (Cq), 126.4 
(CH), 126.2 (CH), 125.7 (CH), 121.6 (CH), 60.7 (CH2), 59.1 (CH), 37.7 (CH2), 13.9 (CH3). 
IR (neat): 2988, 2924, 1727, 1692, 1396, 1374, 1192, 830, 687 cm
–1
. 
MS (EI) m/z (relative intensity): 424 (15) [M]
+
, 379 (5), 351 (100), 272 (10), 242 (10), 229 (10), 
128 (10). 






 424.0417, found 424.0424. 
 
Ethyl 2-{6-iodo-3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate (132fb): 
The general procedure E was followed using 4-iodo-N-(quinolin-
8-yl)benzamide (110f) (94.0 mg, 0.25 mmol) and ethyl acrylate (46b) 
(50.0 mg, 0.50 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 2/1→1/1) yielded 132fb (94.0 mg, 80%) as a colorless 
solid. 
M. p. = 176−178 °C. 
1
H NMR (400 MHz, CDCl3): δ = 8.84 (dd, J = 4.2, 1.7 Hz, 1H), 8.19 (ddd, J = 8.3, 1.8, 0.4 Hz, 
1H), 7.96 (dt, J = 1.4, 0.7 Hz, 1H), 7.89–7.83 (m, 3H), 7.70 (ddd, J = 8.0, 0,6, 0.3 Hz, 1H), 7.65–
7.59 (m, 1H), 7.42 (dd, J = 8.3, 4.2 Hz, 1H), 6.42–6.12 (m, 1H), 3.84 (q, J = 7.1 Hz, 2H), 2.72 (dd, 
J = 16.1, 5.3 Hz, 1H), 2.57 (dd, J = 16.1, 7.2 Hz, 1H), 1.00 (t, J = 7.1 Hz, 3H). 
13
C NMR (100 MHz, CDCl3): δ = 170.0 (Cq), 167.6 (Cq), 150.3 (CH), 147.3 (Cq), 144.5 (Cq), 137.7 
(CH), 136.3 (CH), 133.0 (Cq), 132.1 (CH), 131.7 (Cq), 130.4 (CH), 129.4 (Cq), 128.3 (CH) , 126.3 
(CH), 125.7 (CH), 121.6 (CH), 98.9 (Cq), 60.7 (CH2), 59.0 (CH), 37.7 (CH2), 13.9 (CH3). 
IR (neat): 2981, 2914, 1729, 1683, 1400, 1191, 826, 687 cm
–1
. 
MS (EI) m/z (relative intensity): 472 (35) [M]
+
, 427 (5), 399 (100), 385 (10), 272 (25), 243 (10), 
229 (10), 102 (10). 









Ethyl 2-{6-cyano-3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate (132gb): 
The general procedure E was followed using 4-cyano-N-(quinolin-
8-yl)benzamide (110g) (68.3 mg, 0.25 mmol) and ethyl acrylate (46b) 
(50.0 mg, 0.50 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 2/1→1/1) yielded 132gb (54.0 mg, 58%) as a 
colorless solid. 
M. p. = 179−181 °C. 
1
H NMR (500 MHz, CDCl3): δ = 8.84 (dd, J = 4.2, 1.7 Hz, 1H), 8.21 (dd, J = 8.3, 1.7 Hz, 1H), 
8.12–8.03 (m, 1H), 7.92 (s, 1H), 7.87 (dd, J = 8.2, 1.4 Hz, 1H), 7.85 (dd, J = 7.4, 1.4 Hz, 1H), 
7.82 (d, J = 8.0 Hz, 1H), 7.63 (dd, J = 8.2, 7.4 Hz, 1H), 7.44 (dd, J = 8.3, 4.2 Hz, 1H), 6.36 (dd, J 
= 7.7, 4.8 Hz, 1H), 3.89 (q, J = 7.1 Hz, 2H), 2.77 (dd, J = 16.5, 4.8 Hz, 1H), 2.57 (dd, J = 16.5, 7.7 
Hz, 1H), 1.02 (t, J = 7.1 Hz, 3H).
 
13
C NMR (125 MHz, CDCl3): δ = 169.6 (Cq), 166.4 (Cq), 150.5 (CH), 145.9 (Cq), 144.3 (Cq), 
136.4 (CH), 136.1 (Cq), 132.5 (Cq), 132.3 (CH), 130.2 (CH), 129.4 (Cq), 128.6 (CH), 127.0 (CH), 
126.3 (CH), 125.1 (CH), 121.7 (CH), 118.3 (Cq), 115.4 (Cq), 60.9 (CH2), 59.3 (CH), 37.2 (CH2), 
13.9 (CH3). 
IR (neat):3077, 2978, 2938, 2227, 1689, 1259, 787, 681 cm
–1
. 
MS (EI) m/z (relative intensity): 371 (20) [M]
+
, 326 (5), 298 (100), 268 (5), 256 (5), 229 (10), 128 
(10), 43 (25). 




 371.1264, found 371.1266. 
 
Ethyl 2-{6-nitro-3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate(132hb): 
The general procedure E was followed using 4-nitro-N-(quinolin-
8-yl)benzamide (110h) (73.2 mg, 0.25 mmol) and ethyl acrylate (46b) 
(50.0 mg, 0.50 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 2/1→1/1) yielded 132hb (49.0 mg, 50%) as a 
colorless solid. 
M. p. = 178−180 °C. 
1
H NMR (500 MHz, CDCl3): δ = 8.86 (dd, J = 4.2, 1.7 Hz, 1H), 8.47 (dt, J = 1.8, 0.7 Hz, 1H), 8.42–
8.40 (m, 1H), 8.23 (dd, J = 8.3, 1.7 Hz, 1H), 8.13–8.11 (m, 1H), 7.88 (ddd, J = 14.0, 7.8, 1.4 Hz, 
2H), 7.65 (dd, J = 8.2, 7.4 Hz, 1H), 7.45 (dd, J = 8.3, 4.2 Hz, 1H), 6.42 (dd, J = 7.4, 4.9 Hz, 1H), 3.90 
(q, J = 7.1 Hz, 2H), 2.82 (dd, J = 16.4, 4.9 Hz, 1H), 2.63 (dd, J = 16.4, 7.4 Hz, 1H), 1.03 (t, J = 7.1 
Hz, 3H). 
13




144.2 (Cq), 137.6 (Cq), 136.5 (CH), 132.6 (Cq), 130.2 (CH), 129.4 (Cq), 128.7 (CH), 126.4 (CH), 
125.3 (CH), 124.1 (CH), 121.8 (CH), 118.6 (CH), 61.0 (CH2), 59.5 (CH), 37.2 (CH2), 13.9 (CH3). 
IR (neat): 3081, 2980, 2927, 1725, 1687, 1527, 1341, 788, 737 cm
–1
. 
MS (EI) m/z (relative intensity): 391 (20) [M]
+
, 346 (5), 318 (100), 304 (5), 272 (30), 243 (10), 
229 (10), 43 (10). 




 391.1163, found 391.1174. 
 
Ethyl 2-{3-oxo-2-(quinolin-8-yl)-6-(trifluoromethyl)isoindolin-1-yl}acetate(132ib): 
The general procedure E was followed using N-(quinolin-8-yl)-4-
(trifluoromethyl)benzamide (110i) (79.2 mg, 0.25 mmol) and ethyl 
acrylate (46b) (50.0 mg, 0.50 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 132ib (83.0 mg, 
80%) as a colorless solid. 
M. p. = 103−105 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.85 (dd, J = 4.2, 1.8 Hz, 1H), 8.21 (dd, J = 8.3, 1.8 Hz, 1H), 8.08 
(dt, J = 7.9, 0.8 Hz, 1H), 7.90–7.83 (m, 3H), 7.82– 7.78 (m, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.43 (dd, 
J = 8.3, 4.2 Hz, 1H), 6.36 (dd, J = 7.3, 5.1 Hz, 1H), 3.86 (q, J = 7.1 Hz, 2H), 2.79 (dd, J = 16.1, 5.1 
Hz, 1H), 2.61 (dd, J = 16.1, 7.3 Hz, 1H), 0.99 (t, J = 7.1 Hz, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 170.0 (Cq), 166.9 (Cq), 150.4 (CH), 145.8 (Cq), 144.4 (Cq) , 136.4 
(CH), 135.4 (q, J = 1.4 Hz, Cq), 133.8 (q, 
2
JC-F = 32.7 Hz, Cq) 132.8 (Cq), 130.4 (CH), 129.4 (Cq), 
128.4 (CH), 126.4 (CH), 125.7 (q, 
3
JC-F = 3.7 Hz, CH), 124.9 (CH), 123.8 (q, 
1
JC-F = 272.6 Hz, Cq) 
121.7 (CH), 120.1 (q, 
3
JC-F = 3.9 Hz, CH), 60.8 (CH2), 59.5 (CH), 37.5 (CH2), 13.8 (CH3). 
19
F NMR (282 MHz, CDCl3) δ =–62.4. 
IR (neat): 3346, 1667, 1532, 1323, 1114, 828, 794, 765 cm
–1
. 
MS (EI) m/z (relative intensity): 414 (20) [M]
+
, 369 (5), 341 (100), 327 (10), 229 (5), 197 (5), 101 
(5). 




 414.1186, found 414.1183. 
Ethyl 2-{4-fluoro-3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate(132jb): 
The general procedure E was followed using 2-fluoro-N-(quinolin-
8-yl)benzamide (110j) (66.7 mg, 0.25 mmol) and ethyl acrylate (46b) (50.0 
mg, 0.50 mmol). Purification by column chromatography (n-hexane/EtOAc: 
2/1→1/1) yielded 132jb (49.0 mg, 54%) as a colorless solid. 
M. p. = 63−65 °C. 
1
H NMR (500 MHz, CDCl3): δ = 8.86 (dd, J = 4.2, 1.7 Hz, 1H), 8.20 (dd, J = 8.3, 1.7 Hz, 1H), 7.85–




(dd, J = 7.5, 0.8 Hz, 1H), 7.16–7.12 (m, 1H), 6.30 (t, J = 6.1 Hz, 1H), 3.81 (q, J = 7.2 Hz, 2H), 2.72 
(dd, J = 16.1, 5.4 Hz, 1H), 2.60 (dd, J = 16.1, 6.9 Hz, 1H), 0.97 (t, J = 7.2 Hz, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 169.8 (Cq), 165.1 (d, 
3
JC-F = 2.5 Hz, Cq), 159.3 (d, 
1
JC-F = 261.0 
Hz, Cq), 150.2 (CH), 148.2 (d, 
3
JC-F = 2.8 Hz, Cq), 144.4 (Cq), 136.6 (CH), 133.9 (d, 
3
JC-F = 7.7 Hz, 
CH), 132.9 (Cq), 130.6 (CH), 129.4 (Cq), 128.2 (CH), 126.4 (CH), 121.6 (CH), 119.5 (d, 
2
JC-F = 12.9 
Hz, Cq), 118.5 (d, 
4
JC-F = 4.2 Hz, CH), 115.7 (d, 
2
JC-F = 19.3 Hz, CH), 60.6 (CH2), 59.2 (CH), 37.9 
(CH2), 13.8 (CH3). 
19
F NMR (282 MHz, CDCl3): δ = –117.8. 
IR (neat): 3046, 2981, 1696, 1626, 1477, 1394, 1028, 830 cm
–1
. 
MS (EI) m/z (relative intensity): 364 (25) [M]
+
, 319 (5), 291 (100), 277 (10), 249 (10), 84 (20), 43 
(35). 




 364.1218, found 364.1227. 
 
Ethyl 2-{4-methyl-3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate(132kb): 
The general procedure E was followed using 2-methyl-N-(quinolin-
8-yl)benzamide (110k) (67.5 mg, 0.26 mmol) and ethyl acrylate (46b) (50.0 
mg, 0.50 mmol). Purification by column chromatography (n-hexane/EtOAc: 
2/1→1/1) yielded 132kb (48.0 mg, 51%) as a colorless solid. 
M. p. = 99−101 °C. 
1
H NMR (500 MHz, CDCl3): δ = 8.86 (dd, J = 4.2, 1.7 Hz, 1H), 8.18 (dd, J = 8.3, 1.8 Hz, 1H), 7.85–
7.82 (m, 2H), 7.61 (dd, J = 8.3, 7.3 Hz, 1H), 7.46–7.43 (m, 1H), 7.40 (dd, J = 8.3, 4.2 Hz, 1H), 7.35–
7.33 (m, 1H), 7.25–7.24 (m, 1H), 6.21 (t, J = 6.3 Hz, 1H), 3.80–3.73 (m, 2H), 2.76 (s, 3H), 2.71 (dd, 
J = 15.8, 5.8 Hz, 1H), 2.61 (dd, J = 15.8, 6.6 Hz, 1H), 0.94 (t, J = 7.2 Hz, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 170.2 (Cq), 169.1 (Cq), 150.2 (CH), 146.0 (Cq), 144.9 (Cq), 138.3 
(Cq), 136.3 (CH), 133.6 (Cq), 131.5 (CH), 130.6 (CH), 130.4 (CH), 129.3 (Cq), 129.0 (Cq), 128.0 
(CH), 126.3 (CH), 121.4 (CH), 119.9 (CH), 60.6 (CH2), 58.8 (CH), 38.4 (CH2), 17.4 (CH3), 13.8 
(CH3). 
IR (neat): 2978, 2925, 1729, 1688, 1473, 1394, 789, 624 cm
–1
. 
MS (EI) m/z (relative intensity): 360 (20) [M]
+
, 315 (5), 288 (20), 287 (100), 273 (10), 243 (5), 143 
(10), 115 (10). 




 360.1468, found 360.1468. 
 
Ethyl 2-{4,6-dimethyl-3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate(132lb): 
The general procedure E was followed using 2,4-dimethyl-N-(quinolin-




(50.0 mg, 0.50 mmol). Purification by column chromatography (n-hexane/EtOAc: 2/1→1/1) 
yielded 132lb (57.0 mg, 61%) as a colorless solid. 
M. p. = 100−102 °C. 
1
HNMR (500 MHz, CDCl3): δ = 8.85 (dd, J = 4.2, 1.7 Hz, 1H), 8.18 (dd, J = 8.3, 1.8 Hz, 1H), 7.84–
7.80 (m, 2H), 7.60 (dd, J = 8.3, 7.3 Hz, 1H), 7.39 (dd, J = 8.3, 4.2 Hz, 1H), 7.14 (d, J = 1.5 Hz, 1H), 
7.06 (d, J = 1.5 Hz, 1H), 6.17 (t, J = 6.2 Hz, 1H), 3.80–3.73 (m, 2H), 2.71 (s, 3H), 2.68 (dd, J = 15.8, 
5.9 Hz, 1H), 2.60 (dd, J = 15.8, 6.6 Hz, 1H), 2.42 (s, 3H), 0.95 (t, J = 7.2 Hz, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 170.3 (Cq), 169.1 (Cq), 150.2 (CH), 146.5 (Cq), 144.9 (Cq), 142.0 
(Cq), 138.0 (Cq), 136.2 (CH), 133.8 (Cq), 131.4 (CH), 130.6 (CH), 129.3 (Cq), 127.8 (CH), 126.6 
(Cq), 126.2 (CH), 121.4 (CH), 120.4 (CH), 60.4 (CH2), 58.7 (CH), 38.5 (CH2), 21.8 (CH3), 17.3 
(CH3), 13.8 (CH3). 
IR (neat): 2980, 2926, 1717, 1683, 1395, 1158, 1139, 796, 694 cm
–1
. 
MS (EI) m/z (relative intensity): 374 (25) [M]
+
, 329 (5), 301 (100), 287 (10), 257 (10), 128(10), 
43 (10). 




 374.1625, found 374.1627. 
 
Ethyl 2-{5,7-dimethyl-3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate (132mb): 
The general procedure E was followed using 3,5-dimethyl-N-(quinolin-
8-yl)benzamide (110m) (68.0 mg, 0.25 mmol) and ethyl acrylate (46b) 
(50.0 mg, 0.50 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 2/1→1/1) yielded 132mb (65.0 mg, 70%) as a 
colorless solid. 
M. p. = 151−152 °C. 
1
H NMR (400 MHz, CDCl3): δ = 8.85 (dd, J = 4.2, 1.8 Hz, 1H), 8.18 (ddd, J = 8.3, 1.8, 0.4 Hz, 1H), 
7.96 (dd, J = 7.4, 1.4 Hz, 1H), 7.82 (dd, J = 8.3, 1.4 Hz, 1H), 7.63 (dd, J = 8.3, 7.4 Hz, 1H), 7.61 (s, 
1H), 7.40 (dd, J = 8.3, 4.2 Hz, 1H), 7.20–7.19 (m, 1H), 6.30 (t, J = 4.8 Hz, 1H), 3.63–3.53 (m, 2H), 
2.73–2.72 (m, 2H), 2.44 (s, 3H), 2.42 (s, 3H), 0.82 (t, J = 7.1 Hz, 3H). 
13
C NMR (100 MHz, CDCl3): δ = 169.5 (Cq), 168.6 (Cq), 150.0 (CH), 144.8 (Cq), 140.2 (Cq), 138.5 
(Cq), 136.3 (CH), 134.5 (CH), 133.4 (Cq), 132.7 (Cq), 132.2 (Cq), 130.8 (CH), 129.3 (Cq), 127.7 
(CH), 126.4 (CH), 122.0 (CH), 121.3 (CH), 60.3 (CH2), 59.3 (CH), 36.3 (CH2), 21.2 (CH3), 18.3 
(CH3), 13.6 (CH3). 
IR (neat):2980, 2925, 2897, 1732, 1691, 1398, 1181, 794 cm
–1
. 
MS (EI) m/z (relative intensity): 374 (25) [M]
+
, 329 (5), 301 (100), 287 (10), 257 (5), 157 (5), 129 
(10). 









Ethyl 2-{2-(5-methoxyquinolin-8-yl)-6-methyl-3-oxoisoindolin-1-yl}acetate (132nb): 
The general procedure E was followed using N-(5-methoxy-
quinolin8-yl)-4-methylbenzamide (110n) (72.5 mg, 0.25 mmol) and 
ethyl acrylate (46b) (50.0 mg, 0.50 mmol) Purification by column 
chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 132nb (61.0 
mg, 63%) as a colorless solid. 
M. p. = 137−139 °C. 
1
H NMR (500 MHz, CDCl3): δ = 8.81 (dd, J = 4.2, 1.8 Hz, 1H), 8.57 (dd, J = 8.5, 1.8 Hz, 1H), 
7.83 (d, J = 7.7 Hz, 1H), 7.71 (d, J = 8.2 Hz, 1H), 7.36 (dd, J = 8.5, 4.2 Hz, 1H), 7.32 (dd, J = 1.6, 
0.8 Hz, 1H), 7.31–7.29 (m, 1H), 6.90 (d, J = 8.2 Hz, 1H), 6.05 (t, J = 6.3 Hz, 1H), 4.00 (s, 3H), 
3.85–3.76 (m, 2H), 2.72 (dd, J = 15.9, 5.6 Hz, 1H), 2.60 (dd, J = 15.9, 6.9 Hz, 1H), 2.46 (s, 3H), 
0.96 (t, J = 7.1 Hz, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 170.1 (Cq), 168.4 (Cq), 154.9 (Cq), 150.4 (CH), 145.7 (Cq), 
145.2 (Cq), 142.3 (Cq), 130.9 (CH), 130.6 (CH), 129.6 (Cq), 129.2 (CH), 125.8 (Cq), 123.9 (CH), 
122.9 (CH), 121.5 (Cq), 120.4 (CH), 103.8 (CH), 60.5 (CH2), 59.3 (CH), 55.9 (CH3), 38.1(CH2), 
22.0 (CH3), 13.9 (CH3). 
IR (neat): 3049, 2980, 2941, 1695, 1404, 1271, 1242, 1150 cm
–1
. 
MS (EI) m/z (relative intensity): 390 (25) [M]
+
, 345 (5), 317 (100), 302 (10), 287 (5), 245 (5), 159 
(5), 115 (5). 




 390.1574, found 390.1570. 
 
2-{2-(5-Methoxyquinolin-8-yl)-6-methyl-3-oxoisoindolin-1-yl}acetonitrile (132nh): 
The general procedure E was followed using N-(5-methoxy-
quinolin8-yl)-4-methylbenzamide (110n) (72.5 mg, 0.25 mmol) 
and acrylonitrile (46h) (29.0 mg, 0.55 mmol). Purification by 
column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 
132nh (55.0 mg, 64%) as a colorless solid. 
M. p. = 227−228 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.83–8.81 (m, 1H), 8.65–8.61 (m, 1H), 7.90 (d, J = 7.8 Hz, 1H), 
7.84 (dd, J = 8.3, 0.6 Hz, 1H), 7.49–7.48 (m, 1H), 7.44–7.38 (m, 2H), 6.96 (d, J = 8.3 Hz, 1H), 
6.08 (dd, J = 6.9, 3.9 Hz, 1H), 4.05 (s, 3H), 2.84 (dd, J = 16.8, 3.9 Hz, 1H), 2.62 (dd, J = 16.7, 6.9 
Hz, 1H), 2.53 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 168.2 (Cq), 155.2 (Cq), 150.5 (CH), 145.0 (Cq), 143.6 (Cq), 143.2 




(Cq), 120.7 (CH), 116.0 (Cq), 104.1 (CH), 57.8 (CH), 56.0 (CH3), 22.1 (CH3), 22.0 (CH2). 
IR (neat): 2964, 2930, 2912, 1686, 1587, 1407, 1274, 1080 cm
–1
. 
MS (EI) m/z (relative intensity): 343 (100) [M]
+
, 328 (10), 303 (65), 260 (25), 232 (15), 
160(75),115 (20). 




 343.1315, found 343.1318. 
 
Reaction with 3-fluoro-N-(quinolin-8-yl)benzamide (110s):  
The general procedure E was followed using 3-fluoro-N-(quinolin-8-yl)benzamide (110s) (65.6 
mg, 0.25 mmol) and ethyl acrylate (46b) (50 mg, 0.50 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 132sb (46.0 mg, 51%) and 132sb' (21.0 mg, 
23%) as colorless solids. 
 
Ethyl 2-{5-fluoro-3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate (132sb): 
M. p. = 168−170 °C.
 
1
H NMR (300 MHz, CDCl3): δ = 8.85 (dd, J = 4.2, 1.8 Hz, 1H), 8.19 (dd, J 
= 8.3, 1.8 Hz, 1H), 7.85 (d, J = 7.7 Hz, 2H), 7.64–7.59 (m, 2H), 7.53 (ddt, J 
= 8.3, 4.4, 0.6 Hz, 1H), 7.42 (dd, J = 8.3, 4.2 Hz, 1H), 7.29 (ddd, J = 9.1, 
8.4, 2.5 Hz, 1H), 6.26 (dd, J = 7.2, 5.3 Hz, 1H), 3.83 (q, J = 7.2Hz, 2H), 2.72 (dd, J = 16.0, 5.3 Hz, 
1H), 2.56 (dd, J = 16.0, 7.2 Hz, 1H), 0.99 (t, J = 7.2 Hz, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 169.9 (Cq), 167.2 (d, 
4
JC-F = 3.5 Hz, Cq), 163.0 (d, 
1
JC-F = 247.5 
Hz, Cq), 150.3 (CH), 144.5 (Cq), 140.9 (d, 
4
JC-F = 2.4 Hz, Cq), 136.3 (CH), 134.3 (d, 
3
JC-F = 8.8 Hz, 
Cq), 133.1 (Cq), 130.3 (CH), 129.4 (Cq), 128.3 (CH), 126.3 (CH), 124.3 (d, 
3
JC-F = 8.3 Hz, CH), 
121.6 (CH), 119.4 (d, 
2
JC-F = 23.6 Hz, CH), 110.9 (d, 
2
JC-F = 23.4 Hz, CH), 60.6 (CH2), 59.2 (CH), 
37.9 (CH2), 13.8 (CH3). 
19
F NMR (282 MHz, CDCl3): δ = –(112.9–113.0) (m). 
IR (neat): 3047, 1733, 1697, 1619, 1502, 1424, 1376, 1226 cm
–1
. 
MS (EI) m/z (relative intensity): 364 (20) [M]
+
, 319 (5), 291 (100), 277 (10), 248 (10), 101 (10), 
43 (20). 




 364.1218, found 364.1231. 
 
Ethyl 2-{7-fluoro-3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate (132sb'): 
M. p. = 144−146 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.87 (dd, J = 4.2, 1.7 Hz, 1H), 8.21 (dd, J = 
8.4, 1.7 Hz, 1H), 7.90–7.84 (m, 2H), 7.78 (d, J = 7.5 Hz, 1H), 7.63 (dd, J = 8.3, 




1H), 6.44 (t, J = 5.2 Hz, 1H), 4.26–3.36 (m, 2H), 2.85 (dd, J = 15.5, 5.8 Hz, 1H), 2.77 (dd, J = 15.5, 
4.6 Hz, 1H), 0.88–0.83 (m, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 169.2 (Cq), 167.3 (d, 
4
JC-F = 2.3 Hz, Cq), 157.6 (d, 
1
JC-F = 250.2 
Hz, Cq), 150.3 (CH), 144.6 (Cq), 136.4 (CH), 135.5 (d, 
3
JC-F = 4.3 Hz, Cq), 132.9 (Cq), 130.8 (d, 
2
JC-F 
= 16.7 Hz, Cq), 130.7 (CH), 130.5 (d, 
3
JC-F = 6.6 Hz, CH), 129.3 (Cq), 128.2 (CH), 126.4 (CH) , 
121.6 (CH), 120.3 (d, 
4
JC-F = 3.7 Hz, CH), 118.7 (d, 
2
JC-F = 20.0 Hz, CH), 60.5 (CH2), 57.7 (d, 
3
JC-F 
= 2.1 Hz, CH), 36.4 (d, 
4
JC-F = 1.1 Hz, CH2), 13.7 (CH3). 
19
F NMR (283 MHz, CDCl3): δ = –119.95 (dd, J = 9.2, 4.6 Hz). 
IR (neat): 2920, 1731, 1695, 1615, 1501, 1393, 1247, 1144, 749 cm
–1
. 
MS (EI) m/z (relative intensity): 364 (20) [M]
+
, 319 (5), 291 (100), 277 (10), 248 (10), 101(10), 
43 (20). 




 364.1218, found 364.1231. 
 
Reaction with 3-methyl-N-(quinolin-8-yl)benzamide (110t):  
The general procedure E was followed using 3-methyl-N-(quinolin-8-yl)benzamide (110t) (65.3 
mg, 0.25 mmol) and ethyl acrylate (46b) (50 mg, 0.50 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 132tb (38.0 mg, 42%) and 132tb' (12.0 mg, 
13%) as colorless solids. 
Ethyl 2-{5-methyl-3-oxo-2-(quinolin-8-yl)isoindolin-1-yl}acetate (132tb): 
M. p. = 171−172 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.85 (dd, J = 4.2, 1.8 Hz, 1H), 8.18 (dd, 
J = 8.3, 1.8 Hz, 1H), 7.86–7.81 (m, 2H), 7.78−7.77 (m, 1H), 7.61 (dd, J = 
8.3, 7.3 Hz, 1H), 7.43–7.38 (m, 3H), 6.24 (t, J = 6.3 Hz, 1H), 3.79 (q, J = 
7.2 Hz, 2H), 2.70 (dd, J = 15.8, 5.6 Hz, 1H), 2.57 (dd, J = 15.8, 6.9 Hz, 1H), 2.46 (s, 3H), 0.99–0.94 
(m, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 170.2 (Cq), 168.4 (Cq), 150.2 (CH), 144.7 (Cq), 142.7 (Cq), 138.4 
(Cq), 136.3 (CH), 133.6 (Cq), 132.9 (CH), 132.2 (Cq), 130.4 (CH), 129.4 (Cq), 128.0 (CH), 126.3 
(CH), 124.5 (CH), 122.3 (CH), 121.5 (CH), 60.5 (CH2), 59.4 (CH), 38.2 (CH2), 21.3 (CH3), 13.8 
(CH3). 
IR (neat): 2981, 2928, 1731, 1692, 1494, 1227, 1188, 1161, 1139 cm
–1
. 
MS (EI) m/z (relative intensity): 360 (25) [M]
+
, 315 (5), 287 (100), 273 (10), 243 (5), 143 (10), 
115 (20). 




 360.1468, found 360.1471. 
 




M. p. = 139−141 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.86 (dd, J = 4.1, 1.7 Hz, 1H), 8.19 (dd, J = 
8.3, 1.8 Hz, 1H), 7.98 (dd, J = 7.4, 1.4 Hz, 1H), 7.85–7.79 (m, 2H), 7.71–7.56 
(m, 1H), 7.44–7.36 (m, 3H), 6.36 (t, J = 4.7 Hz, 1H), 3.69–3.38 (m, 2H), 2.75 
(d, J = 4.7 Hz, 2H), 2.48 (s, 3H), 0.80 (t, J = 7.1 Hz, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 169.4 (Cq), 168.4 (Cq), 150.1 (CH), 144.8 (Cq), 142.9 (Cq), 136.3 
(CH), 133.5 (CH), 133.2 (Cq), 132.6 (Cq), 132.5 (Cq), 130.8 (CH), 129.3 (Cq), 128.5 (CH), 127.8 
(CH), 126.4 (CH), 121.8 (CH), 121.4 (CH), 60.3 (CH2), 59.5 (CH), 36.1 (CH2), 18.4 (CH3), 13.6 
(CH3). 
IR (neat): 2974, 2922, 1725, 1686, 1503, 1395, 1285, 1141 cm
–1
. 
MS (EI) m/z (relative intensity): 360 (25) [M]
+
, 315 (5), 287 (100), 273 (10), 245 (5), 143 (10), 43 
(20). 




 360.1468, found 360.1469. 
 
Intermolecular Competition Experimentsbetween Amides 110c and 110d 
 
The general procedure E was followed using 4-chloro-N-(quinolin-8-yl)benzamide (110d) (140.0 
mg, 0.50 mmol), 4-methoxy-N-(quinolin-8-yl)benzamide (110c) (139.0 mg, 0.50 mmol), ethyl 
acrylate (46b) (25.0 mg, 0.25 mmol), Co(OAc)2 (9.0 mg, 20 mol %) and AgOPiv (105.0 mg, 0.50 
mmol). Purification by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 132db (27.0 
mg, 28%). 











The general procedure E was followed using 4-methyl-N-(quinolin-8-yl)benzamide (110a) (65.5 
mg, 0.25 mmol), ethyl acrylate (46b) (51.0 mg, 0.51 mmol), Co(OAc)2 (9.0 mg, 20 mol %) and 
AgOPiv (105.0 mg, 2.0 equiv) in a solvent mixture of PEG 400/CF3CH2OH/CD3OD (2.0/0.3/0.2 
mL). Purification by column chromatography (n-hexane /EtOAc: 2/1→1/1) yielded 132ab (60.0 
mg, 66%) as a colorless solid. Its spectral data were identical to those reported above. The 
negligible deuterium incorporation in 132ab was confirmed by 
1
H NMR spectroscopy. 
 
Studies on Cobalt-Catalyzed H/D Exchange with Substrate [D]5-110b 
 
A mixture of N-(quinolin-8-yl)benzamide-2,3,4,5,6-d5 ([D]5-110b) (62.5 mg, 0.25 mmol), ethyl 
acrylate (46b) (50.0 mg, 0.50 mmol), Co(OAc)2 (9.0 mg, 20 mol %) and AgOPiv (105.0 mg, 2.0 
equiv) in PEG 400/CF3CH2OH (2.0/0.5 mL) was stirred at 100 °C for 18 h under an ambient 
atmosphere of air. The reaction mixture was diluted with H2O (20 mL) and extracted with tBuOMe 
(3  25 mL). The combined organic layers were washed with brine (50 mL) and dried over Na2SO4. 
After filtration and evaporation of the solvents in vacuo, the crude product was purified by column 
chromatography on silica gel (n-hexane/EtOAc: 2/1) to yield [D]4-132bb (64.0 mg, 73%) as a 





Ethyl 2-{3-Oxo-2-(quinolin-8-yl)isoindolin-1-yl-4,5,6,7-d4}acetate ([D]4-132bb): 
M. p. = 149−151 °C. 
1
H NMR (500 MHz, CDCl3): δ = 8.86 (dd, J = 4.2, 1.8 Hz, 1H), 8.19 (dd, J 
= 8.4, 1.8 Hz, 1H), 7.86 (dd, J = 7.3, 1.4 Hz, 1H), 7.84 (dd, J = 8.3, 1.4 Hz, 
1H), 7.62 (dd, J = 8.3, 7.4 Hz, 1H), 7.41 (dd, J = 8.3, 4.2 Hz, 1H), 6.31 (dd, 
J = 7.0, 5.5 Hz, 1H), 3.80 (q, J = 7.1 Hz, 2H), 2.72 (dd, J = 15.9, 5.5 Hz, 1H), 2.60 (dd, J = 15.9, 7.0 






CNMR (125 MHz, CDCl3): δ = 170.1 (Cq), 168.3 (Cq), 150.2 (CH), 145.4 (Cq), 144.7 (Cq), 136.3 
(CH), 133.5 (Cq), 132.0 (Cq), 131.4 (CD), 130.4 (CH), 129.3(Cq), 128.0 (CH), 127.9 (CD), 126.4 
(CH), 123.9 (CD), 122.2 (CD), 121.5 (CH), 60.5 (CH2), 59.5 (CH), 38.1 (CH2), 13.8 (CH3). 
IR (neat): 3061, 2968, 2927, 1727, 1694, 1405, 1159, 1028 cm
–1
. 
MS (EI) m/z (relative intensity): 350 (20) [M]
+
, 305 (5), 277 (100), 263 (10), 235 (5), 133(5), 43 
(10). 




350.1563, found 350.1575. 
 
 
Studies on the Kinetic Isotope Effect. 
 
The representative procedure E was followed using N-(quinolin-8-yl)benzamide (110b) (37.0 mg, 
0.15 mmol), N-(quinolin-8-yl)benzamide-2,3,4,5,6-d5 ([D5]-110b) (38.0 mg, 0.15 mmol) and ethyl 
acrylate (46b) (14 mg, 0.14 mmol). Purification by column chromatography (n-hexane/EtOAc: 2/1) 
yielded a mixture of [D]4-132bb and [H]4-132bb. The kinetic isotope effect of this reaction was 





The representative procedure Ewas followed using [D]1-110b (62.0 mg, 0.25 mmol) and ethyl 
acrylate (46b) (50.0 mg, 0.25 mmol). Purification by column chromatography (n-hexane/EtOAc: 
2/1) yielded [D]n-132bb (37.0 mg, 43%) as a colorless solid. The intramolecular KIE was estimated 
to be 1.6, as determined by 
1
H NMR spectroscopy. 
8.4.5 Analytical Data for the Products of Silver-Mediated Alkyne Annulations by 






1-Ethoxy-2,3-diphenylphosphindole 1-Oxide (117aa): 
The general procedure F was followed using ethyl phenylphosphinate (121a) 
(82.1 mg, 0.48 mmol) and diphenylacetylene (11a) (178.0 mg, 1.00 mmol), 
heating at 120 °C for 12h. Purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 117aa (99.0 mg, 60%) as an off-white oil. 
1
H NMR (300 MHz, CDCl3): δ = 7.83–7.64 (m, 1H), 7.48–7.32 (m, 7H), 7.32–7.14 (m, 5H), 
7.13–7.18 (m, 1H), 4.41–3.86 (m, 2H), 1.23 (t, J = 7.0 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 148.5 (d, J = 27.6 Hz, Cq), 141.8 (d, J = 34.0 Hz, Cq), 133.8 (d, J 
= 18.1 Hz, Cq), 132.9 (d, J = 2.1 Hz, CH), 132.4 (d, J = 9.3 Hz, Cq), 131.4 (d, J = 125.0 Hz, Cq), 
128.9 (d, J = 10.8 Hz, CH), 128.9 (d, J = 5.8Hz, CH), 128.8 (CH), 128.5 (CH), 128.4 (CH), 127.9 
(CH), 127.6 (d, J = 8.8 Hz, CH), 127.1 (d, J = 134.0 Hz, Cq), 126.2 (CH), 123.8 (d, J = 13.4 Hz, 
CH), 62.0 (d, J = 6.4 Hz, CH2), 16.4 (d, J = 6.2 Hz, CH3). 
31
P NMR (122 MHz, CDCl3): δ = 45.9. 
IR (film): 3058, 2979, 1440, 1221, 1026, 939, 697, 524 cm
–1
. 
MS (EI) m/z (relative intensity): 346 (100) [M]
+
, 317 (90), 299 (80), 252 (50), 77 (10).  




 347.1195, found 347.1220. 




1-(tert-Butyl)-2,3-diphenyl-1H-phosphindole 1-Oxide (117ba): 
The general procedure F was followed using tert-butyl(phenyl)phosphine oxide 
(121b) (91.3 mg, 0.50 mmol) and diphenylacetylene (11a) (178.0 mg, 1.00 mmol), 
heating at 120 °C for 12h. Purification by column chromatography 
(n-hexane/EtOAc: 2/1) afforded 117ba (98.0 mg, 55%) as a colorless solid. 
M. p. = 215–217 °C. 
1
H NMR (300 MHz, CDCl3): δ = 7.81–7.75 (m, 1 H), 7.44–7.28 (m, 7 H), 7.20–7.07 (m, 6 H), 
1.05 (d, J = 15.2 Hz, 9 H). 
13
C NMR (75 MHz, CDCl3): δ = 150.2 (d, J = 19.0 Hz, Cq), 144.0 (d, J = 24.0 Hz, Cq), 134.5 (d, J 
= 9.4 Hz, Cq), 134.1 (d, J = 13.9 Hz, Cq), 132.4 (d, J = 2.0 Hz, CH), 132.1 (d, J = 84.7 Hz, Cq), 
129.6 (d, J = 8.5 Hz, CH), 129.5 (d, J = 94.4 Hz, Cq), 129.1 (d, J = 4.9 Hz, CH), 129.0 (CH), 
128.7 (CH), 128.4 (CH), 128.2 (d, J = 8.7 Hz, CH), 127.7 (CH), 123.8 (d, J = 9.8 Hz, CH), 32.8 (d, 
J = 68.1 Hz, Cq), 24.2 (CH3). 
31
P NMR (122 MHz, CDCl3): δ = 60.3. 
IR (neat): 3055, 2963, 1863, 1439, 1259, 1174, 1065, 1021 cm
–1
. 
MS (EI): m/z (relative intensity): 358 (25) [M]
+








 359.1559, found 359.1554.  
The spectral data were in accordance with those reported in the literature.
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1-Isopropyl-2,3-diphenyl-1H-phosphindole 1-Oxide (117ca): 
The general procedure F was followed using isopropyl(phenyl)phosphine oxide 
(121c) (84.0 mg, 0.50 mmol) and diphenylacetylene (11a) (178.0 mg, 1.00 mmol), 
heating at 120 °C for 12h. Purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 117ca (85.0 mg, 49%) as colorless solid. 
M.p. = 153–155 °C. 
1
H NMR (300 MHz, CDCl3): δ = 7.91–7.67 (m, 1H), 7.49–7.31 (m, 7H), 7.29–6.97 (m, 6H), 
2.32–2.14 (m, 1H), 1.25 (dd, J = 16.4, 7.2 Hz, 3H), 0.90 (dd, J = 18.0, 7.2 Hz, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 148.4 (d, J = 19.1 Hz, Cq), 142.7(d, J = 24.4 Hz, Cq), 133.1 (d, 
J = 13.9 Hz, Cq), 132.4 (d, J = 9.7 Hz, Cq), 131.4 (d, J = 1.9 Hz, CH), 130.8 (d, J = 87.8 Hz, CH), 
128.0 (d, J = 96.5 Hz, Cq), 128.0 (d, J = 8.8 Hz, CH), 127.8 (CH), 127.8 (d, J = 5.4 Hz, CH), 
127.7 (CH) , 127.4 (d, J = 9.8 Hz, CH), 127.2 (d, J = 14.3 Hz, CH), 127.2 (CH), 126.7 (CH) , 
122.7 (d, J = 10.0 Hz, CH), 26.5 (d, J = 68.2 Hz, CH), 14.5 (CH3), 14.1 (d, J = 2.3 Hz, CH3). 
31
P NMR (122 MHz, CDCl3): δ = 56.7.  
IR (neat): 3056, 2961, 2928, 1444, 1256, 1181, 1068, 1028, 694 cm
–1
. 
MS (EI) m/z (relative intensity): 344 (25) [M]
+
, 302 (100), 283 (15), 252 (20), 196 (5), 57 (10).  




 344.1325, found 344.1331.  
 
1-Methyl-2,3-diphenyl-1H-phosphindole 1-Oxide (117da): 
The general procedure F was followed using methyl(phenyl)phosphine oxide 
(121d) (71.9 mg, 0.51 mmol) and diphenylacetylene (11a) (178.0 mg, 1.00 mmol), 
heating at 100 °C for 2h. Purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 117da (87.0mg, 54%) as a colorless solid. 
M.p. = 162–164 °C. 
1
H NMR (300 MHz, CDCl3): δ = 7.90–7.70 (m, 1H), 7.45–7.27 (m, 7H), 7.25–7.02 (m, 6H), 1.68 
(d, J = 13.1 Hz, 3H).
 
13
C NMR (75 MHz, CDCl3): δ = 147.0 (d, J = 21.0 Hz, Cq), 141.7 (d, J = 26.6 Hz, Cq), 133.1 (d, J 
= 14.7 Hz, Cq), 133.0 (d, J = 93.9 Hz, Cq), 131.8 (d, J = 10.3 Hz, Cq), 131.7 (d, J = 2.4 Hz, CH), 
130.6 (d, J = 103.0 Hz, Cq), 128.0 (CH), 127.9 (CH), 127.9 (d, J = 5.6 Hz, CH), 127.7 (CH), 127.5 
(d, J = 9.5 Hz, CH), 127.4 (CH), 127.2 (d, J = 9.6 Hz, CH), 127.0 (CH), 122.9 (d, J = 10.6 Hz, 





P NMR (122 MHz, CDCl3): δ = 45.2. 
IR (neat): 3056, 3029, 1715, 1290, 1179, 759, 744, 729, 694 cm
–1
.  
MS (EI) m/z (relative intensity): 315 (100) [M]
+
, 301 (5), 252 (20), 157 (5), 43 (25).  




 316.1012, found 316.1005.  
 
1-Cyclohexyl-2,3-diphenylphosphindole 1-Oxide (117ea): 
The general procedure F was followed using cyclohexyl(phenyl)phosphine oxide 
(121e) (104.0 mg, 0.50 mmol) and diphenylacetylene (11a) (178.0 mg, 1.00 
mmol), heating at 100 °C for 2h. Purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 117ea (88.0 mg, 46%) as a yellow gum. 
1
H NMR (300 MHz, CDCl3): δ= 7.79–7.67 (m, 1H), 7.42–7.24 (m, 7H), 7.24–7.07 (m, 5H), 7.12–
7.00 (m, 1H), 2.10–1.84 (m, 2H), 1.81–1.63 (m, 2H), 1.61–1.44 (m, 2H), 1.42–1.27 (m, 1H), 
1.22–0.89 (m, 4H), 0.88–0.69 (m, 1H). 
13
C NMR (125 MHz, CDCl3): δ= 148.4 (d, J = 19.4 Hz, Cq), 142.6 (d, J = 24.8 Hz, Cq), 133.1 (d, 
J = 14.0 Hz, Cq), 132.5 (d, J = 9.7 Hz, Cq), 131.3 (d, J = 2.0 Hz, CH), 131.0 (d, J = 87.8 Hz, Cq), 
128.4 (d, J = 96.5 Hz, Cq), 128.0 (d, J = 8.6 Hz, CH), 127.8 (CH), 127.8 (d, J = 5.3 Hz, CH), 
127.6 (br, CH), 127.3 (d, J = 9.7 Hz, CH), 127.2 (d, J = 11.8 Hz, CH), 127.1 (CH), 126.7 (CH) , 
122.6 (d, J = 10.0 Hz, CH), 36.4 (d, J = 68.4 Hz, CH), 25.3 (d, J = 13.5 Hz, CH2), 25.1 (d, J = 
14.4 Hz, CH2), 24.8 (d, J = 1.7 Hz, CH2), 24.2 (d, J = 3.4 Hz, CH2), 24.1 (CH2). 
31
P NMR (122 MHz, CDCl3): δ = 53.8.  




MS (EI) m/z (relative intensity): 384 (100) [M]
+
, 329 (20), 302 (80), 283 (20), 252 (35).  




 384.1638, found 384.1559.  




6-Ethoxy-4,5-diphenylphospholo[2,3-b]thiophene 6-Oxide (117fa): 
The general procedure F was followed using ethyl thiophen-2-ylphosphinate (121f) 
(86.8 mg, 0.49 mmol) and 1,2-bis(4-chlorophenyl)ethyne (11a) (178.0 mg, 1.00 
mmol), heating at 100 °C for 2h. Purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 117fa (71.0 mg, 41%) as a yellow gum. 
1
H NMR (300 MHz, CDCl3): δ = 7.36–7.28 (m, 8H), 7.26–7.24 (m, 1H), 7.22–7.19 (m, 3H), 
4.09–3.94 (m, 2H), 1.23 (t, J = 7.0 Hz, 3H).  
13
C NMR (125 MHz, CDCl3): δ = 154.6 (d, J = 47.0 Hz, Cq), 141.1 (d, J = 22.1 Hz, Cq), 134.0 (d, 
J = 17.1 Hz, Cq), 132.5 (d, J = 8.7 Hz, Cq), 129.9 (d, J = 136.6 Hz, Cq), 129.7 (d, J = 130.4 Hz, Cq), 




(CH), 127.9 (d, J = 1.3 Hz, CH), 125.3 (d, J = 14.8 Hz, CH), 62.4 (d, J = 6.4 Hz, CH2), 16.4 (d, J 
= 6.2 Hz, CH3).  
31
P NMR (122 MHz, CDCl3): δ = 36.7. 
IR (neat): 3062, 2981, 2926, 1710, 1224, 1019, 951, 695 cm
–1
. 
MS (EI) m/z (relative intensity): 352 (100) [M]
+
, 323(70), 305 (75), 276 (15), 258 (25), 213 (20), 
105 (40).  




 353.0760, found 353.0760. 
 
 
1-Ethoxy-2,3-bis(4-fluorophenyl)phosphindole 1-Oxide (117ad): 
The general procedure F was followed using ethyl phenylphosphinate 
(121a) (87.4 mg, 0.51 mmol) and 1,2-bis(4-fluorophenyl)ethyne (11d) 
(217.0 mg, 1.01 mmol), heating at 120 °C for 12h. Purification by column 
chromatography (n-hexane/EtOAc: 2/1) yielded 117ad (96.0 mg, 50%) as 
a yellow solid.  
M. p. = 99–101 °C. 
1
H NMR (300 MHz, CDCl3): δ = 7.77–7.70 (m, 1H), 7.47–7.30 (m, 4H), 7.24–7.20 (m, 2H), 
7.13–7.06 (m, 3H), 6.94–6.87 (m, 2H), 4.16–4.02 (m, 2H), 1.23 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 162.7 (d, 
1
JC-F = 249.5 Hz, Cq), 162.3 (d, 
1
JC-F = 249.5 Hz, Cq), 
147.4 (dd, J = 28.0, 1.4 Hz, Cq), 141.5 (d, J = 34.0 Hz, Cq), 133.1 (d, J = 2.2 Hz, CH), 130.9 (d, J 
= 8.2 Hz, CH), 130.7 (dd, 
3
JC-F = 8.0, 5.8 Hz, CH), 129.5 (d, J = 125.8 Hz, Cq), 129.4 (dd, J = 18.3, 
3.5 Hz, Cq), 129.1 (d, J = 11.3 Hz, CH), 128.3 (dd, J = 9.2, 3.5 Hz, Cq), 127.7 (d, J = 8.9 Hz, CH), 
127.0 (d, J = 134.4 Hz, Cq), 123.7 (d, J = 13.4 Hz, CH), 116.2 (d, 
2
JC-F= 21.6 Hz, CH), 115.5 (d, 
2
JC-F= 21.9 Hz, CH), 62.1 (d, J = 6.6 Hz, CH2), 16.4 (d, J = 5.9 Hz, CH3).  
19
F NMR (282 MHz, CDCl3): δ = –(111.7–117.8) (m), –(112.4–112.5) (m),  
31
P NMR (122 MHz, CDCl3): δ = 45.19, 45.18. 
IR (neat): 3057, 2985, 1498, 1217, 1031, 955, 774, 526 cm
–1
. 
MS (EI) m/z (relative intensity): 382 [M]
+
 (100), 353 (100), 335 (80), 288 (50), 123 (20), 95 (10).  








2,3-Bis(4-chlorophenyl)-1-ethoxy-1H-phosphindole 1-Oxide (117ae): 
The general procedure F was followed using ethyl phenylphosphinate 




(250.0 mg, 1.01 mmol), heating at 120 °C for 12h. Purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 117ae (132.0 mg, 64%) as a yellow gum. 
1
H NMR (300 MHz, CDCl3): δ = 7.78–7.71 (m, 1H), 7.49–7.35 (m, 4H), 7.32–7.29 (m, 2H), 
7.21–7.16 (m, 4H), 7.10–7.06 (m, 1H), 4.16–4.02 (m, 2H), 1.24 (t, J = 7.1 Hz, 3H).  
13
C NMR (75 MHz, CDCl3): δ = 147.7 (d, J = 28.0 Hz, Cq), 141.1 (d, J = 34.0 Hz, Cq), 134.9 (Cq), 
134.1(Cq), 133.1 (d, J = 2.2 Hz, CH), 131.9 (d, J = 18.1 Hz, Cq), 130.7 (d, J = 8.8 Hz, Cq), 130.3 
(CH), 130.1 (d, J = 5.9 Hz, CH), 130 (d, J = 125.1 Hz, Cq), 129.4 (CH), 129.3 (d, J = 11.6 Hz, 
CH), 128.8 (CH), 127.8 (d, J = 8.9 Hz, CH), 127.1 (d, J = 134.4 Hz, Cq), 123.7 (d, J = 13.5 Hz, 
CH), 62.2 (d, J = 6.4 Hz, CH2), 16.5 (d, J = 6.0 Hz, CH3).  
31
P NMR (122 MHz, CDCl3): δ = 46.0. 




MS (EI) m/z (relative intensity): 414 (100) [M]
+
, 385 (90), 367 (60), 322 (20), 286 (20), 250 (35), 
139 (20). 
HR-MS (ESI) m/z calcd for C22H18Cl2O2P [M+H]
+
415.0416, found 415.0409.  
 
1-Ethoxy-2,3-bis{4-(trifluoromethyl)phenyl}-1H-phosphindole 1-Oxide (117am): 
The general procedure F was followed using ethyl phenylphosphinate 
(121a) (84.9 mg, 0.50 mmol) and 1,2-bis{4-(trifluoromethyl)phenyl}-
ethyne (11m) (318.0 mg, 1.01 mmol), heating at 120 °C for 12h. 
Purification by column chromatography (n-hexane/EtOAc: 2/1) yielded 
117am (127.0 mg, 53%) as a colorless gum. 
1
H NMR (300 MHz, CDCl3): δ = 7.85–7.75 (m, 1H), 7.70 (d, J = 8.3 Hz, 2H), 7.62–7.42 (m, 6H), 
7.45–7.34 (m, 2H), 7.14–7.01 (m, 1H), 4.19–4.09 (m, 2H), 1.27 (t, J = 7.0 Hz, 3H).  
13
C NMR (125 MHz, CDCl3): δ = 148.5 (d, J = 27.7 Hz, Cq), 140.6 (q, J = 33.8 Hz, Cq), 137.1 (d, 
J = 17.8 Hz, Cq), 135.7 (d, J = 9.0 Hz, Cq), 133.2 (d, J = 2.3 Hz, CH), 132.4 (d, J = 2.9 Hz, CH), 
132.0 (d, J = 9.8 Hz, CH), 131.0 (q, J = 33.3 Hz, Cq), 130.2 (d, J = 97.1 Hz, Cq), 129.7 ( d, J = 
11.2 Hz, CH), 129.3 (CH) , 129.0 (d, J = 5.7 Hz, CH), 128.5 (d, J = 13.1 Hz, CH), 128.1 (d, J = 
8.9 Hz, CH), 127.1 (d, J = 133.6 Hz, Cq), 125.7–125.5 (m, CH), 125.4 (q, J = 4.0 Hz, CH), 123.9 
(d, J = 13.4 Hz, CH), 123.7 (q, J = 272 Hz, Cq), 123.6 (q, J = 272 Hz, Cq), 62.4 (d, J = 6.4 Hz, 
CH2), 16.6 (d, J = 6.0 Hz, CH3). 
19
F NMR (282 MHz, CDCl3): δ = –(62.6–63.0) (m). 
31
P NMR (122 MHz, CDCl3): δ = 44.4.  
IR (neat): 2984, 1736, 1616, 1320, 1163, 1109, 1065, 1016 cm
–1
. 
MS (EI) m/z (relative intensity): 482 (85) [M]
+








 482.0865, found 482.0850.  
 
1-Ethoxy-2,3-bis(4-methoxyphenyl)-1H-phosphindole 1-Oxide(117ac): 
The general procedure F was followed using ethyl phenylphosphinate 
(121a) (84.9 mg, 0.50 mmol) and 1,2-bis(4-methoxylphenyl)ethyne (11c) 
(238.0 mg, 1.00 mmol), heating at 120 °C for 12h. Purification by 
column chromatography (n-hexane/EtOAc: 2/1) yielded 117ac (55.0 mg, 
27%) as a yellow solid. 
M. p. = 111–113 °C. 
1
H NMR (300 MHz, CDCl3): δ = 7.73–7.67 (m, 1H), 7.42–7.30 (m, 4H), 7.17 (d, J = 8.3 Hz, 2H), 
7.13–7.09 (m, 1H), 6.92 (dd, J = 7.4, 1.6 Hz, 2H), 6.74–6.71 (m, 2H), 4.11–3.96 (m, 2H), 3.82 (s, 
3H), 3.74 (s, 3H), 1.21 (t, J = 7.0 Hz, 3H).  
13
C NMR (75 MHz, CDCl3): δ = 159.6 (Cq), 159.1 (Cq), 146.6 (d, J = 28.1 Hz, Cq), 142.4 (d, J = 
34.6 Hz, Cq), 132.9 (d, J = 2.2 Hz, CH), 130.4 (CH), 130.3 (d, J = 6.3 Hz, CH), 128.8 (d, J = 
125.3 Hz, Cq), 128.5 (d, J = 11.2 Hz, CH), 127.5 (d, J = 8.7 Hz, CH), 127.1 (d, J = 125.5 Hz, Cq), 
126.1 (d, J = 11.2 Hz, Cq), 125.0 (d, J = 9.3 Hz, Cq), 123.5 (d, J = 13.5 Hz, CH), 114.4 (CH), 
113.8 (CH) , 61.9 (d, J = 6.3 Hz, CH2), 55.2 (CH3), 55.1 (CH3), 16.4 (d, J = 6.2 Hz, CH3). 
31
P NMR (122 MHz, CDCl3): δ = 47.5. 
IR (neat): 2988, 2933, 2836, 1243, 1218, 1174, 1022, 508 cm
–1
.  
MS (EI) m/z (relative intensity): 406 (100) [M]
+
, 377 (40), 359 (30), 345 (10), 226 (10), 135 (10), 
43 (30). 




 407.1407, found 407.1404. 
 
1,2,3-Triphenylphosphindole 1-Oxide (117ga): 
The general procedure F was followed using diphenylphosphine oxide (121g) 
(99.1 mg, 0.49 mmol) and diphenylacetylene (11a) (178.0 mg, 1.00 mmol), 
heating at 120 °C for 12h. Purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 117ga (123.0 mg, 66%) as an off-white solid. 
M. p. = 177–179 °C 
1
H NMR (300 MHz, CDCl3): δ = 7.81−7.68 (m, 3H), 7.48−7.31 (m, 10H), 7.25−7.22 (m, 3H), 
7.11−7.07 (m, 3H).  
13
C NMR (75 MHz, CDCl3): δ = 150.0 (d, J = 21.8 Hz, Cq), 143.7 (d, J = 27.2 Hz, Cq), 134.2 (d, J 
= 95.7 Hz, Cq), 134.2 (d, J = 15.2 Hz, Cq), 132.9 (d, J = 2.0 Hz, CH), 132.6 (d, J = 10.0 Hz, Cq), 
132.12 (d, J = 2.9 Hz, CH), 132.0 (d, J = 105.7 Hz, Cq), 130.91 (d, J = 10.6 Hz, CH), 129.9 (d, J = 




128.8 (d, J = 12.7 Hz, CH), 128.6 (CH), 128.2 (CH), 127.8 (CH), 124.0 (d, J = 10.8 Hz, CH).
 
31
P NMR (122 MHz, CDCl3): δ = 40.2.  
IR (neat): 3067, 3043, 1436, 1194, 766, 723, 691, 519 cm
–1
. 
MS (EI) m/z (relative intensity): 378 (60) [M]
+
, 377 (100), 299 (25), 252 (20), 77 (5).  




 378.1168, found 378.1184.  
The spectral data were in accordance with those reported in the literature.
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2,3-Bis(4-chlorophenyl)-1-phenyl-1H-phosphindole 1-Oxide (117ge): 
 
The general procedure F was followed using diphenylphosphine oxide 
(121g) (101.0 mg, 0.50 mmol) and 1,2-bis(4-chlorophenyl)ethyne (11e) 
(246.0 mg, 1.00 mmol), heating at 120 °C for 12h. Purification by column 
chromatography (n-hexane/EtOAc: 2/1) yielded 117ge (143.0 mg, 64%) as 
a yellow gum. 
1
H NMR (300 MHz, CDCl3): δ = 7.67–7.60 (m, 3H), 7.42–7.28 (m, 7H), 7.19–7.07 (m, 5H), 
7.02–6.99 (m, 2H). 
13
C NMR (75 MHz, CDCl3): δ = 149.0 (d, J = 21.5 Hz, Cq), 143.1 (d, J = 26.5 Hz, Cq), 134.9 (Cq), 
134.0 (Cq), 133.8 (d, J = 95.6 Hz, Cq), 133.05 (d, J = 2.0 Hz, CH), 132.38 (d, J = 2.6 Hz, CH), 
132.2 (d, J = 15.4 Hz, Cq), 131.7 (d, J = 106.2 Hz, Cq), 130.9 (d, J = 10.2 Hz, Cq), 130.8 (d, J = 
10.7 Hz, CH), 130.4 (CH), 130.1 (d, J = 5.5 Hz, CH), 129.5 (d, J = 10.6 Hz, CH), 129.4 (CH), 
129.3 (d, J = 9.8 Hz, CH), 129.2 (d, J = 100.0 Hz, Cq), 128.9 (d, J = 12.4, CH), 128.7 (CH), 123.9 
(d, J = 10.9 Hz, CH).
 
31
P NMR (122 MHz, CDCl3): δ = 39.9.  
IR (neat): 3056, 2961, 1733, 1585, 1195, 1088, 1014, 844, 725 cm
–1
. 
MS (EI) m/z (relative intensity): 445 (100) [M–H]
+
, 411 (10) [M–Cl]
+
, 367 (15), 322 (10), 252 
(15).  




 446.0389, found 446.0386. 




2,3-Bis(4-methoxyphenyl)-1-phenylphosphindole 1-Oxide (117gc): 
The general procedure F was followed using diphenylphosphine oxide 
(121g) (101.0 mg, 0.50 mmol) and 1,2-bis(4-methoxylphenyl)ethyne 
(11c) (238.0 mg, 1.00 mmol), heating at 120 °C for 12h. Purification by 
column chromatography (n-hexane/EtOAc: 2/1) yielded 117gc (70.0 mg, 




M. p. = 85−87 °C 
1
H NMR (300 MHz, CDCl3): δ = 7.79–7.62 (m, 3H), 7.48–7.31 (m, 5H), 7.28–7.18 (m, 5H), 6.96 
(dd, J = 8.8, 1.1 Hz, 2H), 6.62 (d, J = 8.8 Hz, 2H), 3.84 (s, 3H), 3.67 (s, 3H). 
13
C NMR (125 MHz, CDCl3): δ= 159.5 (Cq), 158.8 (Cq), 148.1 (d, J = 21.9 Hz, Cq), 144.0 (d, J = 
27.2 Hz, Cq), 132.7 (d, J = 2.0 Hz), 132.6 (d, J = 97.0 Hz, Cq), 131.6 (d, J = 106 Hz, Cq), 130.8 (d, J 
= 10.6 Hz, CH), 130.3, 130.2 (d, J = 6.0 Hz, CH), 129.9 (d, J = 99 Hz, Cq), 128.8 (d, J = 9.4 Hz, CH), 
128.7 (d, J = 12.2 Hz, CH), 128.5 (d, J = 10.6 Hz, CH), 128.4 (d, J = 12.2 Hz, CH), 126.3 (d, J = 15.5 
Hz, CH), 125.1(d, J = 10.2 Hz, Cq), 123.6 (d, J = 10.9 Hz, Cq), 114.3 (CH), 113.6 (CH), 55.2 (CH3), 
55,0 (CH3). 
31
P NMR (122 MHz, CDCl3): δ = 39.5. 
IR (neat): 3004, 2960, 2836, 1604, 1500, 1437, 1245, 1174 cm
–1
.  
MS (EI) m/z (relative intensity): 438 (100) [M]+, 423(10), 394 (10), 351 (5), 277 (15), 226 (5), 77 
(5). 




 438.1379, found 438.1364. 
The spectral data were in accordance with those reported in the literature.
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1-Phenyl-2,3-di-n-propyl-1H-phosphindole 1-Oxide (117gh): 
The general procedure F was followed using diphenylphosphine oxide (121g) 
(103.0 mg, 0.51 mmol) and oct-4-yne (11h) (115.0 mg, 1.04 mmol), heating at 
100 °C for 4h. Purification by column chromatography (n-hexane/EtOAc: 2/1) 
yielded 117gh (87.0 mg, 55%) as a colorless solid. 
M. p. = 78–80 °C 
1
H NMR (300 MHz, CDCl3): δ = 7.61–7.54 (m, 2H), 7.50–7.38 (m, 3H), 7.35–7.27 (m, 3H), 
7.23–7.17 (m, 1H), 2.55–2.50 (m, 2H), 2.44–2.11 (m, 2H), 1.60–1.54 (m, 2H), 1.40–1.29 (m, 2H), 
0.99 (t, J = 7.3 Hz, 3H), 0.78 (t, J = 7.3 Hz, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 150.2 (d, J = 19.9 Hz, Cq), 143.5 (d, J = 29.2 Hz, Cq), 134.6 (d, 
J = 95.8 Hz, Cq), 132.6 (d, J = 2.0 Hz, CH), 132.2 (d, J = 105.3 Hz, Cq), 131.7 (d, J = 2.7 Hz, CH), 
130.8 (d, J = 10.6 Hz, CH), 130.2 (d, J = 96.9 Hz, Cq), 128.6 (d, J = 11.8 Hz, CH), 128.5 (CH), 
128.1 (d, J = 10.5 Hz, CH), 121.3 (d, J = 11.3 Hz, CH), 28.6 (d, J = 13.2 Hz, CH2), 28.3 (d, J = 
10.8 Hz, CH2), 22.4 (d, J = 1.9 Hz, CH2), 21.9(d, J = 1.9 Hz, CH2), 14.5 (CH3), 14.4 (CH3). 
31
P NMR (122 MHz, CDCl3): δ = 40.0.  
IR (neat): 3060, 2959, 2935, 2871, 1434, 1195, 1104, 690 cm
–1
. 
MS (EI) m/z (relative intensity): 310 (50) [M]
+
, 295 (30), 281 (100), 265 (10), 253 (30).  












2-Methyl-1,3-diphenylphosphindole 1-Oxide (117gi): 
The general procedure F was followed using diphenylphosphine oxide (121g) 
(120.0 mg, 0.59 mmol) and (prop-1-yn-1-ylbenzene) (11i) (120.0 mg, 1.03 mmol), 
heating at 100 °C for 2h. Purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 117gi (99.0 mg, 53%) as a colorless solid. 
M. p. = 87–89 °C. 
1
H NMR (300 MHz, CDCl3): δ = 7.71–7.64 (m, 2H), 7.61–7.55 (m, 1H), 7.47–7.32 (m, 7H), 
7.29–7.19 (m, 3H), 7.04 (dd, J = 7.6, 3.0 Hz, 1H), 1.83 (d, J = 12.4 Hz, 3H).  
13
C NMR (75 MHz CDCl3): δ = 150.0 (d, J = 21.9 Hz, Cq), 144.2 (d, J = 28.1 Hz, Cq), 133.5 (d, J 
= 15.7 Hz, Cq), 132.8 (d, J = 2.0 Hz, CH), 132.2 (d, J = 2.9 Hz, CH), 132.0 (d, J = 96.7 Hz, Cq), 
131.5 (d, J = 105.6 Hz, Cq), 130.9 (d, J = 10.6 Hz, CH), 129.2 (d, J = 98.2 Hz, Cq), 129.0(d, J = 
9.5 Hz, Cq), 128.9 (d, J = 12.3 Hz, CH), 128.7 (CH), 128.6 (CH), 128.6 (CH), 128.3 (d, J = 10.6 
Hz, CH), 123.1 (d, J = 11.1 Hz, CH), 10.7 (d, J = 10.7 Hz, CH3).  
31
P NMR (122 MHz, CDCl3): δ = 41.5.  
IR (neat): 3055, 1734, 1588, 1436, 1198, 1153, 1129, 722 cm
–1
. 




, 301 (5), 237 (15), 191 (15), 165 
(15), 77 (15).  




 316.1012, found 316.0997. 
The spectral data were in accordance with those reported in the literature.
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2-n-Butyl-1,3-diphenylphosphindole 1-Oxide (117gn): 
The general procedure F was followed using diphenylphosphine oxide (121g) 
(122.0 mg, 0.60 mmol) and (hex-1-yn-1-yl)benzene (11n) (179.0 mg, 1.13 
mmol), heating at 100 °C for 2h. Purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 117gn (127.0 mg, 59%) as a colorless gum.  
1
H NMR (300 MHz, CDCl3): δ = 7.71–7.64 (m, 2H), 7.55–7.49 (m, 1H), 7.47–7.36 (m, 5H), 7.29 
(dt, J = 7.6, 1.5 Hz, 2H), 7.23–7.16 (m, 3H), 6.93 (ddt, J = 7.6, 3.0, 0.9 Hz, 1H), 2.43–2.28 (m, 
1H), 2.19–2.04 (m, 1H), 1.35–1.17 (m, 2H), 1.12–0.93 (m, 2H), 0.56 (t, J = 7.3 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 150.2 (d, J = 22.2 Hz, Cq), 144.2 (d, J = 28.0 Hz, Cq), 136.7 (d, J 
= 93.5 Hz, Cq), 133.8 (d, J = 16.2 Hz, Cq), 132.7 (d, J = 2.1 Hz, CH), 132.0 (d, J = 2.9 Hz, CH), 
131.7 (d, J = 105.1 Hz, Cq), 130.8 (d, J = 10.6 Hz, CH), 130.0 (d, J = 97.2 Hz, Cq),128.7 (d, J = 




123.09 (d, J = 10.9 Hz, CH), 30.7 (d, J = 1.9 Hz, CH2), 26.3 (d, J = 10.1 Hz, CH2), 22.5 (CH2), 
13.4 (CH3).  
31
P NMR (122 MHz, CDCl3): δ = 39.9. 
IR (neat): 3057, 2956, 2930, 2870, 1588, 1437, 1194, 699 cm
–1
. 
MS (EI) m/z (relative intensity): 358 (20) [M]
+
, 329 (40), 316 (100), 237 (15), 189 (10), 165 (10).  




 358.1481, found 358.1473. 




2-Cyclopropyl-1,3-diphenylphosphindole 1-Oxide (117go):  
The general procedure F was followed using diphenylphosphine oxide (121g) 
(104.0 mg, 0.51 mmol) and (cyclopropylethynyl)benzene (11o) (142.0 mg, 1.00 
mmol), heating at 100 °C for 2h. Purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 117go (73.0 mg, 42%) as a colorless solid. 
M. p. = 141–143 °C. 
1
H NMR (300 MHz, CDCl3): δ = 7.73–7.66 (m, 2H), 7.47–7.33 (m, 9H), 7.28 (td, J = 7.6, 1.5 Hz, 
1H), 7.19–7.12 (m, 1H), 6.96 (dd, J = 7.6, 3.0 Hz, 1H), 1.64–1.50 (m, 1H), 1.22–1,14 (m, 1H), 
0.73–0.64 (m, 1H), 0.47 (dd, J = 7.4, 7.4 Hz, 2H). 
13
C NMR (75 MHz, CDCl3): δ = 149.9 (d, J = 21.8 Hz, Cq), 143.5 (d, J = 26.6 Hz, Cq), 137.2 (d, J 
= 96.6 Hz, Cq), 134.0 (d, J = 15.3 Hz, Cq), 132.7 (d, J = 2.1 Hz, CH), 132.0 (d, J = 2.9 Hz, CH), 
131.7 (d, J = 106.4 Hz, Cq), 130.7 (d, J = 10.7 Hz, CH), 130.4 (d, J = 97.6 Hz, Cq),128.9 (CH), 
128.8 (d, J = 12.3 Hz, CH) 128.6 (CH), 128.5 (d, J = 10.1 Hz, CH), 128.4 (CH), 128.1 (d, J = 10.7 
Hz, CH), 122.4 (d, J = 10.8 Hz, CH), 10.9 (d, J = 9.3 Hz, CH), 7.3 (d, J = 3.0 Hz, CH2), 6.9 (d, J = 
2.3 Hz, CH2).  
31
P NMR (122 MHz, CDCl3): δ = 38.6. 
IR (neat): 3056, 1585, 1438, 1191, 1173, 778, 753, 719 cm
–1
. 
MS (EI) m/z (relative intensity): 342 (100) [M]
+
, 327 (10), 263 (20), 215 (20), 43 (20).  




 342.1168, found 342.1169. 
 
Annulation with di-o-tolylphosphine oxide (121h): 
The general procedure F was followed using di-o-tolylphosphine oxide (121h) (115.0 mg, 0.50 
mmol) and diphenylacetylene (11a) (179.0 mg, 1.00 mmol), heating at 120 °C for 12h. 
Purification by column chromatography (n-hexane/EtOAc: 2/1) yielded 117ha (47.0 mg, 23%) 
and117ha'(95.0 mg, 47%) ascolorless solids. 
 




M. p. = 163–165 °C 
1
H NMR (300 MHz, CDCl3): δ = 8.32 (ddd, J = 13.5, 7.3, 1.9 Hz, 1H), 7.41–7.28 
(m, 6H), 7.16–7.08 (m, 2H), 7.16–7.08 (m, 4H), 7.06–6.98 (m, 4H), 2.29 (s, 3H), 
2.16 (s, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 150.0 (d, J = 21.6 Hz, Cq), 144.5 (d, J = 27.1 Hz, Cq), 141.0  
(d, J = 9.2 Hz, Cq), 140.4 (d, J = 11.3 Hz, Cq), 134.7 (d, J = 8.9 Hz, CH), 134.5 (d, J = 14.9 Hz, 
Cq), 133.6 (d, J = 95.2 Hz, Cq),132.9 (Cq), 132.8 (d, J = 1.1 Hz, CH), 132.0 (d, J = 2.8 Hz, CH), 
131.3 (d, J = 11.2 Hz, CH), 130.6 (d, J = 9.3 Hz, CH), 129.4 (d, J = 104.3 Hz, Cq), 128.8 (CH), 
128.7 (CH), 128.7 (CH), 128.4 (CH), 128.0 (CH), 127.4 (d, J = 94.9 Hz, Cq), 127.5 (d, J = 1.2 Hz, 
CH), 126.1 (d, J = 11.5 Hz, CH), 121.8 (d, J = 10.7 Hz, CH), 20.0 (d, J = 4.2 Hz, CH), 19.3 (d, J = 
4.6 Hz, CH).  
31
P NMR (122 MHz, CDCl3): δ = 37.4. 
IR (neat): 3057, 1560, 1444, 1186, 793, 753, 714, 686 cm
–1
. 
MS (EI) m/z (relative intensity): 406 (100) [M]
+
, 391 (10), 329 (15), 313 (10), 265 (10), 228 (40), 
181 (10).  




 406.1481, found 406.1497. 
The spectral data were in accordance with those reported in the literature.
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4-Methyl-2,3-diphenyl-1-(o-tolyl)phosphindole 1-Oxide (117ha'): 
M. p. = 69–71 °C 
1
H NMR (300 MHz, CDCl3): δ = 8.16 (ddd, J = 13.6, 7.6, 1.5 Hz, 1H), 7.48 (ddd, 
J = 10.4, 6.8, 1.5 Hz, 1H), 7.39–7.27 (m, 5H), 7.26–7.18 (m, 4H), 7.16–7.05 (m, 
3H), 7.04−6.99 (m, 3H), 2.25 (s, 3H), 1.74 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 152.3 (d, J = 21.3 Hz, Cq), 141.1 (d, J = 10.8 Hz, Cq), 140.8 (d, J 
= 26.3 Hz, Cq), 137.6 (d, J = 15.1 Hz, Cq), 137.3 (d, J = 2.1 Hz, CH), 135.6 (d, J = 10.7 Hz, Cq), 
135.3 (d, J = 91.5 Hz, Cq), 134.2 (d, J = 9.5 Hz, CH), 132.9 (d, J = 9.5 Hz, Cq), 132.6 (d, J = 104 
Hz, Cq), 132.2 (d, J = 2.9 Hz, CH), 131.4 (d, J = 11.3 Hz, CH), 129.1 (d, J = 11.2 Hz, CH), 128.8 
(d, J = 5.4 Hz, CH), 128.5 (d, J = 3.8 Hz, CH), 128.1 (d, J = 12.9 Hz, CH), 128.1 (d, J = 1.3 Hz, 
CH), 128.0 (CH), 127.6 (d, J = 96.5 Hz, Cq), 127.5 (CH), 127.0 (d, J = 10.3 Hz, CH), 126.0 (d, J = 
11.8 Hz, CH), 21.4 (CH3), 20.2 (d, J = 4.1 Hz, CH3). 
31
P NMR (122 MHz, CDCl3): δ = 38.2.  
IR (neat): 3056, 2928, 1591, 1442, 1194, 1173, 812, 714 cm
–1
. 
MS (EI) m/z (relative intensity): 406 (100) [M]
+
, 391 (5), 329 (15), 313 (5), 265 (15), 228 (80), 








 406.1481, found 406.1485. 
The spectral data were in accordance with those reported in the literature.
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Intermolecular Competition Experiment between Alkynes 11e and 11c: 
 
A mixture of ethyl phenylphosphinate (121a) (85.0 mg, 0.50 mmol), 
1,2-bis(4-chlorophenyl)ethyne (11e) (248.0 mg, 1.00 mmol), 1,2-bis(4-methoxyphenyl)ethyne 
(11c) (238.0 mg, 1.00 mmol) and AgOAc (166.0 mg, 1.0 mmol) in DMSO (2.0 mL) was stirred at 
120 °C for 12h under N2. At ambient temperature, the reaction mixture was diluted with H2O and 
extracted with EtOAc (3  25 mL). The combined organic layers were dried over Na2SO4. After 
filtration and evaporation of the solvents in vacuo, the crude products were purified by column 
chromatography on silica gel (n-hexane/EtOAc: 5/1→ 2/1) to yield 117ae (60 mg, 29%) and 
117ac (37.0 mg, 18%) as light yellow solids. The spectral data of compounds 117ae and 117ac 
were identical to those reported above. 
 
Intermolecular Competition Experiment between Alkynes 11a and 11h 
 
A mixture of diphenylphosphine oxide (121g) (100.4 mg, 0.50 mmol), diphenylacetylene (11a) 
(178.0 mg, 1.00 mmol), oct-4-yne (11h) (110.0 mg, 1.00 mmol) and AgOAc (332.0 mg, 2.00 
mmol) in DMSO (2.0 mL) was stirred at 120 °C for 6h under N2. At ambient temperature, the 
reaction mixture was diluted with H2O and extracted with EtOAc (3  25 mL). The combined 
organic layers were dried over Na2SO4. After filtration and evaporation of the solvents in vacuo, 
the crude products were purified by column chromatography on silica gel (n-hexane/EtOAc: 5/1→ 




data of compounds 117ga and 117gh were identical to those reported above. 
 
Intermolecular Competition Experiment between Phosphine Oxides 121b and 121g 
 
 
A mixture of diphenylacetylene (11a) (89.0 mg, 0.50 mmol), tert-butyl(phenyl)phosphine oxide 
(121b) (91.3 mg, 0.50 mmol), diphenylphosphine oxide (121g) (101.0 mg, 0.50 mmol), AgOAc 
(168 mg, 1.00mmol) in DMSO (2.0 mL) was stirred at 120 °C for 4h under N2. At ambient 
temperature, the reaction mixture was diluted with water and extracted with EtOAc (3  25 mL). 
The combined organic layers were dried over Na2SO4. After filtration and evaporation of the 
solvents in vacuo, the crude product was purified by column chromatography on silica gel 
(n-hexane/EtOAc: 5/1→ 2/1) to yield 117ba (40.0 mg, 22%) and 117ga (32.0 mg, 17%) as light 












9 List of Abbreviations 
Å Ångström ESI electronspray ionization  
Ac acetyl Et ethyl 
Ad adamantly FG functional group 
Alk alkyl  g gram 
AMLA ambiphilic metal-ligand activation GC gas chromatography 
aq. aqueous  h hour 
Ar aryl Het hetero(aryl) 
APT attached proton test  Hept heptyl 
atm atmospheric pressure HPLC high performance liquid chromatography 
ATR attenuated total reflectance HR-MS high resolution mass spectrometry 




BINAP 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl IES internal electrophilic substitution 
Bn benzyl IR infrared spectroscopy 
Boc tert-butyloxycarbonyl J coupling constant 
Bu butyl KIE kinetic isotope effect 
Bz benzoyl L ligand  
calc. calculated  Leu leucine 
cat. catalytic m meta 
CMD concerted-metalation-deprotonation m multiplet 
cod 1,5-cyclooctadien M molar  
conv. conversion [M+] molecular ion peak  
Cp cyclopentadienyl Me methyl  
Cy cyclohexyl Mes mesityl  
δ chemical shift  mg milligram 
d doublet MHz megahertz 
DCM dichloromethane min minute  
dd doublet of doublet mL milliliter 
DFT density functional theory mmol millimol 
DG directing group M. p. melting point 
DMA N,N-dimethylacetamide MPV membrane pump vacuum 
DME dimethoxyethane MS mass spectrometry 
DMF N,N-dimethylformamide m/z mass-to-charge ratio 
DMSO dimethyl sulfoxide n normal 
DPPB 1,4-Bis(diphenylphosphino)butane NBS N-bromosuccinimide 
DPPH 2,2-diphenyl-1-picrylhydrazyl NHC N-heterocyclic carbene 
dt doublet of triplet NIS N-iodosuccinimide 
Ed. editor NMP N-methylpyrrolidinone 
EI electron ionization NMR nuclear magnetic resonance 





o ortho SPS solvent purification system 
OPV oil pump vacuum t tert 
p para t triplet 
Ph phenyl  T temperature 
Piv pivaloyl TEMPO 2,2,6,6-tetramethylpiperidin-1-yloxy 
ppm parts per million  Tf trifluoromethanesulfonate 
Pr propyl TFA trifluoroacetic acid 
PTSA p-toluenesulfonic acid TFAA trifluoroacetic anhydride 
Py pyridyl THF tetrahydrofuran 
PyDipSi pyridyldiisopropylsilyl TLC thin layer chromatography 
pym pyrimidyl TM transition metal 
q  quartet TMS trimethylsilyl 
R rest Ts para-toluenesulfonyl 
rac racemic TS transition state 
ref. reference ṽ absorption 
s singlet wt% weight by volume  
sat. saturated X (pseudo)halide 
sec secondary PyDipSi pyridyldiisopropylsilyl 
SE
Ar electrophilic aromatic substitution XPhos 2-dicyclohexylphosphino-2′,4′,6′-tri- 
SET single electron transfer  isopropylbiphenyl 
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